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Hepatocellular carcinoma (HCC) is a major health problem and is the third leading cause of 
cancer-related mortality worldwide. The prevalence of non-alcoholic fatty liver diseases 
(NAFLD) is on the rise, and the possibility for the development of HCC in NAFLD patients is 
increasing in the western countries. HCC driver mutations are not druggable and the median 
improvement of life expectancy in treated HCC patients doesn’t exceed, at best, 2 years. 
Therefore, novel rewarding targets should be identified, from whom the components of the 
liver microenvironment represent a fertile field of research and drug discovery.   
SULFATASE 2 (SULF2), an extracellular sulfatase, was markedly upregulated in the cancer 
associated fibroblasts (CAFs) in more than half of HCC biopsies, and CAF-SULF2 expression was 
associated with poor prognosis and sorafenib tolerance in HCC patients. In vitro, stromal 
SULF2 induced the proliferation, migration, invasion and therapy evasion of HCC cell lines. 
Stromal SULF2 activated JNK/IL6 pathway in the fibroblast cell lines, while SULF2-rich 
secretome activated NF-kB/CD44 stemness pathway in the tumour cells justifying the 
aggressive, SULF2-dependent tumour cell phenotype. 
In a mouse model of NAFLD-induced HCC, Sulf2, as well as other targets, was upregulated in 
the non-tumour liver tissue of the dietary-challenged mice compared to matched controls. 
Pathway analysis and immunohistochemistry (IHC) validation in mouse and human tissue 
supported the profound role of different immune cells in the process of tumour development. 
We have identified a novel Cd44-positive macrophage phenotype that worked in concert with 
certain T cell subsets to develop HCC in mice. The number of CD44 positive macrophages in 
the non-tumour liver biopsies of NAFLD patients who developed HCC was higher than CD44 
positive macrophages in patients who didn’t develop malignancy.  
In conclusion, non-parenchymal cell compartments play an essential role in HCC development 
and progression. Therapeutics targeting the activities of these cells represent a novel strategy 
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Chapter 1 - Introduction 
Hepatocellular carcinoma (HCC)  
Primary liver cancer is a major health issue that ranks seventh in world-wide cancer incidence 
and accounts for around 6% of overall cancer cases1, 2. The heterogeneous distribution of liver 
cancer is due to the regional prevalence of its risk factors; and generally speaking, more than 
three quarters of liver cancer cases arise in patients from developing countries compared with 
cases from the developed countries3. Indeed, liver cancer is the third most prevalent cancer 
in developing countries after lung and stomach cancer4. While the incidence of liver cancer 
showed a 30% decline in high risk countries, in other countries Hepatocellular carcinoma (HCC) 
incidence doubled in the period between 1978 and 19924. HCC; that is liver cancer initiated 
by malignant changes in hepatocytes, is the most common type of liver cancer and about 
800,000 cases were reported in 20125. HCC accounts for 75-80% of total primary liver cancer 
cases, whilst the remaining cases develop on the background of carcinoma of the bile ducts or 
cholangiocarcinoma6.  
1.1. Risk factors for the development of HCC 
Major risk factors for the development of HCC include the presence of cirrhosis, viral hepatitis 
B and C, non-alcoholic fatty liver diseases (NAFLD), obesity, presence of type-2 diabetes 
mellitus (T2DM), ingestion of aflatoxin and alcohol (Figure 1.1).  
1.1.1 Cirrhosis  
Cirrhosis is the major risk factor for the development of HCC and it typically develops on the 
background of chronic liver disease. Chronic liver diseases include viral hepatitis, alcohol 
consumption, NAFLD and hemochromatosis7. The incidence of HCC development in cirrhotic 
patients depends on the background liver disease and the severity of this underlying cause 
and approximately 2.5 to 4% of cirrhotic patients develop HCC per year, while 80% of HCC 
cases arise on the background of established cirrhosis8-10. It is, hence, better to describe the 
role of cirrhosis in the development of HCC in the context of other risk factors. 
1.1.2 Hepatitis B virus 
Hepatitis B virus (HBV) infection accounts for 50% of HCC cases worldwide11. HBV infection is 
acquired vertically in the endemic areas where most of patients became chronic carriers for 
the disease. On the other hand, blood transfusion and unsafe sexual habits are the major 
determinants of horizontal HBV infection in the countries with lower viral incidence12. HBV-
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HCC is linked with other factors including gender, age, concurrent ingestion of Aflatoxins as 
well as smoking13. HBV can be considered as an independent risk factor for the development 
of HCC; however, more than 70% of HBV-HCC cases are developed on the background of 
cirrhosis13. In a systematic review in Asia, the odds for the development of HBV-HCC were 
dramatically increased in the presence of cirrhosis14. Two important aspects should be 
highlighted here; the first is that the HBV viral load (estimated by measuring the HBV DNA) 
was proportional to the increased risk of HCC development in patients from Taiwan 
independent of other risk factors15. Secondly, the genotyping of HBV is associated with the 
severity of the disease in a regional pattern; that is, genotype D is associated with the 
development of HCC in western countries and in the USA, whereas, genotype C was associated 
with cirrhosis and HCC development in the Asian population13. 
1.1.3 Hepatitis C virus 
The development of HCC on the background of Hepatitis C virus (HCV) peaked in 
Mediterranean countries, for example, Egypt and Italy, but also in Japan16-18. It is also 
predicted that the incidence of HCV-induced cirrhosis and subsequently HCC will rise within 
the next decade in the USA19. Other case-control studies showed that HCV-positive individuals 
were 17 times more susceptible to develop HCC compared to non-HCV patients20. Unlike HBV 
infection, HCV-HCC is developed in the majority of cases after the establishment of cirrhosis; 
probably because HCV increases the risk of fibrosis and inflammation preceding the cirrhotic 
changes in the liver tissue21, 22. HCV infected patients are more likely to develop HCC in 
presence of other co-factors like age, male gender, genotype 1b, presence of diabetes, 
increased alcohol consumption as well as in presence of HIV or HBV co-infection13. The high 
efficacy of the direct acting antiviral (DAA) therapy managed to abolish viral replication and 
decrease the viral load which should in theory decrease the incidence of cirrhosis and in turn 
the development of HCC23, 24. However, safety studies should be carried on using these drugs 
due to the reported increase in HCC in DAA-treated patients in certain studies25. In addition, 
once the cirrhosis is established the risk of HCC is still independent on efficient viral 
















Figure 1.1 The association of HCC with different risk factors; from Reeves et al26 with 
permission: The development of HCC is associated with co-infection with clinical factors 
(cirrhosis), infection with liver viruses (HBV and HCV), or with environmental factors (obesity, 
excessive alcohol consumption, diet related fatty liver diseases). Preventive strategies for HCC 
may involve adapting better eating habits and healthier life style. Studies performed on 
patients having the antidiabetic metformin or the anti-hyperlipidaemic Statins showed 
delayed or less onset of HCC development27, 28. Abbreviations: HCV; Hepatitis C virus, HBV; 
Hepatitis B virus, NAFLD; non-alcoholic fatty liver disease, ALD; alcoholic liver diseases, IGT; 
impaired glucose tolerance.  
 
1.1.4 Alcohol 
The link between alcohol consumption and HCC development has been extensively studied29-
31. The correlation between alcohol consumption and HCC revealed a dose-dependent 
association, with patients drinking more alcohol or over longer period of time being more 
likely to develop HCC than age matched non-alcoholics31. In the US, individuals with a history 
of alcohol intake were at higher risk to develop HCC relative to those who do not drink. In 
addition, patients who have more than 80 mL/d alcohol had 4.5 higher risk of developing HCC 
compared to other individuals31. Alcohol intake is associated with the development of 




alcoholic steatohepatitis (ASH) with more fat deposition, more inflammation and accumulated 
free radicals that all lead to hepatocarcinogenesis32. 
1.1.5 Aflatoxin 
 Grains, nuts or fermented soybeans stored in humid conditions are susceptible to the 
development of the liver carcinogen Aflatoxin by the Aspergillus flavus and Aspergillus 
parasiticus species33. This carcinogen, especially Aflatoxin B1 (AFB1), is prevalent in sub-
Saharan Africa and East Asia and resulted in a higher HCC prevalence32. Aflatoxin ingestion 
induces a point mutation in codon 249 of the p53 tumour suppressor gene predisposing to 
HCC34. Studies from Sudan35, Taiwan36 and China37 adopted several ways to detect the 
exposure to AFB1, for example, AFB1-DNA and AFB1-albumin in tissues and body fluids. 
Correlation studies revealed an AFB1-synergistic effect on HBV patients developing HCC 
suggesting that AFB1 might potentiate the carcinogenic effect of HbSAg38. 
1.1.6 Non-alcoholic fatty liver disease (NAFLD)        
The Epidemiology of HCC has been significantly altered during the last few years primarily due 
to major breakthroughs in the treatment of viral hepatitis and the increase in NAFLD 
prevalence, resulting in a shift towards NAFLD-driven HCC as a key contributor to the burden 
of HCC. NAFLD prevalence exceeds 25% of the western population given the increase of the 
onset of other comorbidities including obesity, hyperglycaemia and the metabolic 
syndrome39, and this syndrome can progress to the more severe form, non-alcoholic 
steatohepatitis (NASH), that is strongly associated with the development of HCC40. Risk factors 
for the development of HCC on the background of NASH include male gender, age with criteria 
of the metabolic syndrome. Although the other factors increase the risk of developing HCC, it 
is largely after progression to cirrhosis, which is not always the case in patients with NAFLD, 
where cirrhosis is present in only 70% of those developing HCC. In the other 30% of NAFLD 
cases, HCC develops in the absence of established cirrhosis. These patients often present at a 
more advanced stage, as they are not in cirrhosis HCC surveillance programs41, 42. The 
prevalence of NAFLD-HCC in the western countries ranges between 4-22%43, while one study 
has shown that 59% of the US HCC patients had NAFLD background44. This is not the case in 
the Eastern countries and the Middle East where other etiologies are more prevalent.   
1.1.7 Type-2 Diabetes mellitus (T2DM) and obesity  
HCC is closely associated with the prevalence of T2DM, with probably 8-50 % of HCC cases 
arise in diabetic patients45, 46. Different studies from the US45 and Western Europe47 showed 
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that the odds of developing HCC in presence of T2DM are 1.5-4 times higher than the non-
diabetic patients. Increased insulin resistance and hyperglycaemia may have also promote 
DNA and cellular damage consequent to accumulation of hepatic fat and the subsequent 
escalation to NASH, with associated the oxidative stress and production of free radicals48. In 
addition, T2DM together with obesity can be associated with HCC development independently 
of the presence of NAFLD45, 46. 
Patients with body mass index (BMI) of more than 30 have a four times higher risk of 
developing HCC compared to non-obese patients30. The development of HCC in obese patients 
is also associated with environmental factors like alcohol consumption and tobacco49-51. The 
link between obesity and HCC may be through the establishment of NAFLD and T2DM45, 46.    
1.2. Anatomic and histopathological changes in HCC 
Benign hepatocellular tumours are hepatocellular adenoma (HCA) and focal nodular 
hyperplasia, while benign biliary tumours include biliary adeno-fibroma and bile duct 
adenoma. Liver malignancy, on the other hand, may be of hepatocellular (HCC, 
hepatoblastoma and HCC fibrolameller variant), cholangiocellular (cholangiocarcinoma) or 
mixed (hepatocellular cholangiocarcinoma, mixed epithelial mesenchymal hepatoblastoma) 
cell origin52. Macroscopically, HCC may develop as a single lesion or as multiple foci separated 
by non-tumour liver parenchyma. HCC developed on the background of cirrhosis is often 
encapsulated with fibrous tissue, but this feature is not as frequent in the non-cirrhotic 
patients with HCC52, 53.  
Three histological features are assessed in biopsy tissues when considering the diagnosis of 
HCC, including changes in liver architecture and cytological features, as well as the presence 
of portal stromal invasion54. Loss of the intact portal tract and the presence of unaccompanied 
arteries, together with an increase in liver cell plates from 1-2 cells thick to 3 cell thick or more 
are typical features of HCC. Some HCCs have sheet-like growth patterns, while other types 
form pseudo-like or trabecular structures of the liver cell plates54. Changes to cellular 
morphology are often seen in HCC and can be also be a useful tool for diagnosis. These 
changes include the presence of clear or giant cells, as well as fatty deposition within tumour 
associated with some features also seen in their non-tumour counterparts - like Mallory-Denk 
bodies, intracellular inclusions and hyaline globules. Nuclear polymorphism is also seen in 
HCC, especially in the presence of abnormal mitotic figures and changes in the nuclear-to-
cytoplasmic ratio54. These cytological abnormalities together with the changes in the 
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architecture were the basis for Edmondson and Steiner’s classification of HCC tumour 
grades55. This classification includes 4 grades. Grade 1 or well differentiated HCC typically has 
thin trabecular architecture, with slightly enlarged nuclei and abundant eosinophilic 
cytoplasm. Grade 2 or moderately differentiated HCC frequently has a pseudo-glandular 
pattern with a higher nuclear-to-cytoplasmic ratio. Poorly differentiated HCC includes grades 
3 and 4,  with an exponential increase in nuclear hyperchromatic features55. HCC lacks a typical 
pattern of stromal invasion, although more abundant stroma can be feature in fibrolamellar 
and scirrhous subtypes of HCC54.    
In addition to histological assessment of diagnostic biopsies, based on the haematoxylin and 
Eosin stained sections, the presence of other tissue markers can provide a strong additional 
tool to confirm a diagnosis of HCC and distinguish a primary from a secondary or metastatic 
tumour. Immunohistochemistry can also distinguish mixed origin tumours and non-cancerous 
lesions. The presence of canalicular polyclonal carcino-embryonic antigen (pCEA) or CD10, 
with focal or strong hepatocellular Glypican-3 (GPC3) and Arginase-1 (ARG1) expression are 
strong indicators of a primary rather than metastatic cancer and are at least moderately 
sensitive. In parallel, the loss or disorder of reticulin staining with strong sinusoidal expression 
of CD34, especially if associated with cytoplasmic GPC3 and Glutamine synthase (GS) staining, 
strongly support a diagnosis of HCC rather than a benign lesion54.         
1.3. Molecular classification of non-tumour/HCC and their link with clinical features 
The focus of many liver cancer researchers has been directed towards profiling HCC tumours 
into different molecular categories, with the aim of developing a more “personalised” 
approach for the affected patient, with the ability to predict their prognosis, but also their 
likely outcome to a particular treatment. HCCs typically harbour great inter and intra-tumour 
heterogeneity and it was hoped that the innovation of microarray and high throughput 
“omics” techniques would decipher the more meaningful molecular subtypes within a 
tumour. 
One of the first integrated molecular studies was reported in 2007, on tissues from HBV-driven 
HCC in French patients, and combined gene mutation, DNA methylation and expression 
microarray data56. Mutation in TP53, AXIN1, TCF1, PIK3CA, and KRAS genes was evident in this 
cohort of patients with a unique hyper-methylation in the CDKN2A and CDH1 gene promoters. 
Unsupervised clustering of the microarray data identified two robust clusters; each of which 
was divided further into 3 sub-clusters. This 6-G clustering was defined by clinical features as 
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well as mutational status56. A subsequent larger multi-centre study used formalin-fixed, 
paraffin embedded (FFPE) tumour tissues as well as the adjacent non-tumour tissues from a 
primary cohort of early HCC in Japanese patients undergoing tumour resection57. The derived 
gene signature was subsequently validated in patients from the US and western countries, 
with the goals of correlating gene signature from both tumour and non-tumour tissue with 
patient outcome. Outcomes studied included survival and late recurrence (tumours 
developed two years or more after resecting the primary tumour). Interestingly, the gene 
signature of the tumour tissue didn’t show any association with the patients’ survival or 
tumour recurrence, while the non-tumour gene signature was significantly associated with 
patient survival. Particular genes associated with poorer survival were those involved in 
inflammatory processes, with strong enrichment of genes in both the NF-κB and IL6/STAT3 
pathways57.     
One subsequent multi-centre study from Chiang et al58 focused on exploring copy number 
variation and expression microarray in HCV-driven HCC resection tissues from Spain, US and 
Italian patients58. Most of the characterised tumours harboured 1q gain, 8q gain and 8p loss, 
with hierarchical clustering of the microarray expression profile identifying 5, rather than 6, 
patient subgroups. Interestingly, two clusters (CTNNB1 and the proliferation subclasses) were 
concordat with the French clustering groups, while concordance between pathway analyses 
in the Chiang et al. clustering and the previous 6G study was also demonstrated58. Hoshida et 
al59 followed this study up with a meta-analysis combining the previous gene expression 
studies. All the expression data, from the different aetiologies of HCC, was pooled and 
analysed together, with three suggested human HCC sub-clusters emerging. These were 
termed S1-S3 and again, associations with clinical and histological data defined59. S1 and S2 
subgroups shared some common features and together, S1 and S2 were termed the 
proliferative subtype, as opposed to the non-proliferative subtypes made up of S3 cases 
(Figure 1.2). Tumours in the proliferative phenotype reportedly had a more aggressive 
phenotype, with comparatively poorer outcomes for affected patients. This group was 
characterised by activation of RAS, IGF and mTOR signalling pathways59. Two subclasses were 
defined within this proliferative group, based on activation of either the Wnt/TGFβ pathway 
or the EpCam progenitor cell pathway59. Conversely, the non-proliferative phenotype, in 
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which patients had a relatively better prognosis compared to the proliferative subtype, 
included patients with CTNNB1 mutation60, 61. 
Figure 1.2 Hoshida’s classification of HCC patients, from Hoshida et al59 with modification 
HCC patients were classified according to their gene expression profile and to the 
deregulated pathways into three classes (S1-S3). Concordance with previous gene 
signatures revealed an overlap with particular groups (G3, G5/G6) mentioned previously by 
Boyault et al56. Overlapped gene signatures represent two groups of patients based on the 
proliferation index of the tumours; the proliferative phenotype with poor patient outcome 
and the non-proliferative group with good prognosis. 
 
As a result of these studies, there is the possibility of profiling the gene expression of HCC 
and classifying affected patients into categories, supported by clinical data, which are 
associated with outcome. With a view to indentifying signature(s) that predicted disease 
recurrence, Villanueva et al62 went on to evaluate the gene expression profile of 287 early 
HCC from patients cared for at four different centres, exploring the overlap with the 
previously reported gene expression signatures from tumour tissues as well as from the 
non-tumour regions. The Chiang et al proliferation signature58 was the most prevalent in 
the Villanueva et al cases. Pair-wise comparisons confirmed clustering of the most poor 
survival gene signatures together. In contrast, analysis centred on V coefficients showed 
clustering of most signatures into three broad categories. The first category included the 
proliferation subtype58, G356, cluster A63, late TGFB64, Met signature65 and S159 signatures. 
The second category was defined by the poor survival tumour-adjacent signature57, while 
the third category was associated with progenitor cell activation (hepatoblastoma_C266, 
EpCAM67 and S259 signature). Of all the gene signatures within the broader categories, only 
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the G356 signature, poor survival signature and satellites were independently associated 
with tumour recurrence and overall recurrence.   
While these studies have grouped patients based on their gene expression state into certain 
categories with an ability to predict outcome and tumour recurrence, the role of these 
groupings in prospective management decisions for patients remains uncertain.  A further 
limitation of these data thus far, is the limitation to HCC predominantly arising in HBV and HCV 
aetiologies, with little representation of NAFLD-HCC patients. More work is needed to define 
the gene expression profile of NAFLD-HCC patients and to explore possible overlaps between 
the transcriptome of these patients and the publically available viral aetiology HCC datasets.    
1.4 Pathophysiological changes in HCC 
The development of HCC is mostly accompanied by chronic liver diseases, with cirrhosis as the 
most important known factor predisposing to HCC development. The liver malignant process 
is believed to start with chronic liver disease that leads to disruption of the normal liver 
architecture and generating nodules of hepatocytes.  These nodules can undergo a number of 
pre-malignant steps, involving their transformation into low grade dysplastic nodules (LGDN) 
that progress to high grade dysplastic nodules (HGDN). An accumulation of genetic and 
epigenetic events with time increase the likelihood of these premalignant structures 
transforming into malignant early HCC and subsequently more aggressive HCC68. This multi-
stage process is accompanied by the build-up of different mutational loads, deregulated 
signalling pathways as well as changes in the premalignant microenvironment.   
1.4.1 Genetic Factors predisposing HCC 
Several single nucleotide polymorphisms (SNPs) are associated with the development of HCC 
in combination with one or more from HCC risk factors69. SNPs in the cell cycle genes (TP53 
and MDM270), inflammatory genes (TGFβ71, TNFα72 or IL1β73) and oxidative stress genes 
(SOD274) are of special interest. HCV patients with rs4444903 SNP in EGF75 gene and 
rs2596542 SNP in the MICA76 gene responsible for altering immune response are at higher risk 
for developing HCC. PNPLA377 SNP in NAFLD/NASH patients predispose the development of 
HCC, while SNPs in GTSM1 and GSTT1 genes78 are common in HBV infected patients or AFB1 
positive patients who progress to HCC. In isolation these SNPs are not harmful, but they can 
increase the likelihood of HCC development in the presence of other risk factors. 
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1.4.2 Pre-carcinogenic gene alteration  
As reported below, acquired TERT mutations are common in HCC and recently, rare germ line 
mutations in TERT have also recently been reported to increase the risk of HCC79, 80.  TERT 
encodes telomerase, an enzyme important for maintaining the integrity of telomeres – the 
protected DNA repeated sequences at the ends of chromosomes. Changes in the telomere 
and the tolemerase activities are common in the cirrhotic patients and are associated with 
high risk of HCC development. TERT promoter mutations are present in about 5% of LGDN and 
in 19% of the HGDN with marked increase in early HCC patients81. TERT promoter mutation 
can, thereby, be considered as the “guardian” of the malignant transformation of hepatocytes, 
while other mutations are acquired afterwards. Hepatocellular adenomas, a rare type of 
benign hepatic tumours, have β-catenin exon 3 mutations, HNF1A or IL6ST mutations. The 
presence of β-catenin mutation in hepatocellular adenoma increases the risk of the 
development of malignancy. The chromosomal aberrations, hypomethylation and TERT 
promoter mutation are included in the last step of malignant transformation82. 
In human, the insertion of viral DNA particles in the human genes like TERT and CCNE1 can 
lead to genotoxicity and HCC development83. Similarly, infection with adeno-associated virus 
2 (AAV2) leads to insertional mutations in the aforementioned genes together with CCNA1 
and TNFSF10; being correlated with HCC development84. Frequent C>A point mutation and 
R249S mutation in TP53 as a result of AFB1-DNA adduct is commonly seen in HCC patients33. 
Aristolochic acid exposure leads to T>A transverion and was associated with HCC development 
in Chinese population adding another tier of complexity in the process of cancer initiation85.     
In experimental HCC, the mechanism by which carcinogens induced genotoxicity is extensively 
studied. Discovered in the thirties of the last century, N-nitoso compounds were the most 
commonly used carcinogen in hundreds of HCC studies 86. Administration of 
Diethylnitrosamine (DEN) is responsible for the alkylation of the guanine N7 atom leading to 
HCC development in rats. Further investigation identified cytochrome p450 enzyme (CYP2E1)-
mediated metabolism of DEN to dimethyl nitrosamine (DMN) to be responsible for the 
formation of DNA adduct before the development of HCC in mice86. The development of DEN-
induced HCC was partially mediated through the induction of oxidative stress and 
consequently the production of reactive oxygen species (ROS) that affect DNA integrity and 




1.4.3 Main DNA driver mutations 
Whole genome sequencing studies showed that although the number of somatic mutation in 
HCC patients can be between 35 and 80 mutation per case, the optimal number of driver 
mutations required for the initiation of the tumour is between 5 to 887. The rest of these 
mutations are considered as “passenger” mutations that are not able by themselves to initiate 
HCC. Key driver mutations usually happen in the key genes regulating the process of the 
carcinogenesis including genes regulating cell cycle (TP53, CDKN2A, RB1, CCNE1), genes 
preserving telomere function (TERT), genes responsible for cell proliferation (CTNNB1 and 
AXIN1) and oxidative stress (NRF2 and KEAP1) (Figure 1.3). 
1.4.3.1 Cell cycle gene mutations 
Mutation in the tumour suppressor gene P53 is common, reported in 12% - 48% of HCC 
patients88. P53 is crucial for important biological processes like apoptosis, cell cycle arrest and 
DNA repair, with change in its sequence alters the translation or function of the encoded 
protein, pushing cells towards malignant transformation89-94. HBV, HCV, oxidative stress and 
ingestion of AFB1 are associated with TP53 point mutations, leading to G:C to T:A transversion 
33, 95-100. Moreover, the HBV host–integral gene, HBx, reduces the binding of P53 to important 
transcription factors responsible for apoptosis, resulting in disruption of this physiological 
process101-103. Other genes involved in cell cycle regulation, like p21, CCNE1 and RB1 genes are 
vulnerable to mutational changes in HCC patients. Approximately 12% of HCC have 
homozygous deletion in p21104, and a further 8% of patients harbour RB1 mutations105. HBx is 
found to be integrated in the human genome leading to mutation CCNE1 gene in about 5% of 
HCC83 and amplification of FGF19/CCND1 locus in 14% of HBV-related HCC106.    
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1.4.3.2 Telomerase reactivation mutations 
Early changes in the telomere and telomerase activity are seen in liver tissues of cirrhotic 
patients, and in HCCs - with about 90% of HCC having a  higher level of expression of 
telomerase107. This is attributed to amplification in the TERT locus in about 6% of patients108, 
HBx insertion in the region of TERT in 15% of patients and an activating mutation in the TERT 
promoter in more than 50% of patients83. TERT promoter mutation is associated with CTNNB1 
mutation in a number of HCC patients108.   
Figure 1.3 Mutational status in HCC patients, from Zucman-Rossi et al109 with modification 
Driver mutations in HCC take place in key genes responsible for regulating telomerase 
function, cell cycle, Wnt/β-catenin and oxidative stress. Other less-common mutations include 
mutations in the genes responsible for epigenetic regulation of gene expression or genes 
regulating RTK pathways. 
 
1.4.3.3 CTNNB1 mutation 
Wnt/β-catenin pathway is an essential oncogenic pathway in about 40% of HCC and is 
responsible for cell proliferation and metabolic processes within the tumour. CTNBB1 encodes 
β-catenin and in the absence of constitutive activating CTNNB1 mutations, upstream 
dysregulation is typically present, promoting Wnt ligands binding to the Frizzled receptors 
leading to the aberrant translocation of wild type (WT) β-catenin from its membranous 
complex into the nucleus, to activate its specific gene expression. However, CTNNB1 is 
mutated in exon 3 in more than 30% of HCCs, leading to constitutive nuclear translocation of 
β-catenin and persistent activation of the pathway110. Other genes involved in the Wnt/β-
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catenin pathway, like APC and AXIN1111 are also, but less frequently, mutated. Some studies 
suggested a link between HCV infection and AFB1 exposure to the development of HCC with 
CTNNB1110. 
1.4.3.4 Receptor tyrosine kinase-related mutations 
Receptor tyrosine kinases (RTK) comprise a large group of enzymes that phosphorylate 
important downstream targets regulating many physiological, but also oncogenic pathways. 
An activating mutation in any one of these proteins, or deletion mutation in one of their 
inhibitory regulators, will lead to activation of the whole pathway and increase cellular survival 
and proliferation. Amplification of CCND1/FGF19106, activation mutation in PIK3CA or deletion 
mutation in the pathway inhibitor TSC1 or TSC2 will lead to activation of the PI3K/AKT/mTOR 
pathway108. Although RAS mutation is rare in HCV and HBV-infected HCC patients (2%), 
inactivating mutations in the RAS inhibitor RSK2 occurs in about 9% of HCC patients leading to 
activation of this whole pathway104. Mutations in RAS family members also include activation 
mutation in codon 61 in NRas, in codon 12 in both HRas and KRas112-118. Lack of genome wide 
studies in NAFLD-HCC patients might explain the underestimation and the low number of HCC 
patients harbouring mutations in the RAS family members.  
1.4.4 Oncogenic pathways in HCC development and progression 
HCCs are a very heterogeneous group of tumours and many factors can be involved in the 
process of tumour development and progression. As mentioned before, DNA damage and the 
resulting pattern of mutation is essential to the development of the disease. Unfortunately 
many of these changes in the human genome are deemed un-correctable or ‘undruggable’ 
and the focus of the current research is to understand the consequences of changes in the 
gene at the protein level, with the hope of identifying chemopreventive or therapeutic targets 
for HCC. A number of key pathways promoting tumourigenesis are those maintaining the 
oncogenic conditions within the premalignant liver or in the tumour microenvironment. 
Infiltration of different stromal or immune cells to the tumour niche can directly favour 
oncogenesis or activate key pathways that promote chronic liver disease progression to 
cirrhosis, paving the route to HCC development. The interplay between different cell types 
within the liver tissue and the oncogenic pathways potentially activated by cell-cell cross talk 
are summarised here.     
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1.4.4.1 NF-κB pathway 
Inflammatory cytokines like TNFα, IL6, IL8 and IL1β released from dead or damaged cells or 
the bacterial cell wall component Lipopolysaccharides (LPS) can activate the classical NF-κB 
pathway by phosphorylation and degradation of IκBα. Unphosphorylated IκBα sequesters 
members of the NF-κB family in an inactive form in the cytoplasm. As a result of IκBα 
degradation, released NF-κB dimers, typically RelA and P50 homodimers, enter the nucleus to 
activate NF-κB targets. In the alternative pathway, p100 is degraded resulting in a p52 
molecule and enabling the free p52/RelB to translocate to the nucleus promoting 
transcription of a discrete subset of NF-κB dependant genes. Genes regulated by the NF-κB 
pathway include pro-inflammatory genes (iNOS, IL6, TNFα and IL1β), fibrogenic genes (TGFβ), 
cell survival and apoptosis genes (BCL2, BCL-XL, cIAP, GADD45β) and metabolic genes 
(SOD2)119. 
Activation of NF-κB can be associated with the development and progression of HCC 
regardless of its cellular source. In Mdr2 knockout mice that develop spontaneous HCC on a 
background of cholestasis-induced chronic inflammation, the release of TNFα from the bile 
ducts and different inflammatory cells activates the NF-κB pathway in the adjacent 
hepatocytes by recruiting RelA to the nucleus and leading to HCC. Activation of the NF-κB 
pathway reported in this model was associated with the late phase of tumour initiation120, 
mediated by upregulation of the anti-apoptotic and cell survival genes GADD45β and BCL2120. 
Activation of NF-κB in non-parenchymal cells can also contributes to the initiation of HCC. NF-
κB-mediated iNOS production from macrophages and neutrophils can abrogate P53 
transcription, via an increase in free radicals and an enhanced production of macrophage 
Inhibitory Factor, or MIF 121, 122. This pro-tumorigenic effect of macrophages can also be 
promoted by dead or apoptotic hepatocytes, which release characteristic molecules known as 
Danger Associated Molecular Patterns (DAMPs), which activate NF-κB signalling within 
macrophages. This in turn leads to the production of IL6 and TNFα, which have well 
established mitogenic effects on adjacent hepatocytes123-126.  
After tumour initiation and development, activation of NF-κB can contribute to progression 
and a poorer outcome. Tumour cells or tumour associated macrophages secretes CCL22 and 
CC17 chemokine that attract a specific subset of Tcells (Tregulatory or Treg cells) to the site of the 
tumour. This type of T cell is responsible for induction of an immunosuppressive phenotype 
that supresses anti-tumour immunity127. NF-κB activation induces the expression of different 
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matrix modifying proteins and enzymes that are essential for tumour progression128-130. The 
Cyclooxygenase-2 (COX-2) enzyme, a transcriptional target for NF-κB, is responsible for 
production of hypoxia inducible factor-α (HIF-α) that stimulates production of the angiogenic 
factor VEGF 131.  
1.4.4.2 JNK pathway 
The cJun NH2-terminal kinase (JNK) is included in different physiological and pathological 
pathways in the liver as well as in other organs. The JNK pathway regulates the expression of 
different downstream genes that are implicated in apoptosis and proliferation, including cJun, 
JunD and JunB132. The role of JNK pathway activation and the development and the 
progression of HCC has been extensively studied using human and murine models. Early 
reports showed that livers of JNK1-deficient mice133, or those treated with a specific JNK 
inhibitor134, or those of cJun-deficient mice135 , did not regenerate after partial hepatectomy 
(PHx) and were also protected from the development of carcinogen-induced HCC. Moreover, 
deficiency of JNK activation in mouse embryonic fibroblasts impaired cellular proliferation136. 
To dissect the role of JNK activation in different cell types in liver microenvironment, Das et al 
tested the potential of JNK1/JNK2 global or conditional deletion on the ability of the livers to 
regenerate and to develop HCC137. Global deletion of JNK1/JNK2 did not affect liver 
regeneration after PHx, and JNK1/JNK2 hepatocyte conditional-knockout (KO) promoted the 
initiation of HCC in mice liver implying that activation of JNK1/2 in hepatocytes is one of the 
pro-apoptotic mechanisms. However, specific deletion of JNK1/2 from the hepatocytes and 
the non-parenchymal cells did protect mice from DEN-induced HCC by regulating 
compensatory proliferation and regulation of production of pro-tumourigenic cytokines like 
IL6 and TNFα137. In conclusion, the role of JNK seems to be cell-specific, with JNK activation in 
the non-parenchymal cells favouring the development of carcinogenesis by regulating  the 
inflammatory secretome, which in turn, through paracrine signalling mediates hepatocyte 
trans-differentiation and tumourigenecity.   
1.4.4.3 Wnt/β-catenin pathway 
The Wnt/β-catenin pathway is implicated in several functions within the liver 
microenvironment, with roles in liver regeneration, metabolism and cellular proliferation. 
About 19 Wnt members are involved in the Wnt pathway. Upon synthesis, the Wntless 
receptors transfer the Wnt members to the plasma membrane138-142. In the absence of 
receptor ligand, the intracellular, wild type β-catenin molecule is bound to a membrane-
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anchored complex - a destruction complex that involves Axin, APC, GSK3α/β and CK1α/β 
proteins. The pathway is switched on when Wnt ligands bind to and facilitate the dimerization 
of the Frizzled (Fz) and LRP5/6 extracellular receptor complex. Dimerization of Fz-LPR 
receptors stimulates the binding of Dishevelled (Dsh) protein to the cytoplasmic tail of the Fz 
receptor that facilitates further interaction and phosphorylation of Axin and its bound kinases 
GSK3 and CK1 to LPR cytoplasmic tail. This inhibits β-catenin (CTNNB1) proteasome 
degradation and encourages saturation of the destruction complex 143-145146. Downstream 
targets to the β-catenin pathway involve genes responsible for metabolism (GS, CYP2E1 and 
CYP1A2), cell cycle regulation (CCND1; Cyclin D1 and Myc), cytoskeleton remodelling (CDH1 
and MMP7), some fibroblast growth factors (FGFs), epidermal growth factor receptor (EGFR) 
and chemokines (leukocyte cell-derived chemotaxin 2 (LECT2))147-165. Subcellular localisation 
of β-catenin in the healthy and diseased liver, including its role in liver regeneration and HCC, 
has been comprehensively reviewed 166.  
All the recent molecular characterisations attribute β-catenin mutations or activation in the 
WT Wnt/β-catenin pathway as major contributors to HCC malignancy. In the Hoshida et al 
classification59, the TGFβ-Wnt signalling pathway was enriched in the S1 subgroup of HCC 
patients. This group of patients was characterised by poor outcome and high AFP levels. 
Conversely, patients in the S3 subgroup, who showed good prognosis compared to other 
subgroups, were characterised by the activation mutation in exon 3 of the CTNNB1. Murine 
models of β-catenin activation mutations were not able to initiate HCC in isolation. However, 
in the presence of co-activated pathways like the Ras pathway, β-catenin is potentially 
involved in the development of HCC167-171. Any mutational or transcriptional changes in the 
other members of the β-catenin pathway are also associated with the incidence of human 
HCC. Inactivation of the β-catenin negative regulator GSK3β or upregulation of the Wnt 
receptor Frizzled7 (Fr7) were frequently seen in HCC 57, 172-174. Patients with T2DM have SNPs 
in WNT5b and TCF7L2 genes which might predispose HCC175. NF-κB and PI3K/AKT activation 
was linked to the upregulation of cytoplasmic or membranous β-catenin inducing 
experimental HCC in mice, highlighting the importance of the upregulation of the β-catenin 
irrespective to its subcellular localisation166.  
1.4.4.4 TGFβ pathway 
The TGFβ pathway comprises three ligands; TGFβ1, TGFβ2 and TGFβ3 and three receptors 
TGFβR1, TGFβR2 and TGFβR3. Binding of any TGFβ ligand to TGFβR3 induces its binding to the 
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TGFβR2 which then recruites TGFβR1 and the activation of the downstream pathway. Classical 
activation of the TGFβ pathway induces the phosphorylation of SMAD2 and SMAD3, 
facilitating their nuclear translocation and initiation of TGFβ-related gene expression176-182.    
The role of TGFβ in the process of tumourigenesis was highlighted in the high-throughput 
transcriptomic analysis, in which patients in the S1 group were characterised by activation of 
the TGFβ pathway in association with a poorer overall survival compared to the other 
groups59. In a clear contrast, TGFβ is typically considered as a tumour suppressor gene, with 
its dysfunction linked with the development HCC183. This discrepancy was highlighted further 
by a recent study from Chen et al. that was published in gastroenterology in 2018184. By RNA 
sequencing, TGFβ-related genes were deregulated in more than 25% of HCC patients versus 
controls. TGFβ protein expression was absent in normal hepatocytes, although evident in both 
tumour cells and HCC stroma. Unsupervised clustering of their data showed four distinct 
clusters, with descending activation of the TGFβ pathway from cluster A (highest) towards 
cluster D (lowest). Survival analysis revealed that inactivation of the TGFβ pathway (cluster D) 
was linked with shorter survival emphasising the importance of loss of TGFβ tumour 
suppressor function. The active TGFβ groups were enriched with other oncogenes, like MDM2, 
KRAS, IGF2 and KEAP1 in comparison to the other group. In particular, the active group was 
linked with hepatic fibrotic genes (collagens), cytokines (IL6 and IL6ST) together with growth 
factors like PDGF and EGF confirming the active role of TGFβ in the tumour microenvironment 
and the cross talk between different cell types in the process of carcinogenesis. On the other 
hand, loss of TGFβ activity was associated with the deficiency of other tumour suppressor 
genes like ATM, BRCA1 and FANCF184. This implies that treatment with TGFβ pathway 
inhibitors should be targeted for a certain subclass of HCC rather than being a global therapy.     
1.4.4.5 JAK/STAT pathway 
Activation of the JAK/STAT pathway is cytokine-dependent and is usually, but not always 
secondary to activation of other oncogenic pathways, including NF-κB and JNK pathways. Both 
NF-kB and JNK pathways primarily activate gene expression of different cytokines, including 
those activating the JAK/STAT pathway120, 137. Although activation of the JAK/STAT pathway in 
HCC is evident in the epithelial cells, the role of this pathway is more prominent in the non-
parenchymal cell types that foster an aggressive niche and immune suppressive environment. 
Receptor signalling via the JAK/STAT pathway includes 4 members, namely JAK1, JAK2, JAK3 
and TYK2. Activation of these receptors leads to phosphorylation and subsequent 
18 
 
homo/heterodimerisation of different STAT members (STAT1, STAT2, STAT3, STAT4 or STAT5), 
followed by their translocation to the nucleus. In the nucleus they activate a plethora of 
downstream target genes185.     
IL6 is a classical activator of the STAT3 pathway and is one of the well-known protumorigenic 
cytokines in the tumour microenvironment. The major non-parenchymal sources of IL6 are 
tumour associated macrophages (TAMs) and cancer associated fibroblasts (CAFs). Recently, a 
study from Michael Karin’s group186 has shown that the release of IL6 from TAMs induced the 
expression of CD44 in liver parenchymal cells, via the activation of STAT3. CD44 is a cell surface 
glycoprotein and its upregulation in the centrilobular areas lead to its dimerization with EGFR 
and expression of the P53 antagonist MDM2. The consequent loss of P53 function lead to the 
development of tumours in mice challenged with DEN186. In addition, IL6 is known to promote 
inflammation-induced HCC, as well as neo-angiogenesis in established tumours187. Activation 
of STAT3 by IL6 modulates the tumour microenvironment by increasing the infiltration of 
inflammatory cells to the tumour area, while reducing the maturation of dendritic cells and 
inducing the proliferation of the immune suppressive TH17 T-cell subtype188-191. Activation of 
this pathway also increases the expression of cell survival and cell cycle progression genes 
favouring more proliferative niche within the tumour area192-196. 
Other interleukins activating the JAK/STAT pathway can play a role in inflammation-associated 
cancers. The NF-κB related upregulation and secretion of IL23 from myeloid derived 
suppressor cells activates the JAK/STAT pathway together with Wnt pathway, which in turn 
promote an increase in the proliferation index of colorectal cancer cells197. IL10 supresses the 
anti-tumour T-cell activity in premalignant and malignant conditions, via activation of the 
IL10/IL22 receptor family198-203. 
1.4.4.6 mTOR pathway 
The mTOR pathway is activated in a sub-group of HCCs and is usually linked with metabolic 
processes204, 205. This pathway includes two distinct effector complexes, namely mTOR 
complex1 (mTORC1) and mTOR complex2 (mTORC2). mTORC1 includes mTOR, mLST8, 
DEPTOR, RAPTOR and PRAS40, while mTORC2 is composed of mTOR, mLST8, DEPTOR, PROTOR 
and RICTOR. Activation of mTORC1 is mediated via different growth factors, amino acids, 
nutrients and cytokines, which induce activation of the MAPK pathway, leading to 
phosphorylation and inactivation of the mTOR inhibitors TSC1 and TSC2. Although mTORC2 is 
not sensitive to nutrients, it is very sensitive to growth factors that control actin cytoskeleton 
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and cell metabolism206. Activation of mTOR pathway regulates different physiological and 
pathological pathways including ageing, autophagy, metabolism and cell growth207, 208. The 
main determinant of activation of mTORC1 is the over-nutrition that induce metabolism, DE 
NOVO lipogenesis and protein synthesis, while at the same time inhibit autophagy. Activation 
of the mTORC2 pathways is independent on nutrient status but dependent on other growth 
factors like IGF207, 208.  
The mTOR pathway is activated in response to the increased lipogenesis in steatotic liver 
compared to healthy controls, and the pathway is further activated in association with liver 
malignancy. This mechanism is particularily essential for “feeding” the tumour cells as a 
nutrients’ supplier209. It also regulates another process which is key for cancer progression; 
autophagy. In the process of cancer initiation, autophagy plays a protective role by eliminating 
cell debris and damaged cells; however, after the development of tumour, autophagy increase 
tumour cell survival and increase tumour resistance to many anticancer therapies210, 211.  In 
human HCC, more than 50% of patients show upregulation of one or more from the mTOR 
family, and the prognosis of this group of patients is unfavourable and characterised by poor 
survival212, 213. In contrast, the inhibition of the mTOR pathway may be protective.  Metformin 
treatment in diabetic patients reportedly halves the incidence of HCC development compared 
to the diabetic patients receiving non-metformin treatments. The protective effects of 
Metformin therapy is proposed to be via activation of the AMPK pathway, a known inhibitor 
of the mTOR pathway214, 215.  
1.4.5 The role of the liver premalignant/microenvironment in the development of HCC  
The development of HCC is usually preceded by chronic liver diseases which alter the cellular 
landscape in the liver microenvironment and favour certain conditions that permit the 
malignant transformation of hepatocytes or cancer stem cells216. Livers of patients with HCV 
infection are characterised by more hepatocyte damage and infiltration of inflammatory cells 
that contribute to viral clearance, but also to the development of pro-inflammatory, pro-
malignant environment. On the other hand, the double stranded HBV can integrate into the 
human genome and if this occurs in certain areas, the integration can activate oncogenes or 
supress important genes responsible for cellular homeostasis, leading to malignant 
transformation. This is predisposed by infiltration of other stromal cells and cycles of liver 
regeneration that help tumour development. The role of the microenvironment in NASH-
driven HCC is still poorly investigated, but reports link the high oxidative stress status and 
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accumulation of lipids within the hepatocytes as a trigger for their transformation into 
malignant cells26. 
Regardless of the cause of the chronic liver disease, the liver has its own defence mechanism 
against any invading/foreign bodies. In response to chronic liver disease, certain type of cells 
like hepatic stellate cells or fibroblasts, together with inflammatory cells such as macrophages 
and leukocytes, produce or alter the composition of the component proteins in the liver 
microenvironment. The component proteins in the liver microenvironment are termed the 
extracellular matrix (ECM) proteins. This remodelling process of the ECM is associated with 
the development of new blood vessels (neo-angiogenesis) and fibrosis. Although being a 
physiological process for normal wound healing, persistent injury that occurs during chronic 
disease can lead to the establishment of unresolved fibrosis that progresses to cirrhosis. 
Cirrhosis is characterised not just by permanent fibrosis, but also distortion of the architecture 
of the liver by nodules of regenerating hepatocytes, within which malignant transformation 
can occur. Hence, it is important to understand the role of the tumour premalignant niche,  
including the contribution of factors that elicit the growth of a particular clone of cells to form 
the malignant tumour216. 
The tumour premalignant microenvironment is composed of ECM, within which there are 
different types of non-parenchymal cells, each with their own profile of secreted cytokines or 
other factors. This environment can promote the growth of transdifferentiated hepatocytes, 
as well as their invasion and migration through the disrupted basement membrane217, 218.  
1.4.5.1 Cellular components of tumour microenvironment  
The role of the immune cells in the development and progression of HCC is a hot topic, in part 
owing to the breakthrough of immune check-point inhibitors as therapies for other  
 malignancies219. It is now widely accepted that one of the key the cells responsible for anti-
tumour immunity is the CD8 T-cell, which plays a critical role in immune surveillance. Active 
CD8 T-cells recognise damaged or transformed hepatocytes and help eliminate them. Notably, 
exhausted non-proliferating CD8 T-cells are not able to perform this function properly. T-cell 
exhaustion is initiated via binding of inhibitory receptors on the T-cells, such as PD1 and TIM3, 
to ligands on immune suppressor cells – a so called ‘check-point’ to prevent the immune 
system causing tissue damage as a result of continuing T cell activity.  In persistent liver injury, 




















Figure 1.4: The role of the the premalignant/tumour microenvironment in the development 
and progression of HCC; from Hernandez-Gea et al216 with permission: The cascade of the 
development of abnormal microenvironment in the liver starts from the activation of 
Quiescent stellate cells to hepatic active stellate cells which secrete ECM proteins. This 
provides a mechanical stiffness which is linked to the development of HCC. After the primary 
tumour is formed, infiltration of different immune components and proliferation of 
endothelial cells help the process of tumour progression and metastasis. 
 
hepatocytes or tumour cells evade host immunity. Tumour cells can also express the ligands 
which bind the inhibitory receptors on T cells, such as PD-L1 , similarly altering the tumour 
microenvironment in a way which leads to tumour progression219. The class of anti-cancer 
drugs called ‘Check-point inhibitors’ disrupt this ‘switch off’ mechanism, potentially 
unleashing an anti-tumour immune response. 
22 
 
Other types of T-cells which are frequently found within the tumour microenvironment are 
the CD4 T-cells and Treg cells. While CD8 T cells promote an active immune response, Treg 
cells are immunosuppressive and dampen an immune response. The presence of Treg cells in 
particular is linked with poorer patient prognosis, attributed to roles in immune-evasion of 
the tumour cells220. The number of Treg cells is associated with HCC stage and a ratio of higher 
Treg to CD8 T-cell number can predict a worse patient outcome 221. Treg cells secrete cytokines 
that dampen the host immunity, encouraging an immune-null environment that facilitates 
tumour growth. Activation and infiltration of Treg cells in tumour areas is partly mediated by 
myeloid-derived suppressor cells (MDSC) and macrophages, that secrete chemotactic 
cytokines that specifically attract Treg cells220. 
Macrophages, or ‘big eaters’ in the Greek language from which the term comes, are large cells 
recruited to sites of injury. They detect and phagocytose pathogens or debris, for purposes of 
elimination, but also presentation of antigens from the source of potential harm to T cells. 
They can also release cytokines that activate other immune cells. Macrophages can be 
phenotypically diverse, with different lineage or polarisation – most commonly termed 
macrophage 1 (M1) or macrophage 2 (M2) - according to the disease state. M1 macrophages 
are an inflammatory subset of macrophages that secrete a wide spectrum of cytokines and 
growth factors with pro-inflammatory functions within the diseased liver. M2 macrophages, 
on the other hand, adopt a restorative phenotype, with anti-inflammatory and tissue 
regenerative functions222. In malignant conditions, the interaction between the tumour cells 
and the macrophages favours the development of M2-polarised macrophage subset that is 
known as tumour activated macrophage (TAM)223. TAMs have immune supressing roles in the 
tumour microenvironment by cross-talking with other immune cells and increasing the 
infiltration of immune suppressive cells224. TAMs also release other angiogenic and tumour 
cell proliferating factors increasing the proliferation but also the migration and invasion of the 
tumour cells. In human HCC, the number of TAM has been reported an unfavourable 
prognostic marker associated with disease progression225.  
Although the role of immune system is pivotal in the development and the progression of HCC, 
other non-parenchymal cells are still fundamentally important for supporting the tumour 
microenvironment. As mentioned the TGFβ pathway plays a role in tumour development. The 
cellular sources of TGFβ in the tumour niche are the tumour cells, but also activated stromal 
cells known as cancer associated fibroblasts (CAF) and macrophages which have tumour 
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promoting functions within the tumour microenvironment 226. CAFs are the major source of 
collagen that is responsible for increasing tissue stiffness, which is also associated with a more 
aggressive tumour microenvironment. Compared to normal fibroblasts, CAFs secrete a 
different repertoire of chemokines, like CXCL12 and SDF-1 that promote tumour metastasis 
and chemoresistance227. CAFs can also secrete VEGF and HGF, respectively inducing neo-
angiogenesis within the tumour microenvironment and supporting growth and proliferation 
of the tumour cells228. 
By interrogating changes in the immune profile in HCC patients at the transcriptomics level, 
the Llovet group has identified a group of HCC patients characterised by the enrichment of 
immune genes, immune signatures for T-cells, macrophages, tertiary lymphoid structure (TLS), 
PD-1 and immune metagene-related pathways229. This “immune subclass” was defined by the 
upregulation of 108 immune-related genes, with strong enrichment of the TGFβ, JAK/STAT 
signalling pathways. Integration of this subclass with the previously published HCC 
transcriptomic data showed a strong enrichment with the previously described S1 subclass 
(Wnt/TGFβ activation pathway), while immunohistochemistry (IHC) staining confirmed 
significant associations with PD-1 and PD-L1 protein expression. Notably, within the immune 
subclass two distinct groups were further defined. The first group, comprising 33% of cases 
and termed the “exhausted immune group”, was characterised by active stroma, T-cell 
exhaustion, TGFβ expression and an M2 macrophage signature. The other group was termed 
the ‘active immune group’ as it was associated with an “active immune response” 
characterised by T-cell activation and IFN expression. These latter features have previously 
been reported in other cancer types as predictive of a response to treatment with a checkpoint 
inhibitor called pembrolizumab. Patients in the HCC ‘active immune response group’ had a 
lower tumour recurrence after resection and a trend towards better survival. This subclass 
was an independently associated with better overall survival (OR=0.58, p=0.04), reflecting the 




Figure 1.5: The integration of different component/pathways of the microenvironment to 
construct immune response in HCC patients; from Sia et al229 with permission: less than 
quarter of HCCs were characterised by activation of certain immune-related genes. This 
Immune class was characterised by activation of the stroma as well as activation of TGFβ 
pathway. Within this immune class, one third of HCCs had exhausted T cell gene signature in 
association with poor patient prognosis. The rest of tumours showed active CD8 cytotoxic T 
cell and favourable outcome after resection confirming the active anti-tumour immunity.   
 
1.4.5.2 Extracellular matrix proteins and their regulators  
1.4.5.2.1 Heparan sulfate proteoglycans (HSPGs)  
The ECM is a complex network of secreted and post-transcriptionally modified proteins that 
act as a storage platform for growth factors and cytokines. ECM proteins also act as co-
receptors facilitating the ligation of bound growth factors to their receptors on the cell 
surface. Modifiers to the structure and/or function of ECM proteins play an important role in 
changing the structure of these proteins, but also in the liberation and availability of growth 
factors to their binding sites. One important category of the ECM proteins are the heparan 
sulfate proteoglycans (HSPGs), which are composed of heparan sulfate (HS) chains covalently 
bound to a core protein230. The importance of HSPGs derives from their versatile functions 
within the tissue microenvironment. With more than a million HSPG available binding sites, 
groups of proteins can bind, forming the so called ‘Heparan sulfate interactome’231, 232. 
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Heparan sulfate binding proteins (HSBP) include enothelial growth factors (VEGFs), Wnt 
ligands, sonic hedgehog signalling and ligands activating the TGFβ pathway233-236. FGF, HGF, 
RAGE and APP family of protein undergo HS-induced oligomerisation facilitating binding to 
their ligands/receptors237-245. HSPGs may also act as scaffold proteins that block or favour – 
dependent on their post translational modifications - the most suitable configuration for 
associated HSBPs to bind their receptors246.  
Members of the HSPGs family include Syndicans (SDC1-SDC4), Glypicans (GPC1-GPC6), 
perlecan, agrin and collagen XVIII, ECM proteins 247-252. The HS component is a hetero-
polysaccharide chain comprised of heparin, hyaluronic acid, chondroitin sulfate, keratan 
sulfate and dermatan sulfate253-255. Generally, HS chains include repeated di-saccharide units 
of glucuronic acid or its epimer L-iduronic acid, linked in the 1-4 position with unsubstituted, 
N-sulfated or N-acetylated glucosamine. Synthesis of the HS chain is a multi-step process and 
starts with chain initiation where a linker arm is introduced between the core protein and the 
glucose amino glycans (GAGs). Subsequently, glucosamine-transfer and exostosin 
glycosyltransferases enzymes start the second step; chain elongation or polymerisation. 
Further enzyme-directed post transcriptional modifications on the HS chains include 2O-
sulfation on uronic acid moieties or 3O and 6O-sulfation on the glucosamine255. This process 
is not random, but rather specific to the type of cell, the physiological function of the parent 
HSPG and can be influenced by pathological processes within the host organ256-259. Three 
groups of post translational modifying enzymes are involved in the post-polymerisation step 
in the HS synthesis, including (1) N-deacetylase/N-sulfotransferases (NDST1-4) which replace 
the acetyl groups with sulfate groups; (2) epimerases which convert D-glucuronic acid into its 
epimer L-iduronic acid, which has a more flexible ring confirmation; and (3) sulfotransferases, 
which direct O-sulfation of the substituted sulfate groups at the 2,3 and 6-O positions260-266.  
The functional importance of the HSPGs extends beyond the physiological status to exert a 
pivotal role in liver pathology. At first glance, the pattern of HSPGs within the liver 
microenvironment is significantly different between the physiological and pathological state. 
This difference implicates a role of HSPGs in many liver diseases. In viral hepatitis, the viral 
particles invade the host hepatocytes for replication, with entry of both HBV and HCV 
mediated by different kinds of HSPG. In human fibrotic and cirrhotic conditions, the quantity 
and distribution of different HSPGs change in association with the severity and the stage of 
the disease, particularly on the liver non-parenchymal cells. In the physiological state, SDC2, 
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SDC3 and perlican are expressed in the resting myofibroblasts, smooth muscle cells, 
endothelial cells in the portal blood vessels, with SCD1 and perlican expressed in the 
endothelial cells of the sinusoidal wall. In chronic liver diseases, the expression of these HSPGs 
is upregulated and their level of sulfation is altered. In viral hepatitis, SDC1 is unusually 
expressed in the non-sinusoidal hepatocyte interface267, in line with its mechanistic role 
promoting viral invasion of hepatocytes268, 269. As such, SDC-1 has been proposed as a 
candidate therapeutic target for viral hepatitis. 
The role of HSPGs in the tumour microenvironment has also been described in relation to 
disease staging and prognosis267. GPC3 , for example, is absent or scanty in normal or diseased 
liver, but markedly upregulation in a subset of HCCs  and has been adopted as a tissue 
diagnostic marker in HCC270. GPC3 level is upregulated in HCC diagnostic biopsies and 
resections, but not in control nor in chronically diseased livers. GPC3 protein is only detected 
in HCC, while it was absent in the adjacent non-tumour counterparts. GPC3 is usually present 
in the tumour cell membrane, and it can be occasionally detected in the tumour cell 
cytoplasm271 Due to tumour heterogeneity, GPC3 is included in an HCC diagnostic panel 
including GS, Heat shock protein 70 and CD34272. In vitro studies have shown that upregulation 
of GPC3 in HCC cell lines enables Wnt ligands such as Wnt3a to bind to the frizzled receptor, 
activating the Wnt3a/β-catenin pathway. This oncogenic GPC3-mediated activation of the β-
catenin pathway was notably regulated by an important post translational modifier of HSPG 
structure, namely Sulfatase-2 (SULF2)273. 
1.4.5.2.2 Sulfatase 2(SULF2) physiological and pathological roles   
SULF2 belongs to a larger group of 17 sulfatase enzymes274, 275. SULF2, rather than the other 
sulfatases, is an extracellular post-translational modifiers of HSPGs. SULF2 transcript was 
identified as sonic hedgehog response genes involved in the activation of Wnt signalling276, 
277. Subsequent functional analyses at the protein level revealed a role in the selective 
modification (desulfation) at the 6O position of HSPGs – a position known to be associated 
with regulation of ECM  binding of  multiple cytokines and growth factors, including FGFs 278-
281, HGF 282, fibronectin 283, PDGF 284 and VEGF 285. Subsequent to SULF2-mediated removal of 
the 6O sulfate, bound factors can be liberated from their storage sites to bind and activate 
their target pathways, regulating cell survival, differentiation, ECM remodelling and 
angiogenesis. Hence any upregulation or change in SULF2 function or expression level can, in 
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theory, significantly alter the function and composition of the tissue microenvironment - 
making it an interesting protein to study.  
1.4.5.2.2.1. Structure of SULF2 
The structure and maturation of SULF2 is illustrated in (Figure 1.6). Immature SULF2 is 
composed of 870 amino acids comprising 4 unique domains, namely the signal peptide, 
enzymatic, hydrophilic and sulfatase domains286. The similarity of amino acid sequences 
between mouse and human SULF2 exceeds 90%, highlighting a high conservation amongst 
different species286. Much of the protein structure is also common to both SULF1 and SULF2 
proteins, with the most notable differences being in the heparin binding motifs in the 
hydrophilic domain287, 288, perhaps suggesting different target specificity.  
Figure 1.6 SULF2 structure and activation, from Rosen and Lemjabbar 289 with modification 
Immature SULF2 undergoes a two-step activation; loss of signal peptide and cleavage of the 
SULF2 pro-protein into two peptides linked via a di-sulphide bond. Abbreviations: C; C-
terminal, N; N-terminal, S-S; disulphide bond, kDa; Kilo Dalton 
The hydrophilic domain is responsible for the membrane anchorage process as well as the 
interaction of the enzyme with its substrate HSPGs288, 290, 291.  The sulfatase cleavage in the 
target HSPG is mediated by the oxidation of a cysteine residue into a Cα-formylglycine276, 286.  
The SULF2 pre-proprotein has its signal peptide removed within the endoplasmic reticulum 
(ER) (Figure 1.6). A Furin-type proteinase then acts on the hypdrophilic domain of the 
proprotein, cleaving it into two 75 KD and 50 KD288, 292 isoforms. The mature SULF2 is created 
by the binding of these two fragments with a disulphide bond. The resulting active protein has 
membrane-anchored and secreted forms286, 288, 291. Although SULF2 is responsible for the post 
transcriptional modification of the HSPGs, this enzyme is also vulnerable to post-translational 
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modification. The N-terminal region of SULF2 contains more than 10 glycosylation sites, 
although the exact role of glycosylation and whether this affects the enzyme activity or 
membrane binding is unclear. Glycosylation of SULF1 is known to affects its biological 
functions in terms of secretion, activity and membrane binding286, 293.  
1.4.5.2.2.2. The function of SULF2 
Early evidence of the role of SULFs in normal physiological processes came from knock-out 
(KO) mice. SULF2-/- mice had poorer survival, decreased weight gain and developed lung 
abnormailites compared to their wild type littermates294. The mortality of SULF1-/- SULF2-/- 
double mutant mice was nearly 50%, although the mice were able to give birth to normal 
embryos with smaller adult organs295. The double mutant mice had swallowing difficulties 
attributed to weak oesophageal muscles, implicating the importance of both the enzymes in 
muscle cell homeostasis296. The phenotype was similar to that seen in Hs2st, EphrinB1 and 
BMP deficient mice 295. 
The process of desulfation, in which SULF2 eliminates the sulfate group specifically from the 
6O position of the wide range of HSPGs291, is summarised in (Figure 1.7). Briefly, the 
hydrophilic domain of SULF2 binds to its target HS chain, while the sulfatase catalytic domain 
binds to the last 6O-sulfate group in the chain. The process desulfates the entire chain at the 
6O position, before the enzyme dissociates from the desulfated chain, in order to target other 


















A tool to assess the sulfatase activity of the SULFs was developed by Morimoto-Tomita et al286. 
In brief, 4-methylumbelliferyl sulfate (4-MUS) is used as a sulfatase substrate, with 
quantification of intensity of a released fluorescent moiety being proportional to sulfatase 
activity286. The SULF2-mediated desulfation of HSPGs chains in the liver reportedly increases 
the release of endotheial (VEGF, EGF, PDGF), fibrotic (FGF1, FGF2, CXCL12, FN1, SOD), 
hepatocellular (HGF) and inflammatory (IL8, CCL21, TNFα, CSF1, IL7, IFNγ) factors from their 
binding sites within the microenvironment to activate their downstream targets296, 298-300.   
1.4.5.2.2.3. The tumour promoting role of SULF2 
Alongside the important physiological role of SULF2, it is also implicated in pathological 
processes, including malignancy. A malignant proangiogenic role for SULF2 was reported in 
SULF2-/- mice that developed less HCC than their wild type littermates after exposure to the 
carcinogen DEN. Further investigation revealed that SULF2 induced neo-angiogenesis via a 
TGFβ/Periostin (POSTN) dependant mechanism, increasing liver tumour size, number and 
distant metastasis into the lungs301. SULF2 – active at physiologically neutral pH only - initiated 
angiogenesis, with heparinise taking over cleavage of HS chains in more hypoxic and acidic 
conditions in the tumour microenvironment 302, 303. 
Microarray data exploring gene expression in HCC resections previously reported that SULF2 
was upregulated in about 57% of HCC patients304. An elevated level of SULF2 was associated 
with early disease recurrence in these patients. The researchers also reported that SULF2 
stimulated FGF2/GPC3 upregulation and activation in HCC cell lines, as well as in a mouse 
xenograft model. Additionally, SULF2 induced Akt/ERK oncogenic pathways that promoted 
cell growth and migration via phosphorylation of the Akt substrate GSK3β, an established anti-
apoptotic factor 273, 304. Further support for a role regulating apoptosis comes from knockdown 
of SULF2 in HCC cells showing upregulated BAD, a pro-apoptotic molecule that forms 
heterodimer with BCL-2 and BCL-xL survival factors, and hence induces apoptosis 305.  Finally, 
SULF2 has also been found to be a transcriptional target of P53 in different types of cancer, as 
well as in HCC cell lines 306, 307.  
1.5 Experimental mouse models for HCC- a focus on diet-induced HCC 
The use of an experimental mouse model provides a powerful tool for the study of tumour 
biology and for testing new therapeutic targets in preclinical studies in an in vivo context. The 
use of mouse models in cancer research, and particularly in HCC, is context dependent and 
needs careful study design before running any model. HCC usually arises in the background of 
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chronic liver disease, and consequently, inducing these tumour-inducing conditions in mice 
will better reflect the human disease. However, testing new therapeutic treatments doesn’t 
require these conditions especially if the duration of the study is relatively short. Mouse 
models used in HCC can be categorised in four different categories; genetically engineered 
mice (GEM), mice with HCC induced with genotoxic drugs, mice with HCC induced by 
implementation methods and Diet induced HCC.       
1.5.1. Genetically engineered mice (GEM) 
As mutations in certain oncogenes and tumour suppressor genes are actively responsible for 
the development of human HCC, mice with CRISPR/CAS9-induced mutations are commonly 
used in cancer research. This approach is applied if the research group is interested in the 
effect of a certain mutation(s) rather than looking at other aspects like tumour stroma 
interaction or the role of the tumour microenvironment. Mice with activation mutations in 
the oncogene cmyc alone are commonly used in HCC studies308, as are mice with cmyc 
mutations in combination with β-catenin309 or E2F1 overexpression mutations310. 
Combination of more than one mutation decreases the latency period for tumour 
development311. Specific deletion of p53 was sufficient to induce experimental HCC after 56 
weeks312, while deletion of both p53 and pten from mice hepatocytes successfully developed 
visible HCC after 4 month from this manipulation313. Other techniques to induce targeted 
mutations in hepatocytes include the hydrodynamic injection of plasmids in mouse tail vein, 
which induces the permeability of the hepatocytes to the plasmids with high transgene 
expression311. One emerging technique used to produce GEM is the Cre-Lox recombination 
system. Originally developed to manipulate mammalian cell lines genes314, the Cre-Lox system 
is now widely used to target certain genes in cell-specific manner315. This is of particular 
importance if targeting a specific gene globally is lethal. The Cre-recombinase enzyme targets  
LoxP flanked specific chromosomal DNA sequences to control gene expression316. Cre 
recombinase binds 13bp from the beginning and the end of the LoxP site forming a dimer that 
binds to another LoxP site forming a tetramer. The Cre-recombinase enzyme cuts at the LoxP 
sites, which are then joined together with a DNA ligase, leading to either gene inversion (in 
case of two LoxP-flanked sequences in the same chromosomal arm) or gene deletion (in case 
of repeat LoxP-flanked sequences). Gene knock-in (KI) can be achieved by adding floxed 
cassette sequences that compete with the LoxP floxed-cut sequences316.     
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1.5.2 HCC-inducing genotoxic chemicals 
This is probably the most common way of inducing HCC in genetically wild-type mice, thus 
avoiding the use of GEM that have higher costs. The idea behind using the genotoxic chemicals 
is to induce changes in the DNA that eventually lead to more damage, chromosomal 
aberrations and HCC317. Factors affecting the development of HCC using this approach are the 
age and sex of the animal as well as the type of carcinogen used. Diethyl nitrosamine (DEN) is 
a DNA alkylating agent that increases the level of free radicals and oxidative stress in the liver 
microenvironment leading to HCC318. In younger mice (less than 2 weeks old), DEN IP injection 
can alone induce liver carcinogenesis, while in older mice, a second hit of either liver enzyme 
accelerators like phenobarbital or a HCC-inducing diet for tumours to form319. Other less 
commonly used liver carcinogens include the RAS mutation inducer 9,10-dimethyl-1,2-
benzanthracene (DMBA)320. 
1.5.3 HCC-inducing implanted pro-malignant or malignant hepatocytes or progenitor cells 
The idea behind this technique is to implant tumour cell lines from human or mouse origin 
into immunocompromised mice to study the impact of new therapeutic targets on the growth 
or the metastasis of the implanted tumour321. In orthotopic models, tumour cells are 
implanted directly into the liver of the mice to see the interaction of liver stroma to the newly 
existing tumour, while heterotopic models inject tumour cells subcutaneously in mice and 
monitor the development of the tumour216. The mice used have a compromised innate 
immune system to eliminate the possibility of tumour rejection by the immune system, and 
NOD-SCID mice322 and CD1 deficient nude mice are more likely to be used due to lack of T and 
B cells. To knock out the effect of natural killer cells (NK) cells together with other immune cell 
subsets, the NOD/SCID-IL2g-/- is now frequently used in cancer research323.  
1.5.4 Diet-induced NAFLD/NASH and NASH/HCC 
Many attempts have been made to develop a murine model that recapitulates the human 
NAFLD and NASH-driven HCC. As the human disease includes symptoms of the metabolic 
syndrome - including hyperglycaemia, hyperlipidaemia, obesity, insulin resistance - together 
with liver inflammation, a physiologically relevant model should also ideally have these 
deregulated features. Models of liver inflammation includes the major urinary protein (MUP)-
urokinase-type plasminogen activator (uPA) transgenic mice, that develop severe 
inflammation, ballooned hepatocytes and HCC with age324. Upregulation of uPA induces the 
production of ROS as a result of the elevation of oxidative stress; a mechanism driven mainly 
by the activation of the NF-κB pathway. The mdr-/- model is also a classical model of 
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inflammation-induced HCC where phospholipids are trapped in the hepatocytes leading to 
cholastatic inflammation, portal hypertension and bile duct dysplasia with subsequent 
malignancy325. Upregulation of tnfα in the ductular epithelia and in some inflammatory cells 
associate with translocation of the RelA (p65) subunit of the NF-κB from the hepatocytes 
cytoplasm into the nucleus, leading to activation of the whole survival and oncogenic 
pathway120. 
Diet-induced NAFLD and NASH models typically use diets with high levels of fats and trans-fats 
with/without sugar intake in drinking water, or diets deficient in one or more important amino 
acids. Animal model studies generally use the C57BL6 wild type mouse strain. In the 
methionine-deficient and choline-deficient (MCD) diet, mice liver develops severe hepatic 
inflammation with infiltration of different subset of immune cells into the liver leading to 
severe fibrosis and steatohepatitis at 8 weeks from diet intake326. The MCD diet-challenged 
mice, however, don’t develop any signs of insulin resistance or obesity within the time course 
of the study. In fact they have signficant weight loss (>40%)326. The other frequently used 
dietary model is the high fat diet (HFD) that succeeds in producing features of metabolic 
syndrome - like obesity, severe steatosis, impaired glucose tolerance and insulin resistance327. 
Of note, the degree of liver injury is less than observed in the MCD diet model and the 
development of HCC using the high fat diet alone or with sugar water in C57BL/6 mice is 
questioned328. On the other hand, in the HFD-fed B6/129 isogenic mouse model (by crossing 
the C57BL/6 with the 129S1/SvImJ mice), mice do develop insulin resistance with some 
histological features of steatohepatitis, including hepatocellular ballooning and Mallory-Denk 
bodies. These features can be accompanied by the development of predysplastic regenerative 
nodules which progress to HCC after a year from the diet-intake329.  
In 2008, Tetri et al.330 fed C57BL/6 mice with a diet that resembles the fat composition in the 
fast food market. They called this diet the American life style (ALIOS) diet and it included 
partially saturated vegetable oil (this fat is composed of a mixture of saturated, mono and 
polyunsaturated fats) with corn syrup in the drinking water. In their experimental settings, the 
mice developed weight gain, higher plasma triglycerides, higher serum liver enzymes, and 
steatosis. On the other hand, mice failed to show any fibrotic changes, portal inflammation or 
any hepatocyte ballooning in the course of the study (16 weeks)330. In order to see whether 
or not the ALIOS diet can induce liver tumourigenesis with time, Dowman et al331 fed C57BL6 
x 129 mice with the ALIOS diet and monitored the development of tumours with other 
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histopatholigical features of NASH at two time points; 6 month and 12 month. ALIOS-fed mice 
became obese and developed glucose intolerance at 6 month but not at 12 month compared 
to age-matched controls. ALIOS fed mice had higher triglycerides levels and higher liver 
enzyme levels at 12 months compared to their controls. Histologically, ALIOS fed mice had 
more steatosis, fibrosis and higher NAS score compared to the mice on normal chow. These 
mice did not develop hepatocellular ballooning at any time point. They did, however, develop 
small tumours (9 lesions in 6 mice out of 10), while in the control mice, no detectable 
malignant nodules were captured331.  
In summary, the use of a particular type of murine models is subjected to the purpose of the 
study, with no model being able to reflect all the features of the human disease. Manipulating 
the existing diets/mice strains to reach a more universal mouse model that recapitulate all the 
human disease histological, biochemical and transcriptomic spectra may help to understand 
the biology of this disease and evaluate new therapies. 
1.6 Project objectives 
1.6.1 Hypothesis: 
The overarching hypotheses being explored: Host and local factors influence the liver 
microenvironment, promoting the development and progression of NAFLD-HCC. Non-
parenchymal cells in the liver premalignant conditions are “gatekeepers” for expansion of 
abnormal parenchymal clones preceding the development of HCC. Capture of novel 
therapeutic targets for HCC management is achieved using unsupervised clustering of murine 
and human RNA-sequencing transcriptome data. After the establishment of the HCC, the 
tumour cells establish bidirectional relation with tumour infiltrating stromal cells to maintain 
their proliferation and therapy resistance.  
SULF2 is a key modifier of the tumour microenvironment and candidate therapeutic target. 
Initial immunohistochemistry studies exploring SULF2 at the protein rather than mRNA level 
in HCC in the Reeves lab suggested expression in tumour cells, but also non-parenchymal cells. 
Focused on this critical modifier of hepatic HSPGs, the primary goal of this project was to 
further characterise SULF2, including its cellular origin in non-tumour and tumour liver tissues 
and its functional impact on the tumour microenvironment.  
NAFLD-HCC is an emerging global threat and has been the primary HCC aetiology studied in 
this thesis. In addition to studies in formalin fixed human tissues, high through-put RNA 
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sequencing data from tissues generated from an in vivo mouse model of a well characterised 
dietary induced chronic liver disease of NAFLD progressing to HCC (Reeves, Oakley) was 
analysed with bioinformatics tools, alongside publically available HCC transcriptomic data.  In-
vitro work included models to explore cross-talk between hepatic cells. In combination, these 
studies facilitated the characterisation of the contributions of SULF2 in HCC, but also provided 
the resource to explore other key elements of the tumour microenvironment in NAFLD-HCC. 
1.6.2 Specific Aims 
1.6.2.1. To characterise SULF2 within the in vivo tumour microenvironment and explore 
associations with disease stage and patient outcome. 
1.6.2.2 To define the functional impact of SULF2 in vitro, by developing models to assess the 
contribution of different cell types expression or secreted isoforms on the phenotypic 
behavior of HCC cells.  
1.6.2.3 To explore the impact of SULF different oncogenic, cell survival and chemoresistance 
signaling pathways in HCC. 
1.6.2.4 To explore the role of SULF2 in the progression of non-alcoholic fatty liver disease 
(NAFLD) and NAFLD-HCC in a relevant animal model. 
1.6.2.5 To explore additional features promoting the development and progression of diet-
induced HCC in a biologically relevant model recapitulating human disease. 
1.6.2.6 Combine histological data with transcriptomic data to identify SULF2 or novel 








Chapter 2: Materials and methods 
2.1 General Laboratory Practice  
Established experiments in the Institute of Cellular Medicine (ICM) and in the Northern 
Institute for Cancer Research (NICR) followed Newcastle Universities set standards which act 
in accordance with the Control of Substances hazardous to Health Regulations 2002 (COSHH) 
and Biological COSHH (BioCOSHH). 
2.2 Patients 
Human HCC biopsies: This study was classified as retrospective case series involving those with 
sufficient residual tissue for research purposes. The initial pilot study and subsequent larger 
series of cases were approved by and the Newcastle upon Tyne NHS Foundation Trust 
Research and Development department and the Newcastle and North Tyneside Local 
Research Ethics Committee (REC)(Reference 2004/012) and (Reference 04/Q0905/168 and 
10/H0906/41) respectively. Anonymised code-linked datasets were adopted to maintain 
patients’ confidentiality and proper data protection. Preliminary investigation of SULF2 tissue 
protein expression was performed in formalin fixed paraffin embedded tissues (FFPE) from 
HCC diagnostic biopsies collected in the period between 2000 and 2002 of 6 patients. The 
study was then expanded to include 54 more biopsies in the period between 2003 and 2010 
from patients who consented to the availability of their tissues for research use. Exclusion 
criteria included patients with histologically-proven benign tissue or patients with other types 
of liver cancer i.e. cholangiocarcinoma. Patient information was collected from the 
histopathology reports together with patient’s records and radiology data. This data included 
etiology of the underlying liver disease, age, gender, BMI, presence of T2DM, presence of 
cirrhosis, tumour size (in cm), tumour number, tumour grade, presence of portal vein 
thrombosis (PVT), Edmondson-Steiner tumour grade55, tumour node metastasis (TNM) stage, 
Albumin level (g/l), Bilirubin level (µmol/l), AFP, presence of Ascites, Child-pugh score, 
combined Barcelona Clinic for Liver Cancer (BCLC) stages332, patients survival from the time of 
biopsy and the administered treatments (orthotopic liver transplantation (OLTx), resection, 
ablation, trans-arterial chemoembolization (TACE), medication and best supportive care 
(PSC))  
Human HCC biopsies from sorafenib treated patients: Biopsies from small cohort of HCC patients 
who received sorafenib treatment were also stained for SULF2. Biopsies were collected from 
patients at the time of diagnosis before the start of the treatment. In this cohort, patients 
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were classified as sorafenib responders, who had a stable disease on imaging for at least 6 
months, or sorafenib non-responders where treatment was discontinued due to poor 
tolerance or if the disease progressed within three months. 
2.3 Immunohistochemistry 
2.3.1 For the SULF2 study:  
In order to investigate the SULF2 and SULF2-regulated proteins in FFPE diagnostic biopsy 
tissue sections containing both HCC and non-neoplastic liver parenchyma, IHC was performed 
for SULF2, α-smooth muscle actin (αSMA), GPC3, β-Catenin, RelA-P-ser536 and CD44. Slides 
were scanned and assessed digitally with Aperio Imagescope Software. All cases were stained 
for SULF2 and GPC3, while representative cases were stained for αSMA and β-Catenin. 21 
cases previously stained and scored for SULF2 were then stained for RelA-P-ser536 and CD44. 








SULF2 MCA5692GA AbD Serotec Mouse mAb Triology system Cell 
Marque,UK 
1:200 
αSMA ab7817 Abcam Mouse mAb The pressure cooker 
‘decloaking’ 
1:200 
GPC3 sc-65443 Santa Cruz Mouse mAb The pressure cooker 
‘decloaking’ 
1:200 
β-catenin 610514 BD Transduction 
Labs 





ab86299 Abcam Rabbit pAb Tris buffer (pH 9) 1:200 
Pan CD44 ab157107 Abcam Rabbit pAb Citrate buffer (pH6) 1:1000 
CD68 OABB00472 Aviva systems 
biology 
Rabbit pAb Citrate buffer (pH6) 1:200 
F4/80 Ab6640 Abcam Rat mAb 20ug/ml Proteinase-K 1:100 
Table 2.1 list of antibodies used in IHC 
2.3.1.1 Human SULF2 staining 
SULF2 IHC staining was performed using an automated Ventana processor (Roche). Slides 
were deparaffinised using series of Xylene (Fisher Chemicals Code: X/0200/17 Lot: 1556167) 
and then rehydrated through descending concentrations of alcohol (Alcohol (C2H6O): Ethanol 
Absolute from Fisher Chemicals Code: E/0650DF/17). Slides were exposed to cell conditioning 
and antigen retrieval (programme 245) followed by 1:50 SULF2 1ry antibody treatment. Tissues 
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were then incubated with Multimer (AKA Secondary) 2nd antibody (discovery OmniMap anti-
Ms HRP cat 4310) for 16 minutes and SULF2 positive brown colour was developed by treating 
slides with DAB (cat 4304). Slides were counterstained with standard Heamatoxylin II (cat 790-
2208) for 8 minutes followed by Blueing reagent (cat 760-2037) for 4 minutes. Slides were 
then removed, washed with Tris-buffered saline- tween 20 (TBS-T) for 5 minutes and then 
dehydrated in ascending concentrations of alcohol for 30 seconds each and 2X 4 minutes in 
Xylene. Finally, slides were mounted using DPX mounting media (Sigma-Aldrich Code: 06522-
500mL Lot: BCBH4393V). 
2.3.1.2 Human RelA-P-ser536 staining 
RelA-p-Ser536 staining was manually performed using an overnight protocol. On the first day, 
slides were deparaffinised and rehydrated by passing them through Xylene and descending 
serial concentrations of ethanol (100, 70 and 50 %) for 5 minutes each. Tissue endogenous 
peroxidase was blocked by incubating slides with 3% H2O2 in methanol for 15 minutes. Slides 
were then rinsed in phosphate-buffered saline (PBS) before proceeding into the antigen 
retrieval protocol.  
High pH antigen retrieval protocol (Tris-EDTA antigen unmasking solution, pH9, vectors lab, 
catalogue H-3301) was applied in the RelA-P-Ser536 IHC. Slides were microwaved in the 
retrieval buffer at power 80 for 20 minutes. After cooling down with water, slides were 
permealised with 0.25% triton-x100/PBS for 10 minutes and then mounted into a sequenza 
for further processing. Slides were then blocked with an avidin/biotin blocking kit (catalogue 
SP-2001, Vector laboratories) for 15 minutes each separated by three washes with PBS for 5 
minutes. Slides were blocked with 20% goat serum (45 minutes) prior to incubation with the 
primary antibody diluted in 5% of goat serum at 4°C. On the next day, slides were warmed up 
and then incubated with 2 drops of anti-rabbit Envasion+ system HRP labelled polymer (DAKO, 
catalogue K4003) for 30 minutes. Slides were washed 3 times with PBS before incubating with 
100 µl DAB mix (reference number SK 4100, Vector labs) for a maximum of 12 minutes. Slides 
were counterstained with Haematoxylin for 2.5 minutes followed by Scotts water for 1 minute 
before dehydrating, clearing and mounting with DPX mounting media.  
2.3.1.3 Human CD44 staining 
CD44 staining was manually performed in a one-day protocol. Slides were deparaffinised and 
rehydrated by passing them through Xylene and descending serial concentrations of ethanol 
(100, 70 and 50 %) for 5 minutes each. Tissue endogenous peroxidase was blocked by 
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incubating slides with 3% H2O2 in methanol for 15 minutes. Slides were then rinsed in 
phosphate-buffered saline (PBS) before proceeding into the antigen retrieval protocol; low pH 
antigen retrieval protocol (Citrate antigen unmasking solution, pH6, vectors lab, catalogue H-
3300). Slides were microwaved in the retrieval buffer at power 80 for 20 minutes. After cooling 
down with water, slides were mounted in sequenza vertical slides racks for further processing. 
Tissues were then blocked with avidin/biotin blocking kit (catalogue SP-2001, Vector 
laboratories) for 15 minutes each separated by three washes with PBS for 5 minutes. Slides 
were blocked with 20% goat serum prior to incubation with the primary antibody diluted in 
10% goat serum for 2 hours. Slides were washed with 5X PBS and then incubated with 2 drops 
of anti-rabbit Envasion+ system HRP labelled polymer (DAKO, catalogue K4003) for 30 
minutes. Slides were then washed 3 times with PBS before incubating with 100 µl DAB mix 
(reference number SK 4100, Vector labs) for a maximum of 12 minutes. Slides were 
counterstained with Haematoxylin for 2.30 minutes followed by Scotts water for 1 minute 
before dehydrating, clearing and mounting with DPX mounting media.  
2.3.1.4 Scoring system for the applied stains 
For SULF2: Two pathologists blinded to patient outcome assessed SULF2 and GPC3 
immunostained slides. SULF2 in tumour cells was graded as absent or present, where present 
included 5% or more of tumour cells with positive cytoplasmic immunostaining. SULF2 in CAFs 
was graded as absent or present, where ‘absent’ included cases with either no or scant SULF2 
and ‘present’ included cases with intense focally positive or diffusely positive SULF2.  
For GPC3: GPC3 expression in tumour cells was scored from (0-3), corresponding to negative, 
focal or dot like cytoplasmic positivity, more diffuse cytoplasmic positivity, and intense 
cytoplasmic or membranous positivity. 
For RelA-P-ser536: RelA-P-ser536 expression in the tumour cell nuclei was scored as 0 
(negative), 1 (scattered positive nuclei), 2 (more than 50% positive nuclei) or 3 (more than 
90% positive nuclei). 
For CD44: CD44 expression in the tumour cells was scored from (0-3), corresponding to 
negative, scant cytoplasmic or membranous tumour cell positivity, moderate cytoplasmic or 
membranous positivity and strong membranous positivity.  
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2.3.2 For the C3H/He mouse model study: 
As a validation to the RNA-sequencing data, a group of markers was chosen for IHC, which 
included CD44, CD68 and F4/80. The details of the antibodies are listed in Table 2.1 
2.3.2.1 Mouse CD44 staining 
The same human staining protocol was applied to the mouse CD44 staining. 
2.3.2.2 Mouse CD68 staining 
The one-day CD68 staining was manually performed as previously described for CD44 until the 
blocking step. Slides were blocked with 20% pig serum for 45 minutes prior to incubation with 
the primary antibody diluted in the blocking solution for 1.5 hours. Slides were washed with 
5X PBS and then incubated for 60 minutes with 1:200 of biotinylated swine anti-rabbit 
antibody (Dako, catalogue E0353) diluted in PBS. After washing with PBS, the vector avidin 
biotin complex (ABC) was added to each slide (Vector labs, catalogue PK 7100), and incubated 
for 30 minutes. DAB and further processing was performed as previously described in the 
human and mouse CD44 staining. 
2.3.2.3 Mouse F4/80 staining 
F4/80 staining was performed using a one-day protocol, and after deparaffinisation and 
blocking of endogenous peroxidases, slides were then rinsed in phosphate-buffered saline 
(PBS). Antigen retrieval was performed using 20 µg/ml proteinase K in pre-warmed PBS for 20 
minutes at 37°C.  Slides were mounted into sequenza vertical slides racks for further 
processing. Tissues were then blocked with avidin/biotin blocking kit (catalogue SP-2001, 
Vector laboratories) for 15 minutes each separated by three washes with PBS for 5 minutes. 
Slides were blocked with 20% goat serum for 45 minutes prior to incubation with the primary 
antibody diluted in the blocking solution for 1.5 hours. Slides were washed with 5X PBS and 
then incubated for 60 minutes with 1:200 of biotinylated goat anti-rat antibody (star 131B, 
Biorad) diluted in PBS. After washing with PBS, the vector avidin biotin complex (ABC) was 
added to each slide (Vector labs, catalogue PK 7100), and incubated for 30 minutes. DAB and 
further processing was like what was described in the human and mouse CD68 staining. 
2.3.2.4 Scoring procedure for the applied stains 
As the three stains applied to the mouse tissue exclusively stained macrophages, the scoring 
system for these markers depended on counting the number of positive macrophages in 
matched 10 high-power fields (HPF) and the mean number of positive macrophages/10 HPFs 
was representative to number of positive macrophages in each case.   
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2.4 Cell culture 
A combination of different cell lines was used to assess SULF2 function in vitro. Two HCC cell 
lines with different SULF2 expression levels were used including SULF2-null HCC cell line; 
Hep3B cells and the SULF2-expressing Huh7 cells. Both cell lines were from the NICR cell line 
bank and were exported originally from the American Tissue Culture Collection (ATCC).Huh7 
is an adherent, malignant epithelial cell line previously isolated from 57-year old Japanese 
patient in the eighties of the last century, while Hep3B is another malignant hepatocyte cell 
line that was isolated from HCC male patient. Both cell lines are widely used to study different 
HCC oncogenic pathways alongside with testing the effect of new therapeutic targets against 
liver malignancy. LX-2 myofibroblast cell line333 was a kind gift from Professor Scott Friedman, 
Mount Sinai University. LX2 cells represent a model of hepatic activated myofibroblasts and 
are accepted as a tool in preclinical studies for new therapeutic targets. LX2 cells provide a 
valuable source of information in cell-cell cross talk with other cell types in the diseased liver 
environment.   
2.4.1 Culture conditions 
Cells were incubated in Panasonic incubator in 5% CO2 at 37°C degrees in 95% humidified 
conditions. All cell-based experiments were performed under sterile conditions in a class II 
laminar flow BioMAT2 hood (Medair Technologies, USA). Cell lines were cultured in Dulbecco’s 
modified Eagle’s medium (DMEM) media with high glucose concentration (Biosera, UK). Other 
supplements to the media included 10% heat deactivated foetal bovine serum (FBS) (Sigma), 
1% penicillin/streptomycin (100 unit/ml penicillin and 100 μg/ml streptomycin; sigma) and 2 
mM L-glutamine (Sigma). 
2.4.2 Cell line sub-culturing  
When cells reached 60-70% confluency, the media was aspirated and cells were washed with 
5 ml of sterile PBS. 2 ml of ready-to-use trypsin (sigma) was then incubated with cells at 37°C 
for 5 minutes for the purpose of cell detachment. 4 ml of complete media was added to 
deactivate trypsin and cell pellet was collected by centrifugation at 1000 r.p.m for 4 minutes 
at room temperature (RT). Cells were cultured in T75 flasks in fresh media for future use, or 
they were counted for further experiments. 
2.4.3. Mouse hepatocyte isolation 
Hepatocytes were isolated from C57BL/6 mice livers using a two-step perfusion method. Mice 
were culled by an overdose of Ketamine and Xylazine anaesthesia. After opening the 
abdomen, the inferior vena cava was cannulated and the superior vena cava was clamped. 
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Liver retro-perfusion was performed using 50ml of Krebs-ringer bicarbonate buffer (Sigma) 
with EDTA followed by 50ml of Krebs-ringer bicarbonate buffer with calcium chloride and 
1mg/ml Collagenase, and the portal vein was the outlet for the perfusing solutions. 
Hepatocytes from the perfused liver were isolated in Krebs-Ringer buffer and were filtered 
through 70μm cell strainers. Hepatocytes were then centrifuged (50xg for 3minutes) and 
washed with Krebs-Ringer buffer. At the end of the procedure, the pellet was resuspended in 
10% Williams medium E (Gibco) containing 10%FBS, 2mM L-glutamine, 100 u/ml penicillin and 
100 μg/ml streptomycin and plated in rat tail collagen-coated plates. 4 hours later, dead 
floating cells with the old media were replaced by fresh complete Williams E medium. 
2.4.4 Isolation of mouse bone marrow-derived macrophages   
After sacrificing the mice, the femur and tibia are excised and kept in HBSS-. Bone marrow was 
then flushed out using 5ml HBSS- and a 23 gauge needle under laminar flow hood. Cell 
suspension was then disaggregated using 18 gauge needle, and cells were transferred into 50 
ml falcon tube where they were centrifuged at 400xg for 5 minutes. Pellet was resuspended 
in Ammonium Chloride-Potassium (ACK) lysis buffer for 1 minute, and then 1x PBS was added 
to restore osmolarity. Cell suspension was layered onto a 62.5% percoll density gradient, and 
the mixture was centrifuged at 1000 xg for 30 minutes. Cells in the gradient interface; the 
immature mono-nuclear cells, were collected and washed twice with 1X PBS before 
resuspension in RPMI media containing 10% FCS, 1 mM pyruvate-glutamine, penicillin-
steptomycin and 10ng/ml M-CSF. Immature monocytes were kept for 7 days at 37°C with 
5%CO2 to mature into macrophages. 
2.4.5 Macrophage polarisation    
Polarisation of BMDM into M1 and M2 macrophage phenotypes was achieved by treating 
seeded macrophages with either 100ng/ml LPS and 50ng/ml Ifnɣ (for M1 macrophages) or 10 
ng/ml of Il4 and Il13 in the media for 24 hours. 
To collect M0, M1 and M2 CM, media was aspirated after polarisation and cells were washed 
with PBS before adding fresh media for 24 hours. The collected media was 10 x concentrated 
and stored for the desired experiments.   
2.4.6 Cell counting  
Cell counting was performed automatically by using EVE™ Automatic Cell Counter (Germany). 
10 µl of homogenous cell suspension was mixed with 10 µl of trypan blue dye. 10 µl from this 
mix was pipetted into the Eve counting slide to be inserted in the automatic cell counter. 
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2.4.7 Freezing cells 
Cells to be frozen were cultured in T75 flask to reach 60-70% confluency. After trypsinisation 
and cell centrifugation, the resulting pellet was re-suspended in 1 ml of cell freezing media 
(0.8 ml of culture media+0.1 ml FBS+0.1 ml DMSO (Sigma)). Cells were then transferred to 
cryo-vials and loaded into cryo-chamber filled with isopropyl alcohol (Nalgene) to achieve -
1°C/min rate of cooling for overnight. Cryo-vials were then transferred into liquid nitrogen for 
long-term storage. 
2.4.8 Collection and concentration of cell conditioned media   
1 x 106 of LX-2 cells were cultured in 10 mls of media in a 10 cm dishes for 48 hours. Cell-
conditioned media (CM) were then collected and centrifuge at 1600 r.p.m for 5 minutes to 
pellet any cell debris. CM was enriched by 10-fold by using the Amicon Ultra 15 (3000 NMWL) 
centrifugal filters (Merk Millipore, UK, catalogue UFC900324). Media was centrifuged in these 
concentration tubes at 2600 g for 45 minutes at 4°C, and the concentrated CM was sterile 
filtered before storage at -80°C for further experiments. 
2.4.9 Sorafenib, inhibitors and other reagents   
Sorafenib was purchased from Cell signalling technologies (catalogue number 8705). 
SP600125 (JUN N-Terminal Kinase (JNK) inhibitor, catalogue number 1496), (5Z)-7-Oxozeaenol 
(transforming growth factor-β-activated kinase 1 (TAK1) inhibitor, catalogue number 3604) 
and FR 180204 (Selective Extracellular Signal-Regulated Kinase1/2 (ERK1/2) inhibitor, 
catalogue number 3706) pathway inhibitors were purchased from Tocris. IKK-2 Inhibitor IV 
(Inhibitor Of Nuclear Factor Kappa B Kinase Subunit Beta, catalogue number 401483) was 
purchased from Calbiochem. Wnt-3a was purchased from R&D systems. 
2.4.10 Stable SULF2 Knockdown 
LX-2 cells were transduced with mission TRC2 shRNA lentiviral particles targeting SULF2 
(TRCN0000364518, Sigma-Aldrich, USA) or TRC2-pLKO-puro non-targeting (NT) with 
hexadimethrine bromide (shRNA sequences in Table 2.2). Cells were selected using 
puromycin. Successful SULF2 knockdown was confirmed by both real-time PCR and western 
blotting. 
Target Sequence 
SULF2 shRNA CCGGGGGCGAAAGTCATTGGAATTTCTCGAGAAATTCCAATGACTTTCGCCCTTTTTG 








2.4.11 2D Trans-well assay 
Cancer cells were co-cultured with stromal cells with different SULF2 expression levels in order 
to see the impact of stromal SULF2 on the behaviour of the tumour cells as previously 
described in similar conditions334-336. Huh7 and Hep3B cells were incubated in 12- and 24-well 
plates in different cell densities i.e. 10000, 20000 and 50000 cells/well, while control or SULF2 
KD LX-2 cells were cultured in ThinCerts™-TC inserts, pore size 3.0 µm (Greiner bio-one, 
Switzerland, catalogue 662631) in 1:1 ratio on top of the tumour cells. 24, 48 and 72 hours 
later, the impact of the stromal SULF2 on the growth and viability of the tumour cells –after 
removal of the trans-wells with the cultured stromal cells- was assessed with MTT viability 
assay and BrdU cell proliferation ELISA assay as mentioned below. 
2.4.11.1 MTT viability/metabolic activity assay 
The principle of the MTT colorimetric assay is the mitochondrial reduction of the 3-(4,5-
dimethythiazol2-yl)-2,5-diphenyl tetrazolium bromide (MTT) by the mitochondrial enzyme 
succinate dehydrogenase. Such reaction only takes place in viable and metabolically active 
cells where the MTT dye penetrates the cell membrane until reaching the mitochondria where 
it is reduced by succinate dehydrogenase to give a purple insoluble formazan product. The 
resulting product is solubilised with 1-propanol and the intensity of the purple colour (which 
reflects the metabolic activity of the parent cells) is measured using a spectrophotometer.    
At the desired time point, trans-wells including the incubated stromal cells were discarded, 
and the media was replaced by 500µl of 5mg thiazoyl blue tetrazolium bromide (Sigma-
Aldrich, USA, catalogue M2128) /ml complete media. The dye was then incubated with cells 
for 3 hours at 37°C, and then media was aspirated and the plate was allowed to dry at RT for 
5 minutes. The insoluble formazan crystals were dissolved using 1-propanol with shaking for 
5 minutes on an orbital shaker. The resulting solution was then transferred into 96-well plate 
and colour intensity was analysed using plate reader at 570 and 620 nm. 
2.4.11.2 Cell proliferation ELISA, BrdU assay 
The assay principle for this assay relies on the use of 5-bromo-2'-deoxyuridine or 
Bromodeoxyuridine, a synthetic thymidine analogue which replaces thymidine during the 
DNA synthesis of the replicating cells and hence can be used as a marker for cell 
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proliferation337. The ELISA kit (Roche, Germany, catalouge 11647229001) involves BrdU 
labelling agent together with anti-BrdU antibody that recognises the BrdU-labelled DNA. 
Tumour cells were treated with 10µM BrdU labelling agent 20 hours before the desired end 
point to allow the incorporation of BrdU into the newly synthesised DNA of dividing cells. 
Labelling media was removed and cells were fixed for 30 minutes at RT. Anti-BrdU antibodies 
were then incubated with the cells for 90 minutes with subsequent washing with PBS for 5 
minutes at the end of the incubation period. The intensity of the green colour developed after 
adding the substrate solution to the plate was stopped by using H2SO4 stop solution and was 
measured at 450 nm.    
2.4.12 Tumour cell migration assay 
The ability of the stromal SULF2 to regulate the migration of the tumour cells was tested using 
the cell migration inserts (Ibidi, Germany, catalogue 80209). 30000 tumour cells/70 µl media 
were cultured overnight on both sides of the migration inserts to allow for cell attachment. 
The migration insert was removed and media was replaced with CM from control LX-2 or 
SULF2 KD LX-2 cells in 1:1 ratio with complete media. Pictures of the migration front were 
taken 24 hours after incubation with the stromal CM using a Zeiss inverted microscope. 
Pictures were captured at 50x magnification and gap closure was assessed by measuring the 
gap distance at each time point using ImageJ software.  
2.4.13 Tumour cell invasion assay 
Tumour cell invasion assay depends on the ability of the tumour cells to invade through the 
ECM proteins from the Engelbreth Holm-Swarm (EHS) mouse tumour338 forming an artificial 
basement membrane that is dried over the wall of 8 µM pore size polycarbonate inserts. 
After rehydrating the interior of the Boyden chambers with serum-free (SF) media at RT for 2 
hours, tumour cells (300,000 cells per chamber) were suspended in 300µl SF media and were 
pipetted inside the invasion chamber. The chamber was then inserted in 24-well plate 
including different densities from overnight-attached control or SULF2-KD LX-2 cells as a living 
source of SULF2. 72 hours later, inserts were carefully removed using sterilised forceps and 
the un-invading cells together with the ECM matrix gel were carefully, but thoroughly, 
removed from the interior of the chamber inserts using a cotton swab to reduce the 
background. Inserts were then transferred to new 24-well plate containing 500 µl of the 
staining solution to stain for the invading cells on the outer surface of the polycarbonate 
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membrane for 20 minutes. Chambers were then washed with water and the dye was dissolved 
using 10% aceitic acid and the developed colour was measured at 560 nm on a plate reader.   
2.4.14 3D spheroid hanging droplets 
3D spheroid models provide more in vivo-like conditions, which reflect the complexity of the 
tumour microenvironment in terms of drug penetration and absorption as well as the growth 
of cells in a multi-layer, rather than a monolayer339, 340. The rationale of doing this experiment 
in the SULF2 context was to investigate the effect of stromal SULF2 on tumour cell 
proliferation shown by the degree of spheroids growth, and for this reason two procedures 
were adopted; mixed fibroblast-tumour cell spheroids and single tumour spheroids.  
The optimum number of cells forming a single, rounded sphere was investigated by culturing 
different cell densities (12000, 6000, 3000, 1500, 1000, 750, 500, 250, 125 and 62 cells) in 20µl 
of media on the interior surface of a 10 cm3 lid that was then inverted to allow the media 
including the cell suspension to hang over humid environment by adding 10 ml of sterile PBS 
to the bottom of the dish. Droplets were left for 3 or 4 days to reach the best time upon which 
spheroids were formed.  
Mixed cell-type spheroids; Huh7 or Hep3B cells combined in a 1:1 ratio with control or SULF2 
KD LX-2 cells in 20µl media per sphere on a 10cm3 dish lid (n=10 per group). The total number 
of cells mixed to form a single sphere was 3000 cells. Pictures were taken at 50X magnification 
using a Zeiss inverted microscope from day 3 after mixing single cells until day 8 of culture. 
Tumour cells’ spheroids; Huh7 or Hep3B cells were suspended in hanging droplets to form 
spheres. The total number of cells mixed to form a single sphere was 3000 cells. Spheroids 
were transferred into the stromal CM at either 3 days (Hep3B spheroids) or 4 days (Huh7 
spheroids) after the date of hanging the droplets. Pictures were taken at 50X magnification 
using Zeiss fluorescent microscope from day 3 or 4 after mixing single cells until the seventh 
day. 
Calculation of the spheroids volume: the spheroids’ growth was calculated as follows: 
• Spheroids were numbered from 1-10 so that images from matched spheroids could be 
captured daily. 




• Software sittings were changed to allow using the freehand selection to the analysed 
object; spheroid. 
• The analysis option in the software toolbar was chosen to set the analysis 
measurement for the “area” option. This gave the area of the selected object on pixel 
count. 
• The volume of each sphere was calculated using the invented formula: 
Vmm3 = 0.09403 x ((Apixelx0.28)/1000)1.5 
• The output from this experiment was the change of the matched-spheroid volume 
from the first day of image capture. This was to allow for exclusion of any variability 
due to the difference of the initial volume of the spheroids. 
2.5 RNA Extraction, Reverse Transcription and Polymerase Chain Reaction 
2.5.1 RNA extraction  
Total Ribonucleic acids (RNA) was extracted from cell lines seeded in 300,000 cell/well in 6-
well plate at the desired time point and after specific treatment. Media was aspirated, and 
cells were washed with ice –cooled PBS. Isolation of RNA was performed using the Qiagen 
RNeasy Mini kit according to the manufacturer’s protocol. The concentration of the isolated 
RNA was detected using Nanodrop 2000 machine and software (thermos-scientific) and the 
samples were kept undiluted at -80°C for further experiments.  
2.5.2 Reverse transcription 
1µg RNA was used to make complementary DNA (cDNA) using the Promega reverse 
transcription (RT) protocol. The required RNA concentration was added to a total volume of 
8µl using RNase-free water (Qiagen) and the mixture was treated with 1µl RNase-free DNase 
enzyme with 1µl of 10x RQ1 DNase reaction buffer to eliminate any contamination from 
genomic DNA (gDNA). The reaction was kept at 37°C for 30 minutes in GeneAmp PCR system 
2700 thermal cycler (Applied Biosystems). 1 µl of RQ1 DNase stop solution was then added for 
5 minutes to stop the action of the DNase enzyme. Next, 0.5µl random hexamers were 
annealed to the RNA at 70°C for 5 minutes before proceeding into the RT step. To reach a RT 
reaction volume of 20µl, 8.5 µl of RT working solution was added to every sample. The RT 
working solution contained (per sample): 1µl M-MLV RT enzyme, 4µl of 5x M-MLV RT buffer, 
1 µl 10 mM dNTP, 0.5µl of RNasin ribonuclease inhibitor and 2µl of RNase free water. Mixture 
was pipetted and incubated on the thermocycler for 1 hour at 42°C to allow the RT reaction 
to take place. Samples were kept at -80°C for future experiment. 
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2.5.3 Quantitative polymerase chain reaction (qPCR) 
The resulting cDNA (50ng/µl) was diluted 1:5 to 10ng/µl with Nuclease-free water and then 
2µl of the diluted cDNA (20ng/µl) was used for the gene expression protocols. 6.5µl of 2x 
SYBR® Green JumpStart™ Taq ReadyMix (Sigma, catalogue S4438) was mixed with 3.5µl of 
nuclease-free water and with 1µl of both forward and reverse primers (at 10 μM 
concentration) designed for genes of interest. A total reaction volume of 13µl was loaded onto 
96-well plate (MicroAmp optical plate, Applied Biosystems) and the qPCR reaction was 
performed using the 7900HT Fast Real-Time PCR System (Applied Biosystems) equipped with 
the SDS 2.3 software. The standard program was used (50°C for 2 min, 95°C for 10 min 
followed by 40 cycles of 95°C for 15 sec and 60°C for 1 min).  
2.5.4 Primer design 
List of all the designed primers is in Table 2.3 All primers used for this study were self-designed 
using three online bioinformatics software: primer 3 version 1.4 software, PubMed nucleotide 
blast tool software and Primer bank website. Nucleotide sequence of the target genes was 
obtained from PubMed website using Nucleotide search engine. The sequence of the designed 
primers was checked against whole genome using the BLAST option on the PubMed website 
to ensure good alignment and high specificity towards the target gene. Primers were ordered 



















Table 2.3: list of primers used in the current study 
forward and reverse primers were diluted 1:10 in DEPC water for semi-quantitative PCR and 
qPCR. 1:10 serial dilution from control cDNA (20ng/µl) was prepared to test the efficiency of 
the designed primers using the standard curve drawn by 7900HT Fast Real-Time PCR System 
(Applied Biosystems) equipped with the SDS 2.3 software. The slope of the standard curve was 
used to calculate primer efficiency using the qPCR Efficiency Calculator online software 
(Thermo-scientific). Primers with a % of efficiency ranging from 90-110% were considered for 
gene expression analysis. Data analysis of the gene expression experiments adopted the 
Comparative quantification algorithms-ΔΔCt methods in which the expression of the target 
gene in an experimental context is compared to the expression results of both a calibrator 
Gene Forward primer 5’-3’ Reverse primer 5’-3’ 
SULF2 ATGAGTTTGACATCAGGGTCCCGT ATGGATTTCCCGTCCATATCCGCA 
PDGFRβ AGACACGGGAGAATACTTTTGC AGTTCCTCGGCATCATTAGGG 
αSMA GAAGATCAAGATCATCGCCC CTCGTCGTACTCCTGCT 
Col1a1 GTGCGATGACGTGATCTGTGA CGGTGGTTTCTTGGTCGGT 
VIM TGCAGGAGGCAGAAGAATGG AAGGGCATCCACTTCACAGG 
TIMP1 CCTTCTGCAATTCCGACCTC GTATCCGCAGACACTCTCCA 
TNFα GAGGGCTGATTAGAGAGGTC ATGAGCACTGAAAGCATGATCC 
IL6 CCTGAACCTTCCAAAGATGGC TTCACCAGGCAAGTCTCCTCA 
CD44 TCCAACACCTCCCAGTATGACA GGCAGGTCTGTGACTGATGTACA 
CDH1 AAAGGCCCATTTCCTAAAAACCT TGCGTTCTCTATCCAGAGGCT 
EpCAM GAACACTGCTGGGGTCAGAA CTGAAGTGCAGTCCGCAAAC 
KRT7 CAGGATGTGGTGGAGGACTT AGCTCTGTCAACTCCGTCTC 
KRT19 TGAGTGACATGCGAAGCCAAT CTCCCGGTTCAATTCTTCAGTC 
AXIN2 TACACTCCTTATTGGGCGATCA TTGGCTACTCGTAAAGTTTTGGT 
LGR5 AGCAAACCTACGTCTGGACA ACAGAGGAAAGATGGCAGCT 
CDH2 AGCAGTGAGCCTGCAGATTT CTGCCACTTGCCACTTTTCC 
PDGFRα TTTTTGTGACGGTCTTGGAAGT TGTCTGAGTGTGGTTGTAATAGC 
TCF4 ACTGTAGCCTGCATCCACAT TTTCCCCAGAGCATCTCCAG 
CXCR4 CTGGCCTTCATCAGTCTGGA TCATCTGCCTCACTGACGTT 
FZD7 GTGCCAACGGCCTGATGTA AGGTGAGAACGGTAAAGAGCG 
FGFR1 CGCCCCTGTACCTGGAGATCATCA TTGGTACCACTCTTCATCTT 
GADD45β TACGAGTCGGCCAAGTTGATG GGATGAGCGTGAAGTGGATTT 
MDR1 CACGTGGTTGGAAGCTAACC GAAGGCCAGAGCATAAGATGC 
HPRT TTGCTTTCCTTGGTCAGGCA ATCCAACACTTCGTGGGGTC 
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(control or untreated sample) and a normaliser (house-keeping gene, HPRT in our case). The 
resulting ΔΔCt value was used to calculate the fold difference in gene expression. 
2.6 Western blotting 
2.6.1 Total protein extraction 
Protein was extracted from cell lines seeded in 300,000 cell/well in 6-well plate at the desired 
time point and after specific treatment. Media was aspirated, and cells were washed with ice 
–cooled PBS prior to adding the Mammalian Protein Extraction Reagent (M-PER) (thermo-
scientific, catalogue 78503). 10µl of protease inhibitor cocktail (Roche) and 20µl of 
Phosphatase Inhibitor Cocktail 2 (sigma, catalogue p5726) were added per 1ml of the protein 
extraction buffer, and around 70-90µl from this mixture was incubated with cells in 6-well 
plate for 2 minutes on ice to allow detergents and buffer component to lyse the cells. Cells 
were then scrapped from the surface of the plate and the whole lysate was transferred into 
1.5 ml Eppendorf tubes to be centrifuged at 13,000 r.p.m for 20 minutes at 4°C. the 
supernatant including all the soluble proteins was collected in new Eppendorf tube for protein 
quantification. 
2.6.2 Protein quantification and preparation 
The bicinchoninic acid (BCA) assay procedure was performed to measure the total protein 
concentration (Pierce BCA Protein Assay Kit, Thermo Scientific). The intensity of the purple 
colour produced by the reduction of CU+2 into CU+1, by the amino acids present in the total 
proteins, and subsequent detection of the CU+1 ion by the BCA, was proportional to the 
quantity of the total protein present in every tested sample. A serial dilution from the standard 
bovine serum albumin (BSA) was used to create a standard curve from which the 
concentration of the sample protein was interpolated. 10µl of sample was mixed with 80µl of 
the working reagent (50:1 ratio of reagent A and reagent B) and the reaction mix was left for 
30 minutes at 37°C. The absorbance was read by the spectrophotometer at 562 nm. The 
desired concentration of protein (10-20µg) was mixed in a 1:4 ratio with 4x protein loading 
dye and the mixture was heated up at 95°C in the heat-block for 5 minutes for protein 




2.6.3 SDS-PAGE electrophoresis 
According to the size of the tested protein, the resolving gel was made in 7.5, 10 or 12%, while 








Table 2.4 composition of the SDS-PAGE gels 
Samples were loaded on the custom made SDS-PAGE gel and the PageRuler Prestained Protein 
Ladder (thermos-scientific, catalogue 26616) was used as a protein size marker. Samples were 
run at 90 volts for 2 hours and at the end of the electrophoresis, the gel was prepared for 
blotting. 
2.6.4 Protein transfer 
Proteins separated on the SDS-PAGE gel were transferred to Nitrocellulose membrane 
(HyBond-C Extra, Amersham Biosciences, UK) using the wet-transfer method in tris-glycine 
buffer (pH 8.3). The gel, the nitrocellulose membrane, two filter pads and two blotting pads 
were pre-immersed in the transfer gel and the transfer sandwich was set that the negatively 
charged proteins were transferred from the gel (nearest to the cathode probe) to the 
membrane (nearest to the anode probe). Protein transfer was run on 100 volts for 1.30 hours. 
Ponceau s solution (Sigma, catalogue 7170) was used to confirm the correct transfer of the 
proteins to the blotting membrane.   
2.6.5 Membrane blocking and immunoblotting 
Membrane was blocked with either 5% skimmed milk or 5% BSA in 1x TBS-T solution (60 g of 
Tris, 90 g of NaCl and 5 ml of Tween 20 in 1 L of H2O; pH 7.5) to eliminate any unspecific 
binding. All the primary antibodies were incubated with the membrane overnight with gentle 
shaking over orbital centrifuge at 4°C. The following day, the primary antibodies were 
aspirated and the membrane was washed thoroughly with TBS-T 3x 5 minutes while shacked 
 Resolving gel (ml) Stacking gel (ml) 
7.5% 10% 12% 4% 
MilliQ water 5.5 4.85 4.35 6.4 
1.5 M Tris pH 8.8 2.5 2.5 2.5  
0.5 M Tris Ph 6.8    2.5 
40%Acrylamide/bis 
(Biorad, 1610148) 
1.9 2.5 3 1 
10% SDS 0.1 0.1 0.1 0.1 
10% APS 0.05 0.05 0.05 0.05 
TEMED 
(Sigma, T9281) 
0.01 0.01 0.01 0.01 
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to ensure precise removal of the unbound antibody remnants. 1:2000 of the HRP conjugated 
secondary antibodies were then incubated with the membrane for 1 hours RT on the orbital 






SULF2 MCA5692GA AbD Serotec Mouse mAb 1:1000  
Phosphor-SAPK/JNK 
(Thr183/Tyr185) 
9251 Cell signalling Rabbit pAb 1:1000 
SAPK/JNK (Thr183/Tyr185) 9252 Cell signalling Rabbit pAb 1:1000 
Phospho- NF-Kb p65 
(Ser536)(93H1) 
3033 Cell signalling Rabbit mAb 1:1000 
NF-Kb p65 (C-20) sc-372 Santa cruz 
biotechnology 
Rabbit pAb 1:1000 
Phospho-stat3 (Tyr705)(D3A7) 9145 Cell signalling Rabbit pAb 1:1000 
Stat3 9132 Cell signalling Rabbit pAb 1:1000 
Phospho-p44/42 MAPK 
(ERK1/2)(Thr202/Tyr204) 
9101 Cell signalling Rabbit pAb 1:1000 
p44/42 MAPK (ERK1/2) 0102 Cell signalling Rabbit pAb 1:1000 
phospho-ERK 4370 Cell signalling Rabbit mAb 1:2000 
ERK1/2 9107 Cell signalling Mouse mAb 1:2000 
phospho-AKT 4060 Cell signalling Rabbit mAb 1:2000 
AKT 4691 Cell signalling Rabbit mAb 1:2000 
GAPDH ab37168 Abcam Rabbit pAb 1:2000 
β-actin A-5441 Sigma-Aldrich Mouse mAb 1:2000 
Anti-rabbit IgG, HRP-linked 7074 Cell signalling Goat 1:2000 
Anti-Mouse IgG, HRP-linked A4416 Sigma-Aldrich Goat 1:2000 
Table 2.5 List of antibodies used in Western blotting 
2.6.6 Immunodetection 
The membrane was washed 3x 5 minutes after the removal of the 2nd antibodies, and was 
then incubated with the chemiluminescence substrate Pierce ECL Western Blotting Substrate 
(Thermo Scientific, catalogue 23106) for 1 minute before developing the bands using x-ray 
films in the dark room. The film was developed using developing solution (RG X-ray developer, 
Champion) and fixative (RG X-ray fixer, Champion) in the Mediphot 937 developing system. 
2.6.7 Membrane stripping 
For the detection of the phosphorylated and total proteins, the phospho-antibodies were 
applied first to the membrane and after developing the protein bands, the membrane was 
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stripped for the purpose of re-blotting with the total protein primary antibody. The membrane 
was washed with TBS-T for 15 minutes at RT and was then incubated with Restore™ Western 
Blot Stripping Buffer (Thermo-scientific, catalogue 21059) for 20 minutes at RT on orbital 
shaker. The membrane was then re-washed with TBS-T buffer for another 10 minutes before 
blocking with the specific blocking agent prior to retreating with total protein primary 
antibody. 
2.7 Immunofluorescence (IF) 
Cells stained for GP3 and β-Catenin were seeded in 8-chamber slides at 40,000 – 80,000 cells/ 
chamber. At the end of the treatment, the media was aspirated and the cells were washed 
with PBS before fixing them with 6% formalin for 30 minutes at RT. Formalin was removed 
and cells were further fixed and permablised with acetone for 10 minutes prior to wash with 
0.25% PBS-Triton for another 10 minutes. 20% goat serum was used for blocking purposes at 
RT for 45 minutes and the primary antibody was diluted in PBS (1:75 for GPC3 and 1:100 for 
β-Catenin) and incubated with cells in the chambers for 45-60 minutes at RT. The primary 
antibody was then aspirated and cells were washed before incubating them with the 
fluorescent-labelled secondary antibody for 45-60 minutes in the dark. The secondary 
antibody was removed and cells were treated after washing with DAPI (4',6-Diamidino-2-
Phenylindole, Dihydrochloride)(Thermo scientific, catalogue d1306) in 1:5000 dilution. Cells 
were finally washed with distilled water and mounted with the glycerol mounting media. 
2.8 Animal procedures  
6-8 week old male C3H/he mice (Harlan Laboratories, UK) were used in this study and were 
housed 4 per cage to reduce fighting injuries. A simple procedure to remove preputial glands 
was routinely performed at 28 weeks, without complications. Mice were fed an American 
lifestyle diet (ALIOS: 45 % calories from fat, high trans-fat with high sucrose/fructose drinking 
water, TD.110201, Harlan Laboratories, Wisconsin, USA) or a control diet (15% calories from 
fat, low trans-fat without sugar, TD.110196, Harlan Laboratories, Wisconsin, USA) ad libitum. 
Culling was at 4 time-points, namely 12 weeks (1 month on diet; n=8 per group), 24 weeks (4 
months on diet; n=8 per group); 36 weeks (7 month on diet; n=8 per group) and 48 weeks (10 
month on diet; n=24 per group). Additional groups of 12 mice on control diet and 12 on the 
ALIOS diet received a single intraperitoneal injection of DEN (Sigma, N0258-1G) at 16 weeks. 
Upon humane killing, body/liver weight and the macroscopic number and size (using callipers) 
of tumours were recorded. Liver tissues were dissected to fit in to three groups depending on 
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further tissue processing: the first set of liver tissues was treated with RNA later solution for 
RNA long preservation and RNA-sequencing process. Samples were kept in the 4°C overnight 
to ensure adequate tissue penetration, and for long-term storage samples were stored at -
80°C. The second set of tissues was immersed in 10% formalin for fixation and tissue staining 
purposes. Samples were kept in 10% formaldehyde solution overnight and tissues were 
exposed to further procedures to keep them in paraffin-embedded blocks. The last part of 
samples was fresh-frozen in OCT media using liquid nitrogen and was then kept in -80°C for 
further applications.  The in vivo experiments were performed according to ethical guidelines 
under a UK home office licence. 
2.9 Tissue studies  
Formalin fixed paraffin embedded (FFPE) tissue from tumour and non-tumour liver was 
sectioned 5 microns thick for histological assessments. An expert liver pathologist, who was 
blinded to the experimental dietary group assessed the histological features of non-tumour 
and tumour liver using   Haematoxylin and eosin (H&E) and Sirius Red stained slides. The 
degree of steatosis (0-3) according to the percentage of fat deposition in the liver tissue with 
zero is <5%, 1= 5-33%, 2= 33-66% and 3 >66%, hepatocellular ballooning (0-2) with zero means 
no ballooning, 1 is few ballooned hepatocytes and 2 is moderate or marked ballooning, and 
lobular inflammation (0-2) counting the inflammatory foci/HPF with 0=no foci, 1=1-2 foci, 2=2-
4 foci and 3= >4 foci was quantified and the NAFLD activity score calculated341. Other features 
of liver injury and inflammation, including, Mallory-Denk bodies, lipogranulomas, 
microvesicular steatosis was also documented and the degree of fibrosis (pericellular, 
portal/periportal, bridging) was assessed using a four-grade scoring system341.  Histological 
assessment of the tumours was performed using H&E and reticulin staining342 and defined as 
adenomas or HCC grade 1 or 2.  Parameters considered included the presence and degree of 
nuclear atypia, the presence of cytoplasmic hyaline globules and mitotic figures, and the 
thickness of liver cell plates. Additionally, the presence and extent (percentage of the tumour 
area) of steatosis, features of degeneration (Mallory-like bodies, ballooning) and inflammation 
inside the tumours were also assessed.  
2.10 RNA sequencing, statistics and data analysis 
10-20 mg of non-tumour and tumour tissues were shipped in RNAlater on dry ice to AROS 
Applied Technology (Denmark), where RNA was extracted and the quality of each sample 
checked using a Bioanalyser (Agilent). Only samples with at least 400ng of total RNA and a 
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RNA Integrity Number (RIN) greater than 8.0 were included. RNA sequencing was performed 
using Illumina’s Stranded mRNA kit for library preparation, with 100 bp Paired End Reads, five 
samples to be sequenced across one lane. RNA expression and sequence analyses were 
performed with the Newcastle Bioinformatics Support Unit. The mouse genome sequence was 
obtained from “Ensemble” to construct a reference genome index and reads were mapped to 
this using Bowtie tool within the R package. Differentially expressed genes were calculated 
using “DESeq2” tool and data were filtered by adjusted p-value of 0.05 and |Log2FC|in 
different tissues groups. Data visualisation was performed using Heatmapper software343. 
2.10.1 Unsupervised Hierarchical clustering of the mouse model data 
Hierarchical clustering of the mouse non-tumour and tumour RNAseq data was performed to 
visualise the grouping of individual mice and to see whether this grouping reflects the actual 
histopathological criteria and the dietary/carcinogen intervention. Because this grouping was 
not pre-defined with a response variable, this method is considered as un-supervised 
clustering way of gathering the data. The output of this hierarchical cluster is a tree-like graph 
showing the observations; called dendrogram. Unsupervised clustering was performed on the 
R package using the “hclust” function. 
In this function, the hierarchical clustering was performed on the transcriptome of 49 mice 
with every mouse assigned to individual cluster with the algorithm gathering every two most 
similar mice into an individual cluster until there is only one cluster exists. The distance 
“dissimilarity” between the individual mice is every time recalculated by the Lance-Williams 
dissimilarity update formula according to the wards minimum variance method using the 
“Ward.D2” option344. The Euclidean distance is the method that R script uses by default to 
calculate the distance between the two objectives (mice) based on the formula: 
    
 
 
In the non-tumour tissue, a DE gene list was created from the two non-tumour clusters 
identified by the cluster dendrogram. 
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2.10.2 Unsupervised k-means clustering of the human TCGA data 
In order to correlate the human data with the mouse transcriptomics data, clustering of the 
human TCGA publically available transcriptomics data without guide from a response variable 
“unsupervised”. Human data was partitioned using K-means clustering that classifies the data 
into group of k clusters with k representing the number of pre-selected groups. Group of 
observations “patients” with the lowest dissimilarity (high intra-class similarity) were classified 
within the same group, and patients with different transcription profiles were separated in 
different subclasses. This is to determine the major determinants responsible for this 
grouping. 
Unsupervised class discovery by NMF-metagene and K-means clustering was performed on 
the TCGA LIHC project (374 liver cancer samples + 50 normal tissue samples) testing all 
combination of 3-12 metagenes and clusters with a bootstrapped resampling method to test 
for reproducibility. A metagene is a single score that reflects the expression level of several 
genes. This was followed by projecting the mouse transcriptomics onto the identified clusters 
to see the overlapping signatures. This was performed by Sirintra Nakjang from Newcastle 
bioinformatics support unit.   
2.10.3 cBioPortal software analysis 
cBioPortal is an online available software which includes wide amount of information about 
genomic data of different types of cancer based on the TCGA database. This can be a useful in 
silico tool to study the prevalence of a certain gene mutation and copy number variant within 
the TCGA dataset. It also provides a wide group of data concerning the association between 
genes concerning co-expression versus mutual exclusivity, correlation of genes with survival, 
networks in which a particular gene is involved and the clinical data of the group of patients 
expressing this particular gene. The cBioPortal website uses the Spearman and Pearson 
correlation methods to predict the association between the enquired genes.  
In order to confirm the association between SULF2 and other downstream gene, the 
cBioPortal tool was used by searching for SULF2 with correlated genes using the mRNA 
expression z-score in the TCGA dataset. The correlation between SULF2 and other candidate 
genes with spearman’s and Pearson’s correlation coefficients and p-value were retrieved with 
the correlation plot from the website.  
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2.10.4 Ingenuity Pathway Analysis (IPA) software 
The IPA (QIAGEN Inc., https://www.qiagenbioinformatics.com/products/ingenuitypathway-
analysis) is a powerful tool for mapping and networking of the DE gene list calculated 
elsewhere to explain the effect of gene expression on different pathways and downstream 
diseases and functions. The IPA database is constructed from findings manually or 
automatically curated from top journals forming the ingenuity findings, while the ingenuity-
modelled knowledge is an aggregation of the ingenuity expert knowledge and ingenuity 
supported third party information. 
Data uploaded to the IPA software should include gene ID (Observation) with the Log2FC and 
the adjusted p-value for every gene. Data were uploaded on the IPA on an Excel file format 
and data was analysed based on pre-selected cut off values. The ideal number of analysed 
gene in every data set ranges between 200 and 3000. The IPA output shows the pathways 
involved in this particular analysis, the downstream functions of the changed DE genes, the 
upstream genes that regulate the change in the gene list and networks enriched from the 
current analysis. 
IPA uses two statistical tools to explain the analysis; the p-value of overlap between the IPA 
curated list and the current analysis dataset and the activation z-score. P-value is calculated 
using Right-Tailed Fisher’s Exact Test with Benjamin correction for multiple testing in 
predicting the p-value of the canonical pathways and diseases and biofunction. Activation z-
score is used to give a prediction for the direction of change in the particular pathway(s) 
influenced by the analysed gene set. 
Canonical pathways: the first provided piece of information provided by the software gives an 
idea about the IPA pathways directed by the analysed gene list. The bar chart provides the 
significance of the gene enrichment in pathways deregulated from this gene list. The colour 
of the bar chart detects the direction of change in these pathways predicted from the change 
in individual genes’ direction. An absolute z-score of 2 is considered significant in the IPA 
context. 
Upstream regulators: this tool is helpful to identify the transcription factors “or any molecule 
that affects the expression of another molecule” that regulate the changed gene in the 
analysed dataset. The upstream analysis is calculated by defining the direction of change in 
DE genes and mapping them to the already present transcription factors on the IPA dataset. 
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Generally, if the direction of change of certain gene is consistent with a certain activation state 
of the transcription factor either activated or inhibited, a prediction of activation is made by 








𝑥𝑥𝑖𝑖 ∈ (−1,1) 
When +1 is activation sate and -1 is deactivation state of the gene in response to the 
transcription factor 




With 𝑤𝑤𝑖𝑖 is the weight of an edge “relationship between the gene and the relevant 
transcription factor” and 𝑀𝑀𝑎𝑎𝑎𝑎𝑎𝑎𝑖𝑖𝑎𝑎𝑎𝑎𝑎𝑎𝑖𝑖𝑎𝑎𝑎𝑎 is the number of activation finding between the gene and 
the transcription factor and 𝑀𝑀𝑖𝑖𝑎𝑎ℎ𝑖𝑖𝑖𝑖𝑖𝑖𝑎𝑎𝑖𝑖𝑎𝑎𝑎𝑎 is the number of inhibiting finding (this data is from 
what was published before concerning these two genes). 
Diseases and functions: the output from this analysis specifies the cellular processes that are 
changed due to the change in the examined gene list. This analysis also predicts the activation 
or inhibition of the top diseases and functions enriched from the previous analysis. All the 
genes related to every changed function can be retrieved and visually presented for 
subsequent validation. The colours of the heat map produced from this analysis detects the 
direction of change in the function as detected by the activation z-score, and the size of each 
square in the heat map represents the p-value of overlap between the mapping genes and the 
IPA enriched diseases and function. 
Networks: this option in the IPA software allows for concentrating on more “focused 
molecules” or molecules that have high connectivity with other molecules in the dataset. 
These important molecules are the seed to which other important genes are connected and 
the gaps are then filled from the IPA dataset and networks are finally annotated with high-
level functional categories. The networks are ranked according to the number of focused 
molecules in every network. 
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2.10.5 Gene Set Enrichment Analysis (GSEA) 
Gene set enrichment analysis (GSEA) software includes around 18,000 gene lists uploaded in 
the Molecular Signatures Database (MSigDB)345, 346. This large number of gene lists is arranged 
in 8 main categories with smaller sub-categories. Main categories of the GSEA software 
include: 
• Hallmark gene sets (H): the most popular well-defined biological processes and 
functions. 
• Positional gene sets (C1): include gene lists for every human chromosome. 
• Curated gene sets (C2): include gene from publically available databases. 
• Motif gene sets (C3): include lists of genes regulated by the most common 
transcription factors and miRNAs. 
• Computational gene sets (C4): gene listed by reconstructing the large cancer 
microarray data. 
• Gene Ontology (GO) gene sets (C5): include three categories; genes annotated with 
the GO biological processes, CO cellular processes and CO molecular functions. 
• Oncogenic signatures (C6) 
• Immunologic signature (C7) 
The output of the GSEA analysis is the GSEA enrichment score that includes the enrichment 
score (the degree of which DE genes are overrepresented by the GSEA gene list), normalised 
enrichment score (NES) that corrects for the number of gene sets and false discovery rate 
(FDR) that estimate the probability of false positivity of the enrichment score. The larger the 
NES, the smallest the FDR value for a given analysis.    
2.11 Statistical analysis  
Statistical analyses were performed using SPSS version 23 or GraphPad Prism version 7.00. 
The principal documented endpoint in the clinical cases studied was overall survival, recorded 
as months from diagnosis until 01/01/2019. Differences in cumulative survival were 
determined using the Kaplan-Meier method and a Log-Rank test. The Cox proportional 
hazards-regression model was used to identify parameters associated with survival. Data are 
show as a mean ± the standard error of the mean (SEM). Associations were explored by linear 
regression, with differences between groups of continuous variables assessed by t-test 
(parametric data) or Kruskal Wallis (non-parametric data) tests.  Differences between 
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Chapter 3: Characterisation of SULF2 protein expression and 
Function in human HCC 
 
3.1 Background 
HCC represents the majority of Liver cancer cases and is ranked the third cause of cancer 
related mortality worldwide6. Hepatocarcinogenesis is a multi-step process that arises on the 
background of chronic liver diseases, most commonly liver cirrhosis26. Despite the advances 
in diagnostic and predictive tools including high through-put sequencing and novel immune-
therapies that limit the development and the progression of other types of cancers, HCC 
remains a global problem that affects about 850,000 people all over the world6. Molecular 
profiling studies of tumours resected from HCC patients revealed distinct molecular 
subgroups, generating hopes for personalised therapy approaches57, 59, as yet with limited 
success87, 347. DNA changes in HCC patients have also been thoroughly investigated hoping to 
find targetable candidates109, but the trunk “driver” mutations identified have proven to be 
difficult therapeutic targets88. Recent studies have also focused on the role of the tumour 
microenvironment as a potential driver for the development and the progression of HCC57, 229. 
Anti-PD-1 antibodies (eg. Nivolumab) appear to improve the outcome of patients348 beyond 
sorafenib, the standard of care 1st line therapy for HCC349, and have gained approval from the 
FDA for use as 2nd line therapies. 
SULF2 is an endosulfatase enzyme that selectively removes sulfate group from the 6-O 
position in the HSPGs286. In a previous study, elevated SULF2 mRNA levels in resection samples 
from HCC patients was associated with worse outcome and a link with the HCC tissue marker 
GPC3 was suggested304. In vitro studies showed that SULF2 upregulated GPC3 expression and 
facilitated the binding of Wnt-3a ligand to its receptor, leading to activation of the non-
mutated β-catenin pathway273. A further link between SULF2 and HCC was reported in a study 
where SULF2 knock-out mice were shown to develop fewer tumours compared to their 
matched WT controls. In this study, SULF2 reportedly induced neo-angiogenesis via activation 
of the POSTN/TGF-β pathway301. However, the protein expression and cellular distribution of 
SULF2 in HCC tissues, together with the impact this may have on its clinical significance or 
mechanistic roles in HCC have been poorly investigated so far.   
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3.2 Chapter 3 aims  
3.2.1 To characterise SULF2 within the in vivo tumour microenvironment and explore 
associations with disease stage and patient outcome. 
3.2.1 To define the functional impact of SULF2 in vitro, by developing models to assess the 
contribution of different cell types expression or secreted isoforms on the phenotypic 
behaviour of HCC cells.  
 
3.3 SULF2 expression in liver tissues from patients with HCC 
SULF2 protein level was determined by IHC in diagnostic biopsies from 60 HCC patients. The 
IHC was performed by technical staff in the Reeves lab, with details of patients’ selection and 
IHC protocols described in the materials and methods. The demographic and clinico-
pathological features are presented in Table 3.1. and summarised here.  The median age of 
the studied cohort was 69 years. Although at least 80% of HCC arise in cirrhotic livers, liver 
cirrhosis was absent in 29/60 (49%) of the cases studied. This reflects the majority of HCC 
being diagnosed radiologically in patients with cirrhosis, with biopsy – which carries the risks 
of haemorrhage and tumour seeding - advocated either when there is doubt radiologically, or 
in patients without established cirrhosis332. Patients were those with BCLC A-C stage disease, 
rather than those with end stage BCLC-D, as biopsy diagnosis is generally reserved for those 
patients fit enough for therapy. The overall median survival was 20.3 months in this selected 
group. While many did not have cirrhosis or established chronic liver disease (CLD), etiological 
associations included T2DM in 29 patients out of 60 (49%), with NAFLD or ALD being common 
in those that did have CLD.  
3.3.1 SULF2 expression was scant in the non-tumour tissue 
Generally, SULF2 expression in non-tumour liver was low, with scant SULF2 expression 
occasionally detected on the canalicular surface of hepatocytes (Figure 3.1). Notably, SULF2 
expression was detected in smooth muscle cells of the portal tract arteries as well as in the 
non-parenchymal sinusoidal cells and in the endothelial cells. Low background, with 
expression of SULF2 in either smooth muscle or the endothelial cells, were used as an internal 




Figure 3.1: Expression of SULF2 in HCC tissue compared to the adjacent non-tumour tissue. 
Representative images 
from patient 49 showed 
H&E staining of the non-
tumour (A) and the 
tumour (B) tissues. In the 
non-tumour tissue, 
normal hepatocytes were 
arranged in chords with an 
intact portal tract and 
inflammatory cells 
starting to infiltrate into 
the tissue, while 
cytological atypia, dense 
chromatin together with 
loss of liver architecture 




positivity in the non-
tumour (C) versus the 
tumour tissue (D). SULF2 
was scantly expressed in 
the membrane of normal hepatocytes (black arrow) as well as different non-parenchymal cells 
including smooth muscle cells of the arteries (a), the endothelial cells (e) and the sinusoidal 
cells (white arrow). Images were captured at x20 magnification and scale bars represent 50 
microns, n=60 patients. 
3.3.2 SULF2 was upregulated in the tumour cells in biopsies from a subset of patients with HCC 
In contrast to the SULF2 levels in the non-tumour cases, SULF2 was upregulated in 35/60 (58%) 
of HCC biopsies. This finding supports the previous study that reported upregulation of the 
SULF2 mRNA level in about 57% of HCC resection specimens304. Of the cases characterised 
here, SULF2 upregulation relative to non-tumour tissues was common, but more commonly 
in tumour associated stromal cells rather than tumour cells themselves.  SULF2 positivity in 
the membrane/cytoplasm of the tumour cells was present in only 9/60 (15%) of cases (Figure 
3.1). Tumour cell SULF2 positivity was significantly associated with larger tumours (9.6±1.6 
versus 6.2±0.8 cm, p=0.026) and higher median AFP serum level (1400 ng/ml versus 5ng/ml, 
p=0.03), when compared to the negative cases. Notably, most of the tumour-cell positive 
SULF2 patients (7/9) had T2DM compared to 41% (21/51) where SULF2 was absent (p=0.042). 
SULF2 tumour-cell positivity was also associated with extrahepatic diseases (p=0.003) as well 
as advanced TNM stage (p=0.034). Patients were more likely to receive supportive care only. 
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Median survival was reduced compared to the whole cohort, although not significantly so in 
the small numbers considered (Table 3.1). 
 
Table 3.1: Demographic and clinico-pathological features of patients Continuous data are 
presented as mean ± standard error unless otherwise stated, with statistical comparisons 
using a Mann Whitney test. Categorical data were compared using a Chi Square test. Survival 
was assessed by the Kaplan Meier method. ‘Other’ included small numbers with Hepatitis C 
(n=4); haemochromatosis (n=4), cryptogenic cirrhosis (n=4); Hepatitis B (n=1); autoimmune 
hepatitis (n=2); and α-1-antitrypsin deficiency (n=1). Abbreviations: T2DM, Type 2 diabetes 
mellitus; AFP, alphafetoprotein; BMI, body mass index; ALD, alcoholic liver disease; NAFLD, 
non-alcoholic fatty liver disease; HCV, Hepatitis C; HBV, Hepatitis B;AIH, autoimmune 
hepatitis; A1AT, α-1-antitrypsin deficiency; PVT, portal vein thrombosis; EHD, extra-hepatic 
disease; INR, international normalised ratio; BCLC, Barcelona Clinic for Liver Cancer. 
 
3.3.3 SULF2 upregulation in the Cancer-Associated Fibroblasts (CAFs) identified HCC patients with 
poorest outcomes 
Further characterisation of the HCC biopsies revealed intense positive SULF2 expression in the 
non-parenchymal cancer associated fibroblasts (CAFs) invading the tumour area in 52% of 
tumour cases (31/60) (Figure 3.2). To confirm SULF2 positivity in this particular cell type  
 









Age (median) 69 69 65 ns 
Gender (male/female) 49/11 42/9 7/2 ns 
BMI  (median) 27 27 27 ns 
T2DM no/yes 32/28 30/21 2/7 0.042* 
Cirrhosis no/yes 31/29 25/26 6/3 ns 
CLD none/ALD/NAFLD/other 19/10/15/16 16/9/13/13 3/1/2/3 ns 
Grade 1/2/3 18/27/15 17/23/11 1/4/4 ns 
Size (cm) 6.7±0.7 6.2±0.8 9.6±1.6 0.026* 
Tumour number 2.2±0.4 2.0±0.4 3.3±1.1 0.11 
PVT no/yes 52/8 46/6 6/3 0.056 
EHD no/yes 52/8 47/4 5/4 0.003** 
TNM stage 1/2/3/4 29/12/11/8 26/11/10/4 3/1/1/4 0.034* 
INR 1.0±0.02 1.0±0.02 1.0±0.03 ns 
Albumin (g/l) 38.8 ± 0.67  39.2±0.7 36.8±1.9 ns 
Bilirubin (μmol/l)  21.4±7.9  14.1±1.1 63.1±52 ns 
AFP (median) 6 5 1400 0.03* 
Ascites no/yes 55/5 47/4 8/1 ns 
Childs-Pugh A/B/C 53/6/1 46/5/0 7/1/1 ns 
BCLC stage A/B/C/D 17/13/28/2 15/12/22/2 2/1/6/0 ns 










Median survival (months) 20.3 28.7 11.6 ns 
No Surgical treatment  n=50 n=43 n=7  




Figure 3.2: Expression of 
SULF2 in HCC-CAFs 
compared to the 
adjacent non-tumour 
tissue. Representative 
images from patient 59 
show H&E staining of the 
cirrhotic non-tumour (A) 
and the tumour (B) 
tissues. Cirrhotic changes 
in the non-tumour area 
were evident with micro-
nodules and 
inflammatory infiltrate. 
The tumour tissue was 
characterised with 




positivity in the non-
tumour (C) versus the 
tumour tissue (D). SULF2 positivity was stronger and more evident in the CAFs in the tumour 
tissue compared to the non-tumour. Images were captured at x20 magnification and scale 
bars represent 50 microns. 
 
rather than other infiltrating cells such as elongated TAMs, serial section for selected cases 
were stained with αSMA; the classical marker for activated CAFs. Indeed, SULF2 positive cells 
were also positive for αSMA (Figure 3.3). SULF2 expression was not as positive in the αSMA 
positive activated hepatic stellate cells in the portal tract or bridging fibrous septa of the non-
tumour liver (Figure3.3). 
Compared to SULF2 expression in the tumour cells, CAF-SULF2 positivity was more frequent. 
CAF-SULF2 expression was not associated with specific tumour criteria, however, overall 
survival was reduced in CAF-positive SULF2 HCC cases (12.2 months versus 35 months) (Table 
3.2).  In subsequent survival analyses, the small numbers of patients undergoing potentially 
curative treatments (7 that underwent resection and 3 that had a liver transplantation), were 
excluded.  CAF-SULF2 positivity in the remaining 50 patients was significantly associated with 
poorer survival (7.2 months versus 29.2, p=0.005 Kaplan Meier) (Figure 3.4). Moreover, SULF2  
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Figure 3.3: Expression of 
SULF2 in αSMA positive CAFs 
but not αSMA positive 
fibroblasts. Representative 
images from patient 27 show 
H&E staining of the non-
tumour (A) and the tumour 
(B) tissues. This case was 
characterised by fatty 
deposition and immune 
filtration of the non-tumour 




showed αSMA and SULF2 IHC 
in the non-tumour (C,E) 
versus the tumour tissue 
(D,F). αSMA stained 
activated fibroblasts in the 
portal tract in the non-
tumour tissue and the CAFs in 
the tumour tissue. SULF2 
positivity was restricted to 
the CAFs but not fibroblasts 
of the normal non-tumour 
liver. Images were captured 
at x20 magnification and 
scale bars represent 50 
microns. 
 
upregulation in either HCC cells or HCC and CAFs was also strongly associated with poorer 
survival (9.9 versus 29.2 months, p=0.005, Kaplan Meier). 
Figure 3.4 Stromal SULF2 was associated with poorer 
survival. Kaplan Meier survival curve for patients 
scored as having absent or scanty SULF2 in tumour 
stromal cells, versus those with either widespread or 
focally intense expression is shown. The median 
survival was 7.2 months versus 29.2 months, p=0.005, 





Univariate analyses to identify factors associated with survival are shown in Table 3.3. Those 
with a p value <0.01 were entered into a multivariate cox regression analysis and included  
 
Table 3.2: Demographic and clinico-pathological features of patients 
Continuous data are presented as mean ± standard error unless otherwise stated, with 
statistical comparisons using a Mann Whitney test. Categorical data were compared using a 
Chi Square test. Survival was assessed by the Kaplan Meier method. ‘Other’ included small 
numbers with Hepatitis C (n=4); haemochromatosis (n=4), cryptogenic cirrhosis (n=4); 
Hepatitis B (n=1); autoimmune hepatitis (n=2); and α-1-antitrypsin deficiency (n=1). 
Abbreviations: T2DM, Type 2 diabetes mellitus; AFP, alpha fetoprotein; BMI, body mass index; 
ALD, alcoholic liver disease; NAFLD, non-alcoholic fatty liver disease; HCV, Hepatitis C; HBV, 
Hepatitis B;AIH, autoimmune hepatitis; A1AT, α-1-antitrypsin deficiency; PVT, portal vein 
thrombosis; EHD, extra-hepatic disease; INR, international normalised ratio; BCLC, Barcelona 
Clinic for Liver Cancer. 
 
tumour grade, presence of extrahepatic disease, portal vein thrombosis, or ascites, serum 
albumin, performance status (PST), treatment received and SULF2 status. Tumour grade, 
serum albumin and PST were strongly and highly significantly associated with survival. 









Age (median) 69 69 69 ns 
Gender (male/female) 49/11 23/6 26/5 ns 
BMI  (median) 27 25 28 ns 
T2DM no/yes 32/28 14/15 18/13 ns 
Cirrhosis no/yes 31/29 14/15 17/14 ns 
CLD none/ALD/NAFLD/other 19/10/15/16 9/4/7/9 10/6/8/7 ns 
Grade 1/2/3 18/27/15 12/10/7 6/17/8 ns 
Size (cm) 6.7±0.7 6.2±1.1 7.2±1.0 ns 
Tumour number 2.2±0.4 1.6±0.2 2.7±0.7 ns 
PVT no/yes 52/8 27/2 25/6 ns 
EHD no/yes 52/8 27/2 25/6 ns 
TNM stage 1/2/3/4 29/12/11/8 12/7/3/2 15/2/8/6 ns 
INR 1.0±0.02 1.0±0.02 1.03±0.04 ns 
Albumin (g/l) 38.8 ± 0.67  39.4±0.9 38.3±1.0 ns 
Bilirubin (μmol/l)  21.4±7.9  12±.9 30.3±15.2 ns 
AFP (median) 6 6 6 ns 
Ascites no/yes 55/5 28/1 27/4 ns 
Childs-Pugh A/B/C 53/6/1 28/1/0 25/5/1 ns 
BCLC stage A/B/C/D 17/13/28/2 10/7/12/0 7/6/16/2 ns 










Median survival (months) 20.3 35.0 12.2 ns 
No Surgical treatment  n=50 n=25 n=25  
Median survival (months) 16.2 29.2 7.2 0.005** 
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However, SULF2 presence contributed independently of these factors, whether considered 
only in CAFs, or combined in either tumour cells or CAFs (Table 3.3). 
Variable UVA MVA entering elevated stromal  
SULF2  
MVA entering elevated tumour or 
stromal SULF2 
 p value p value HR (CI) p value HR (CI) 
Age 0.195     
Gender 0.197     
AFP 0.014     
Tumour Number 0.046     
Tumour size 0.015     
EHD 0.006 0.057  0.048 0.31 (0.10-0.99) 
PVT <0.001 0.116  0.130  
Edmondson-Steiner 
Grade 
Grade 1 (n=17) 
Grade 2 (n=22) 

















Cirrhosis 0.795     
Ascites <0.001 0.714  0.668  
Albumin <0.001 0.002 0.88 (0.81-0.96) 0.002 0.88 (0.81-0.95) 
Bilirubin 0.036     
INR 0.433     
ECOG PST 
PST 0 (n=23) 
PST 1 (n=21) 









































0.006 0.045 0.46 (0.22-0.98)   




    0.005   0.016 0.38 (0.18-0.73) 
Table 3.3: Multivariate analysis of factors associated with survival in non-surgically treated 
patients Factors associated with survival in 50 patients for whom surgical treatment was not 
an option were assessed by univariate analysis (UVA). Factors with a p-value less than 0.01 
were entered into a multivariate Cox Regression analysis. Two distinct multivariate analyses 
(MVA) are shown, the first considering stromal SULF2 and the second (shaded in grey) showing 
a similar analysis, but in which SULF2 overexpression in either HCC cells or stromal cells was 
classed as ‘present’. Significance and Hazards Ratio (HR) with upper and lower 95% confidence 




3.4 Investigation of the impact of CAF-SULF2 on the behaviour of the tumour cells 
As SULF2 was predominantly expressed in the αSMA positive CAFs in half of the patients, 
rather than the tumour cells, subsequent studies were directed towards understanding the 
role of stromal SULF2 and/or SULF2 regulated factors. The accumulation of activated hepatic 
stellate cells in patients with chronic liver disease contributes to the tissue mechanical 
stiffness and reportedly enhances tumorigenicity350.  Studies by other groups have also 
previously shown the presence of CAFs to be linked with poorer response to treatment in 
patients with HCC patients334, 351. CAFs reportedly also promote cancer stem cell (CSC) 
properties in the neighbouring tumour cells, as well as regulate the secretion of a wide range 
of inflammatory and pro-oncogenic cytokines that regulate intercellular crosstalk within the 
tumour microenvironment (TME)352, 353. The contribution of CAF-derived SULF2 had not been 
previously explored. 
3.4.1 The expression level of SULF2 varied between different HCC and myofibroblast cell lines.  
The protein and mRNA level of SULF2 was investigated in three different HCC cell lines, 
including Huh7, Hep3B and HepG2 cells, in addition to the αSMA positive myofibroblast LX-2 
cell line. SULF2 was expressed in both Huh7 and HepG2 cell lines, while it is expression in 
Hep3B cell line was minimal, as confirmed by WB and q-PCR (Figure 3.5).   
Figure 3.5: Characterisation of SULF2 expression in different HCC cell lines Western blot 
shows the protein expression of SULF2 in Huh7, HepG2 and Hep3B (A). Huh7 and HepG2 
showed a SULF2 band at 110 kiloDalton (kDa) with a non-specific band at 150 kDa, while 
Hep3B protein extract showed no SULF2 expression. Graph shows mRNA expression of SULF2 
in Huh7 and Hep3B cell lines (B). The level of SULF2 in both cell lines was calculated using the 
relative level of transcriptional difference (RLTD) using HPRT as a control. List of antibodies 
and primers is provided in the materials and methods. Experiments were repeated three times 




SULF2 was expressed by the LX-2 myofibroblasts, which we planned to use to model the 
interactions between HCC cells and stromal cells. To create a further in vitro modelling tool, 
SULF2 was knocked-down by shRNA, as described in the materials and methods section. LX2 
SULF2 expression and SULF2 KD were confirmed by WB (Figure 3.6). Conditioned media (CM) 
was collected from LX-2 cells and SULF2 KD LX-2 cells and the level of SULF2 in the CM from 
both cell lines was measured by ELISA (Figure 3.6), as described in the materials and methods 
section.  
Figure 3.6: Confirmation of SULF2 KD from the LX-2 myofibroblast cell line Western blot 
shows SULF2 levels in control and SULF2 KD LX-2 protein extracts (A). SULF2 (110 kDa) was 
successfully knocked down (KD) from the LX-2 cell line. β-actin (42 kDa) was used as a loading 
control. The experiment was repeated three times (n=3). Graph shows the level of secreted 
SULF2 in CM from control and SULF2 KD LX-2 cells (B). SULF2 level in the SULF2 KD LX-2 CM 
was below the SULF2 ELISA kit’s detection limit (313 pg/ml). Details of ELISA are in the 
materials and methods. 
3.4.2 Optimisation of conditions for the 2D co-culture between myofibroblasts and HCC cell lines 
Based on the aforementioned characterisation, Hep3B cells (with no endogenous SULF2 
expression) and Huh7 cells that expressed SULF2 were chosen for further experiments. 
Previous studies showed induction of tumour cell proliferation stimulated by co-culture with 
CAFs and LX-2 fibroblasts cells or cell CM350, 352. In order to optimise the conditions for co-
culturing HCC cell lines with SULF2 manipulated LX-2 cells in the 2D trans-well system, the 
parent LX-2 cell line was cultured in the trans-well in a 1:1 ratio with 10000, 20000 and 50000 
Hep3B and Huh7 cells for different time points.  
Co-culture with LX-2 induced the viability of Hep3B cells after 24 hours at 10000 cell densities 
(p=0.002), after 48 hours at 10000 (p=0.027) and 20000 (p=0.005) cell densities and after 72 
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hours at 50000 cell density (p=0.001), as compared to matched Hep3B controls, measured by 
an MTT viability/metabolic activity test (Figure 3.7).  
Figure 3.7: Effect of LX-2/Hep3B co-culture on the viability of the tumour cells Graphs show 
viability of Hep3B cells cultured alone or in co-culture with parent LX-2 cells at 1:1 ratio of 
10000 (A), 20000 (B) and 50000 (C) cells at three different time points (24, 48 and 72 hours). 
The experiment was repeated 3 times and data are presented as mean ± s.e.m, * p<0.05; ** 
p<0.01; *** p<0.001; ****p<0.0001, n=3 replicates. 
 
MTT viability of Huh7 co-cultured with LX-2 showed trend towards increase at the 10000 cell 
density at 72 hours (p=0.078) and the 20000 cell density after 24 hours (p= 0.077). This 
increase was significant after 24 (p= 0.04) and 72 hours at the 50000 cell density co-culture 
(p=0.011) (Figure 3.8). Other changes towards increase or decrease in viability upon 
fibroblast-tumour cells co-culture failed to reach significance. 
71 
 
To avoid cells becoming over-confluent and to standardise the protocol for the two different 
HCC cell lines, 1:1 co-culture at the 20000 cells per well density for 48 hours was adopted for 
further co-culture protocols.   
 
Figure 3.8: Effect of LX-2/Huh7 co-culture on the viability of the tumour cells Graphs show 
viability of Huh7 cells cultured alone or in co-culture with parent LX-2 cells at 1:1 ratio of 10000 
(A), 20000 (B) and 50000 (C) cells at three different time points (24, 48 and 72 hours). The 
experiment was repeated 3 times (n=3) and data are presented as mean ± s.e.m, * p<0.05. 
 
3.4.3 Stromal SULF2 induced the viability/metabolic activity of the HCC tumour cell lines 
Hep3B and Huh7 HCC cell lines were co-cultured with media, control LX-2 cells or with SULF2 
KD LX-2 cells (Figure 3.9) to assess the impact of stromal SULF2 on the viability of the tumour 
cells as measured by MTT assay. Secreted SULF2 from control LX-2 cells induced the 
viability/metabolic activity of Hep3B and Huh7 cells compared to cells co-cultured with SULF2 
KD LX-2 (p=0.0067 and 0.0013 respectively). Co-culture with control LX-2 cells also significantly 
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increased the MTT activity of the Hep3B and Huh7 cells compared to HCC cells grown in media 
only (p=0.002 and <0.0001 respectively)(Figure 3.10).  
 
Figure 3.9 Schematic diagram for the fibroblast-tumour cells co-culture experiment. Hep3B 
cells (black cells) or Huh7 cells (grey cells) were co-cultured with Control LX-2 cells (blue) or 
with SULF2 KD LX-2 cells (red) on the 2D trans-well inserts. At the due time point, inserts were 










Figure 3.10 Stromal SULF2 induced the viability of the tumour cells Graphs show the impact 
of stromal SULF2 on the viability of HCC Hep3B (A) and Huh7 (B) cell lines. The experiment 
was repeated 3 times (n=3) and data are presented as mean ± s.e.m, ** p<0.01; ****p<0.0001. 
 
3.4.4 Stromal SULF2 promoted the proliferation of the HCC tumour cell lines 
A BrdU proliferation assay was performed to confirm the stromal SULF2-induced proliferation 
of tumour cells within the TME niche. Consistent with the MTT results, stromal SULF2 induced 
the proliferation of both Hep3B and Huh7 cells compared to co-culture with SULF2 KD LX-2 
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cells (p=0.0008 and 0.0094 respectively), an effect that was also significantly higher than cells 







Figure 3.11. The proliferation of the tumour cells was accelerated in the presence of stromal 
SULF2. Graphs show the impact of stromal SULF2 on the proliferation of the HCC Hep3B (A) 
and Huh7 (B) cell lines. The experiment was repeated 3 times (n=3) and data are presented in 
mean ± s.e.m, * p<0.05; ** p<0.01; *** p<0.001; ****p<0.0001. 
 
3.4.5 Stromal SULF2 potentiated the migration of SULF2-null Hep3B cells, but not the Huh7 cells 
In addition to the in vitro impact of stromal SULF2 on the proliferation of the tumour cells, we 
explored the possible impact of stromal SULF2 on the migration of the tumour cells. Hep3B 
cells (with no SULF2 expression) were able to migrate faster into the ‘scratch assay gap’ when 
co-cultured with control LX-2 cell CM compared to CM concentrated from the SULF2 KD LX-2 
cell,  or Hep3B cells grown without fibroblast CM (p<0.0001 for both conditions) (Figure 3.12). 
Figure 3.12 Migration of Hep3B cells under the influence of stromal SULF2 Representative 
images show migration of Hep3B cells at 0 hours (upper row) versus a 24 hour time point (A). 
Stromal SULF2 in CM potentiated the migration of Hep3B cells (middle column) compared to 
Hep3B cell migration without co-culture with CM (left column) or Hep3B cells grown in CM 
from SULF2 LX-2 CM (right column). Graph shows the migration of Hep3B as a percentage of 
Gap closure and the effect of SULF2 on tumour cell migration (B). The experiment was 
repeated 3 times (n=3) and data are presented in mean ± s.e.m, ****p<0.0001. 
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Notably, stromal SULF2 did not significantly impact the migration of the Huh7 cells grown 
without CM (p=0.714), possibly because Huh7 cells express their own SULF2. Migration of 
Huh7 cells in the presence of stromal SULF2 in the CM, however, was higher than Huh7 cells 
co-cultured with SULF2 KD LX-2 CM, although not statistically significantly so (p=0.0614) 
(Figure 3.13).  
 
Figure 3.13 Migration of Huh7 cell line under the influence of stromal SULF2 Representative 
images show migration of Huh7 cells at 0 hours (upper row) versus a 24 hour time point (A). 
Stromal SULF2 in CM slightly increased the migration of Huh7 cells (middle column) compared 
to Huh7 cell migrated without co-culture with CM (left column) or Huh7 grown In CM from 
SULF2 LX-2 CM (right column). Graph shows the migration of Huh7 as a percentage of Gap 
closure and the effect of SULF2 on tumour cell migration (B). The experiment was repeated 3 
times (n=3) and data are presented as mean ± s.e.m, *p<0.05. 
 
3.4.6 Fibroblast-derived SULF2 increased the invasion of the tumour cells. 
Characterising the ability of the stromal cells to promote tumour cells invasion of the 
basement membrane using a Boyden-invasion chamber was the next goal. As a pilot study, 
SULF2-manipulated LX-2 cells were seeded at the bottom of the 24-well plate to act as a 
source of SULF2 that might induce the invasion of Hep3B cell from inner surface of the Boyden 
chamber out to the outer surface (Figure 3.14).  
Figure 3.14 
Schematic 
diagram for the 
chemotaxis of 
the tumour cells 
influenced by 
stromal SULF2. 
Control and SULF2 KD LX-2 cells (red) were cultured in the bottom of 24-well plate at different 
concentration overnight. 300000 Hep3B cells (blue cells) were then incubated in the Boyden-
invasion chambers and co-cultured with the fibroblasts for 72 hours. The invasion of the 
tumour cells to the outer surface of the chamber was investigated.  
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Stromal SULF2 from 5000 cell/well control LX-2 cells significantly increased Hep3B cell invasion 
compared to Hep3B cultured without fibroblast cell lines at 5000 cell/well (p=0.0013) (Figure 
3.15). However, this effect was not significant when compared to Hep3B/SULF2 KD  
Figure 3.15 Optimisation for the tumour invasion assay Graphs show the invasion of the 
Hep3B cells (300000 cells/chamber) influenced by media only, SULF2-producing control LX-2 
and SULF2 KD LX-2 cells at 5000 fibroblast cell/well (A), 10000 fibroblast cell/well (B) and 
50000 fibroblast cell/well (C). Experiments were repeated twice (n=2) and data are presented 
as mean ± s.e.m, * p<0.05; ** p<0.01; *** p<0.001; ****p<0.0001. 
 
LX-2 co-culture at this cell number. At 10000 fibroblast cell/well, secreted SULF2 significantly 
induced tumour cell invasion compared to tumour cells alone or tumour cells co-cultured with 
SULF2 KD LX-2 cells (p<0.0001) (Figure 3.15). This effect was reversed when 50000 fibroblast 
cell/well were co-cultured with the tumour cells (p<0.0001 and 0.005 respectively) (Figure 
3.15). Taken together, co-culture of tumour cells with SULF2 +/- fibroblasts at 10000 fibroblast 
cell/well revealed the impact of SULF2 on Hep3B cell invasion. 
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The experiment was then repeated at 10000 fibroblasts cells/ well to confirm our finding and 
again control LX-2 induced the invasion of Hep3B cells compared either to tumour cells 
growing alone (p<0.0001) or compared to tumour cells co-cultured with SULF2 KD LX-2 
(P=0.0011) (Figure 3.16). 
Figure 3.16 Impact of Stromal SULF2 on the invasion of the tumour cells Representative 
images show invasion of Hep3B cells (stained purple with crystal violet) into the outer surface 
of the Boyden chambers co-cultured with SULF2 KD LX-2 cells (A) and control LX-2 cells (B) at 
10000 cells/well. Graph shows the impact of stromal SULF2 on the invasion of Hep3B tumour 
cells (C). The experiment was repeated three times (n=3) and the data are presented as mean 
± s.e.m, **p<0.01; ****p<0.0001. 
 
3.4.7 The impact of stromal SULF2 on the proliferation of 3D tumour spheroids 
3D tumour spheroids (organoids) are emerging models for improved assessment of drug 
effectiveness for number of reasons, as recently reviewed by Drost J and Clevers H354. 
Essentially, 3D models are considered more physiological models of human cancer, 
representing an advance in the preclinical models necessary for more effective translation of 
basic research into clinical practice. As stromal SULF2 modulated the viability/metabolic 
activity, proliferation, migration and invasion of the tumour cells on various 2D systems, we 
went on to investigate the interaction between SULF2 and tumour 3D spheroids in the TME 
niche in vitro.  
Huh7 cells in hanging droplets failed to form spheres at 62, 125 and 250 cells/droplet after 4 
days (Figure 3.17). At 500, 750 and 1500 cells/droplet, cells started to form a partial sphere 
like structure that improved at 3000 cells/droplet. Conversely, increasing the number of cells 




















Figure 3.17 Characterisation of Huh7 3D spheroids Representative images show the 
formation of Huh7 spheroids in hanging droplets after 4 days at 62 (A), 125 (B), 250 (C), 500 
(D), 750 (E), 1500 (F), 3000 (G), 6000 (H) and 12000 (I) cells/droplet. Separate multi-spheres 
were formed at lower cell concentrations (A, B, C and D), while at slightly higher cell numbers, 
single spheres began to exist, yet with a less spherical configuration (E and F). Perfect rounded 
spheroids were formed at 3000 cells/droplets (G) and, hence, adapted for further Huh7 
spheroids experiments. Less ideal cell aggregates were formed at higher cell concentrations 
(H and I). Experiment was repeated 10 times/condition (n=10).  
 
Consistent with Huh7 cells, Hep3B cells also formed single nicely spherical spheroids with all 
cells attached to the main spheroid at 3000 cells/droplet after 3 days (Figure 3.18). Hence, 













Figure 3.18 Characterisation of Hep3B 3D spheroids Representative images show the 
formation of Hep3B spheroids in hanging droplets after 3 days at 62 (A), 125 (B), 250 (C), 500 
(D), 1500 (E) and 3000 (F) cells/droplet. Separate multi-spheres were formed at lower cell 
concentrations (A-B and C). Nicely rounded spheroids were formed at 500 and 3000 
cells/droplets (D and F). Spheroids formed from 1500 cells/droplet were quite fragile (E). 3000 
cell/droplet was the cell concentration that was taken further. The experiment was repeated 
10 times/condition (n=10).  
 
3.4.7.1 The impact of stromal SULF2 on the proliferation of the 3D mixed spheroids 
Huh7 and Hep3B HCC cells were mixed in 1:1 ratio with either control or SULF2 KD LX2, and 





Figure 3.19 Schematic diagram for the mixed spheroid experiment 1500 cells from Hep3B 
(black cells) or Huh7 (grey cells) were mixed in 1:1 with either control LX-2 cells (blue) or SULF2 
KD LX-2 cells (red). Cell slurry was suspended in hanging droplets with complete media for 3 
days to form spheres. The impact of stromal SULF2 on mixed spheroids growth was measured 
via assessing the change of spheroids volume at days 4, 5, 7 and 8 compared to the initial 
volume at day3.  
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Huh7 cells directly mixed with control LX-2 cells in 1:1 ratio showed significant increase in the 
spheroid volume compared to Huh7 cell mixed with SULF2 KD LX-2 cells. This SULF2-derived 
proliferative effect was significant starting from 5 days after mixing both cell types together 
for the duration of the experiment (p=0.0089 at 5 days, p<0.0001 at 6 and 8 days) (Figures 
20,21). Notably, the change in the volume of the Huh7/control LX-2 mixed spheroids was  
Figure 3.20 Growth rate of Huh7/LX-2 3D mixed spheroids was affected by stromal SULF2 
Representative images show the growth of an Huh7/control LX-2 mixed spheroid (A) versus 
the growth of an Huh7/SULF2 KD LX-2 spheroid (B) starting from day 4 through to day 8. The 
experiment was repeated 10 times (n=10). Scale bars represent 200 microns.  
  
Figure 3.21 stromal SULF2 induced the proliferation of Huh7/LX-2 mixed 3D spheroids Graph 
shows the change of the volume of Huh7/control LX-2 3D spheroids (blue line) compared to 
Huh7/SULF2 KD LX-2 spheres (red line) from day 3 to day 8. Graph shows the change in the 
volume of Huh7/control LX-2 mixed spheroids (solid blue line) versus the sum change in the 
volume of Huh7 and control LX-2 single cell type spheroids (dashed blue line) (B). Graph shows 
the change in the volume of Huh7/SULF2 KD LX-2 mixed spheroids (solid red line) versus the 
sum change in the volume of Huh7 and SULF2 KD LX-2 single cell type spheroids (dashed red 
line)(C). The experiment was repeated 10 times/condition (n=10). Data are presented as mean 
± s.e.m, **p<0.01; ****p<0.0001. 
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significantly higher than the volume of both Huh7 and control LX-2 matched single cell type 
spheroids (p=0.0059 at 4 days and p<0.0001 at 5, 7 and 8 days), while the growth rate of 
Huh7/SULF2 KD LX-2 was more or less the same (except at day 5) to the growth rate of the 
volume of both Huh7 and SULF2 KD LX-2 matched single cell types (Figure 21).  
Co-culturing Hep3B cells with either control LX-2 or SULF2 KD LX-2 in tumour/fibroblast mixed 
spheroids also showed the same SULF2-dependent growth (p=0.0052 at 5 days, p<0.0001 at 
7 and 8 days) (Figures 22-23). Again, this increase of spheroid volume was SULF2 dependent 
rather than being a result of the difference in the volume of spheroids formed from each 
individual cell type (Figure 23). 
Figure 3.22 Growth rate 
of Hep3B/LX-2 3D mixed 
spheroids was affected 
by stromal SULF2 
Representative images 
show the growth of a 
Hep3B/control LX-2 
mixed spheroid (A) versus 
the growth of a 
Hep3B/SULF2 KD LX-2 
spheroid (B) starting from day 4 to day 8. The experiment was repeated 10 times (n=10). Scale 
bars represent 200 microns.   
Figure 3.23 stromal SULF2 induced the proliferation of Hep3B/LX-2 mixed 3D spheroids 
Graph shows the change of the volume of Hep3B/control LX-2 3D spheroids (blue line) 
compared to Hep3B/SULF2 KD LX-2 spheres (red line) from day 3 to day 8 (A). Graph shows 
the change in the volume of Hep3B/control LX-2 mixed spheroids (solid blue line) versus the 
sum change in the volume of Hep3B and control LX-2 single cell type spheroids (dashed blue 
line) (B). Graph shows the change in the volume of Hep3B/SULF2 KD LX-2 mixed spheroids 
(solid red line) versus the sum change in the volume of Hep3B and SULF2 KD LX-2 single cell 
type spheroids (dashed red line)(C). The experiment was repeated 10 times/condition (n=10). 
Data are presented as mean ± s.e.m, **p<0.01; ****p<0.0001. 
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3.4.7.2 The impact of stromal SULF2 in CM on the proliferation of the 3D tumour spheroids 
Hep3B single type 3D spheroids were bigger when grown in CM from control LX-2 cells or 
SULF2 KD LX-2 CM compared to Hep3B cells in non-fibroblast CM at day 5 (p<0.0001 and 
p=0.0009 respectively) (Figure 3.24). Although Hep3B spheroids grew larger in control LX-2 
CM than in SULF2 KD LX-2 CM, from day 4 until the end of the experiment, it was significant 
only at day 6 (p<0.0001). At this time point, the difference in spheroids grown in SULF2 KD LX-
2 was not statistically significant compared to Hep3B in non-fibroblast CM (P=0.078). On the 
other hand, the difference between tumour spheroids in SULF2-containing CM was 
significantly different from tumour spheroids in non-fibroblasts CM (P<0.0001) (Figure 3.25).    
Figure 3.24 Growth rate of Hep3B 
3D spheroids was affected by 
stromal SULF2.  
Representative images show the 
growth of matched Hep3B 3D 
spheroids in complete, non-
fibroblast (left column), SULF2 KD 
LX-2 (middle column) and control 
LX-2 (right column) CM at 3 days 
(upper row) and 6 days (lower 
row) from pipetting individual 
cells in hanging droplets to form 
the 3D spheroids. Scale bars 
represent 200 microns. The experiment was repeated 10 times/time point/condition (n=10).   
 
 
Figure 3.25 stromal SULF2 induced the proliferation 
of Hep3B 3D spheroids Graph shows the change in 
volume of Hep3B tumour spheroids when grown in 
non-fibroblast media (black line), CM from control LX-
2 cells (blue line) or in CM from SULF2 KD LX-2 cells 
(red line). The experiment was repeated 10 times, per 
time point, per condition (n=10). Data are presented 




3.4.8 The effect of SULF2 blockade on the behaviour of the tumour cells 
A SULF2 monoclonal antibody (Ab) was used to test whether targeting SULF2 in vitro in the 3D 
spheroid system would limit their SULF2-dependent proliferation. The SULF2-dependent 
proliferation of Hep3B spheroids in control LX-2 CM was significantly diminished at 10, 20 and 
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50 ng/ml of SULF2 Ab at days 4 (p=0.0034, p=0.0054 and p<0.0001), 5 (p<0.0001 for all) and 6 
(p<0.0001 for all) (Figure 3.26). The isotype control IgG Ab did not affect the growth of Hep3B 
spheroids at 10 ng/ml (p=0.9967 at day 4, p=0.91 at day 5 and p=0.08 at day 6), but at higher 
concentrations (20 and 50 ng/ml) there was a significant, dose dependent, non-SULF2 related 
growth inhibitory effect on the Hep3B spheroids, attributed to toxicity (Figure 3.26). As a 
result, 10ng/ml for both antibodies was chosen as the optimal concentration in further 
experiments on Hep3B spheroids. 
Figure 3.26 Optimisation of SULF2 Ab concentration Graph shows the growth of Hep3B 
spheroids in control LX-2 CM (blue line), in control LX-2 plus SULF2 Ab at 10 ng/ml (solid red 
line), 20 ng/ml (dashed red line) or 50 ng/ml (dotted red line) concentration, or in control LX-
2 cells plus isotype control IgG at 10 ng/ml (solid green line), 20 ng/ml (dashed green colour) 
or 50 ng/ml (dotted green line). The experiment was repeated 10 times/condition (n=10). Data 
are presented as mean ± s.e.m, ****p<0.0001. 
 
Hep3B spheroids grown in CM from either control or SULF2 KD LX-2 cells were subsequently 
treated with either the SULF2 or IgG control antibody at 10ng/ml. Confirming the previous 
result, the SULF2 Ab significantly diminished the SULF2-dependent growth of Hep3B spheroids 
(p<0.0001), with no effect on the growth of spheroids in SULF2 KD CM (P<0.99) (Figure 3.27). 
The growth of the tumour spheroids in both CMs was not affected by adding the IgG control 






Figure 3.27 Blockade of stromal SULF2 diminished the growth of Hep3B tumour spheroids 
Representative images show the growth of matched Hep3B spheroids in the SULF2 containing 
stromal CM in presence of either control isotype IgG (upper row) or SULF2 Ab (lower row) at 
day 3 (left column) and day 6 (right column) after hanging individual Hep3B cells to form 3D 
spheroids (A). Graph shows the effect of treating Hep3B spheroids grown CM from control or 
SULF2 KD with either SULF2 or isotype control IgGs at day 6 (B). The experiment was repeated 
10 times/condition (n=10). Data are presented as mean ± s.e.m, ***p<0.001;****p<0.0001. 
The growth of the Huh7 spheroids (with a continuous production and secretion of tumour 
SULF2 in their media) was blocked by adding the SULF2 Ab (p=0.0074 at day 6 and p<0.0001 
at day7), but not by adding the isotype control IgG Ab (p=0.37 at day6 and p=0.08 at day7) 
(Figure 3.28).  
Figure 3.28 Blockade of tumour SULF2 diminished the growth of Huh7 spheroids 
Representative images show the growth of matched Huh7 spheroids in the presence of either 
control isotype IgG (upper row) or SULF2 Ab (lower row) at day 4 (left column) and day 7 (right 
column) after hanging individual Huh7 cells to form 3D spheroids (A). Graph shows the effect 
of treating Huh7 spheroids with either the SULF2 or isotype control IgG at days 6 and 7 (B). 




Moreover, the growth promoting effect of Huh7 CM (SULF2 positive) on the Hep3B spheroids 









Figure 3.29 Blockade of tumour SULF2 diminished the growth of Hep3B spheroids Graph 
shows the effect of treating Hep3B spheroids in Huh7 CM with either SULF2 or isotype control 
IgG at day 6. Experiment was repeated 10 times/condition (n=10). Data are presented as mean 
± s.e.m, ****p<0.0001. 
 
3.4.9 Stromal SULF2 reduced the sensitivity of tumour cells to sorafenib therapy 
Sorafenib is the standard of care, 1st line therapy for patients with advanced HCC, although 
the benefit afford to most patients is modest349.  There are no clinically useful biomarkers to 
predict response and novel approaches to select monotherapies or combination therapies are 
needed for this group of patients.  Elevated SULF2 expression in tumour cells was associated 
with advanced stage disease, while elevated in either tumour cells or CAFs it was associated 
with poorer patient outcome. Hence we investigated whether SULF2 had a modulatory effect 
on the response of tumour cells to sorafenib therapy. 
To test the cytostatic/cytotoxic effect of sorafenib on both Hep3B and Huh7, the cells were 
treated with different concentrations of sorafenib and a viability assay was performed (Figure 
3.30). Viability of both cell lines was reduced by sorafenib in a dose dependent manner as 
measured by an MTT viability assay.  Huh7 cells were less sensitive to sorafenib treatment 
than the Hep3B cells, demonstrated by more viable residual Huh7 cells than Hep3B cells at 5 
µM sorafenib at both 48 (55.2% versus 42.2%) and 72 hours (46.2% versus 20.9%). Huh7 have 
more endogenous expression of SULF2 than Hep3B cells, potentially rendering them more 
resistant to sorafenib, was one potential explanation (Figure 3.30).     
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Figure 3.30 viability of Hep3B and Huh7 in response to sorafenib treatment Graphs show 
viability of Hep3B (A) and Huh7 (B) treated with 0.62, 1.25, 2.5, 5, 10, 16 and 20 µM sorafenib 
for 24 hours (black line), 48 hours (blue line) and 72 hours (red line) calculated as percentage 
viability compared to control cells treated with DMSO. Read-out was MTT cell viability assay. 
The experiment was repeated 3 times (n=3). Data are presented as mean ± s.e.m.  
 
In BrdU proliferation assay of the tumour cells co-cultured with fibroblast in the 2D co-culture 
system, sorafenib failed to significantly reduce the proliferation of Hep3B cells co-cultured 
with control LX-2 cells compared to the co-cultured cells treated with DMSO only (p=0.23). 
However, Hep3B cells co-cultured with SULF2 KD LX-2 cells were sensitive to sorafenib 
treatment compared to cells in DMSO (P=0.0085). In addition, the proliferation of the 
sorafenib-treated control non-co-cultured Hep3B cells was also significantly reduced 
compared to DMSO-treated cells (p=0.02) (Figure 3.31). 
Figure 3.31. The impact of stromal SULF2 on 
Hep3B cells response to sorafenib Graph 
shows the proliferation of Hep3B cells co-
cultured with either control LX-2 or SULF2 KD 
LX-2 cells in the presence of sorafenib 
treatment, expressed as % BrdU proliferation 
compared to Hep3B treated with DMSO only. 
The experiment was repeated 3 times (n=3). 




Interestingly, Huh7 cells co-cultured with control LX-2 cells with or without sorafenib 
proliferated at the same rate (p<0.99). Tumour cells responded to sorafenib treatment when 
86 
 
co-cultured with SULF2 KD LX-2 compared to cells treated with the vehicle, yet this did not 
reach statistical significance (p=0.6). Sorafenib had the same trend with no statistical 
significance in the non-co-cultured Huh7 cells (p=0.6), supporting a role for SULF2, either from 
tumour cells or LX-2 cells, in sorafenib resistance in vitro (Figure 3.32).    
Figure 3.32. The impact of stromal SULF2 on 
Huh7 cells response to sorafenib Graph shows 
the proliferation of Huh7 cells co-cultured with 
either control LX-2 or SULF2 KD LX-2 cells in the 
presence of sorafenib treatment, expressed as 
% BrdU proliferation compared to Huh7 
treated with DMSO only. The experiment was 
repeated 3 times (n=3). Data are presented as 
mean ± s.e.m, *p<0.05. 
 
 
Sorafenib exerted its cytostatic/cytotoxic effect on the 3D Hep3B spheroids at 4 different 






Figure 3.33. Sorafenib diminished the proliferation of Hep3B tumour spheroids Graph shows 
the proliferation of Hep3B spheroids, as a change in spheroid volume, treated with DMSO, 
1.25, 2.5, 5 and 10 µM sorafenib from day 3 to day 6 after hanging individual cells to form 
spheres. Experiment was repeated 10 times/condition (n=10). 
 
from control LX-2 cells proliferated in the same rate with/without adding sorafenib to the CM 
at 1.25, 2.5 and 5 µM. In the absence of SULF2 from the stromal CM, the anti-tumour effect 
of sorafenib on the spheroids was restored, compared to spheroids grown in SULF2 KD CM 
with DMSO (p=0.0029)(Figures 3.34 and 3.35). 
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Figure 3.34 Stromal SULF2 
decreased the sensitivity of Hep3B 
tumour spheroids to sorafenib 
treatment at 5 and 2.5 µM 
concentrations. Representative 
images show the growth of matched 
Hep3B spheroids in CM from control 
LX-2 (upper rows) or SULF2 KD LX-2 
cells (lower rows) at day 3 (left rows) 
and 6 days (right rows) after adding 5 
µM (A) or 2.5 µM sorafenib (B). 
Experiment was repeated 10 
times/condition (n=10). 
 
Figure 3.35 Stromal SULF2 
decreased the sensitivity of Hep3B 
tumour spheroids to sorafenib 
treatment at 1.25 µM 
concentration Representative 
images show the growth of 
matched Hep3B spheroids in CM 
from control or SULF2 KD LX-2 cells 
in the presence of 1.25 µM 
sorafenib (A). Spheroid 
proliferation was comparable in 
presence or absence of sorafenib in 
control LX-2 CM. The cytostatic 
effect of sorafenib was restored 
when spheroids were cultured in 
SULF2 KD LX-2 CM. Graph shows 
the proliferative rate of Hep3B 
spheroids, as a change in spheroid 
volume, treated with 1.25 µM 
sorafenib from day 3 to day 7 after 
hanging individual cells to form 
spheres (B). The experiment was 
repeated 10 times/condition 
(n=10). Data are presented as mean ± s.e.m, **p<0.01. 
 
Blockade of stromal SULF2 in the control LX-2 CM using SULF2 Ab retrieved the sorafenib 
impact on the growth of the Hep3B spheroids (p<0.001) (Figure 3.36). 
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Figure 3.36 stromal SULF2 induced resistance to sorafenib was inversed by blocking SULF2  
Representative images show the growth of matched Hep3B spheroids in CM from control LX-
2 cells in the presence of 1.25 µM sorafenib and SULF2/isotype control IgG (A). Spheroids 
proliferated with the same rate in presence or absence of sorafenib in control LX-2 CM with 
the Isotype control IgG. The cytostatic effect of sorafenib was restored when spheroids were 
cultured in control LX-2 CM plus SULF2 Ab. Graph shows the proliferation of Hep3B spheroids, 
as a change in spheroid volume, treated with 1.25 µM sorafenib ± SULF2/isotype control IgG 
at day 6 after hanging individual cells to form spheres (B). The experiment was repeated 10 
times/ condition (n=10). Data are presented as mean ± s.e.m, ***p<0.001; ****p<0.0001. 
 
 
The potential translational impact of these findings was investigated in vivo by performing 
SULF2 IHC staining in biopsies from nine patients with HCC who received sorafenib treatment. 
Biopsies were at the time of diagnosis and the patients were classified as responders if they 
had a partial response or stable disease for at least 3 months. Those patients who showed 
progression of their disease on imaging at 3 month or who did not tolerate the treatment, 
were classified as non-responders. In one patient sorafenib was stopped because of toxicity. 
In six patients there was evidence of progression on their scan at 3 months. These patients 
were classed as non-responders and all of them had SULF2 positive CAFs present on their 
tumour biopsy (Figure 3.37). In one of these patients, CAF SULF2 positivity was scant, but the 
HCC cells were SULF2 positive. By contrast, two patients who maintained stable disease on 
imaging at 6 months, classed as responders, had no evidence of SULF2 positive CAFs (Figure 
3.37). The observed difference in SULF2 expression in non-responders versus responders in 
this pilot study (non-responders 7/7; responders 0/2; p=0.028, Pearson Chi-Square), in 
combination with the in vitro experiments, these data, support a role for presence of stromal 
SULF2 in the mediation of sorafenib resistance. 
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Figure 3.37 Expression of SULF2 in biopsies from sorafenib treated HCC patients 
Representative images show SULF2 IHC staining in biopsies from a sorafenib-responder (A) 
versus a sorafenib non-responder (B). The presence of endothelial cell SULF2 is marked with 




The realisation and understanding of the importance of the tumour microenvironment in the 
development, behaviour and progression of HCC has steadily increased in the last decade. This 
has followed the application of sophisticated and high-throughput multi-Omics technologies 
– focused initially on characterising the molecular aberrations in the tumours - opening the 
door to a new era of research, but largely failing to deliver significant improvements in 
prognosis for patients with liver cancer.  It is recognised that the treatment paradigm of 
targeting the highly proliferative tumour cells may be insufficient and that strategies aimed at 
targeting components of the TME, either alone or in combination, may be more beneficial. 
While the immune TME has received a lot of attention, CAFs are at the heart of the TME and 
help to nourish the tumour cells and stimulate their growth. CAFs are the predominant non-
parenchymal cells in the TME and can modulate the behaviour of the neighbouring tumour 
cells355. They are believed to be derived from the hepatic stellate cells (HSC)356. The overall 
predictive value of both HSC and CAFs in patients with HCC was described previously in an 
elegant study that identified an activated hepatic stellate cell (A-HSC) gene signature in the 
90 
 
non-tumour tissues, but not the matched tumour pairs, that could predict the prognosis of 
well-defined HCC patients with metastasis promoting microenvironment. The gene signature 
was associated with the presence of cirrhosis, the size of the tumour and with vascular 
invasion in a univariate analysis and was independently associated with poorer survival in a 
multivariate analysis357.  Similarly, another research group defined a 122-HSC gene signature 
that included many ECM proteins related to fibrosis358. Combining the 122-HSC gene signature 
with bilirubin and platelet count created a prognostic index that was associated with HCC, 
Child-Pugh class and overall survival358. Notably, presence of αSMA in the peritumoural area 
as a predictor of poorer prognosis in HCC patients after curative resection has been recognised 
for over a decade351. 
Here, we have introduced SULF2 as a key regulator of TME associated HCC progression. SULF2 
was upregulated in 58% of diagnostic biopsies from HCC patients. Of these cases, SULF2 
expression was elevated in the tumour cells in 15% of patients. Albeit small numbers, tumour 
SULF2 was associated with T2DM, tumour size, AFP level and TNM stage. Notably, SULF2 was 
upregulated in 52% of cases in the αSMA positive CAFs and this unique pattern was 
independently associated with poorer patient survival as shown by multivariate analysis. The 
pattern of SULF2 expression in the adjacent non-tumour tissues was different from the 
tumour tissue. In the non-tumour tissue, SULF2 was expressed in the smooth muscle cells 
lining the portal tract arteries, in the endothelial cells, in the sinusoidal cells and in the 
immature bile ductules, raising a potential role of SULF2 in both the premalignant as well as 
in the tumour microenvironments. The expression of SULF2 in more than half of the biopsies 
together with its predictive significance in the CAFs was the justification for the subsequent 
thorough investigation of the role of CAF-derived SULF2 and its impact on the behaviour of 
the tumour cells. 
To discern the role of SULF2 from stromal cells on the behaviour of the tumour cells, two 
different HCC cell lines with different levels of SULF2 were co-cultured with SULF2 
producing/SULF2 deficient LX-2 cells or CM. In our 2D trans-well co-culture system, secreted 
stromal SULF2 induced the viability and the proliferation of the HCC cells regardless of their 
SULF2 status. An advantage of using the 2D trans-well system was that the two different cell 
types were kept physically separate, although cultured as a monolayer, enabling us to 
ascertain that the changes observed in cell phenotype were mediated by soluble 
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communication, rather than direct cell-cell contacts. Stromal SULF2 also increased the 
migration of the SULF2 null Hep3B cell line, supporting a role promoting invasive capacity. 
Advantages of the 2D systems used include them being less expensive and convenient, as they 
are relatively easily handled. On the other hand, 2D systems have significant limitations, the 
major one being that cells grown in 2D systems, as monolayers on polystyrene surfaces, do 
not recapitulate the in vivo conditions359.  Monolayer cultures cannot mimic the actual 3D cell 
aggregates that impact penetration and response of solid tumours to anti-cancer therapies. 
The rounded 3D structured spheroids are an excellent alternative to the conventional 2D 
cultures, especially in the field of cancer research, due to their ability to recreate the structural 
features of human tumour in vitro. 3D spheroids reportedly recapitulate essential features of 
human malignancies, including tumour 3D multi-layered composition, physical cell-cell 
interaction in the tumour context, deposition of ECM protein as well as response to anti-
cancer drugs340, 359, 360.  
Stromal SULF2 induced the growth of the tumour 3D spheroids, either when directly mixing 
tumour/fibroblasts cells together, or by growing tumour 3D spheroids in stromal CM with 
different levels of SULF2. These 3D data complimented our 2D results. Moreover, blockade of 
SULF2 from the SULF2-rich stromal or tumour CM successfully limited SULF2-dependent 
growth on the tumour 3D spheroids. Tumour 3D spheroids responded to sorafenib treatment 
in a dose dependent fashion, but interestingly, the presence of stromal SULF2 in the CM 
converted this drug-responsive phenotype into a drug-resistant one. Finally, in a small cohort 
of patients, we could identified fewer SULF2 positive CAFS in sorafenib responders. 
In conclusion, SULF2 mainly upregulated in the CAFs in HCC, was associated with poor 
outcome in HCC patients. In vitro studies showed that stromal SULF2 could induce a more 
aggressive tumour cell phenotype by increasing tumour cell viability, proliferation, migration, 










The potential importance of SULF2 in HCC had been previously reported by the Roberts’s 
group, in two successive publications in 2008 and 2010, implicating it in the regulation of 
FGF/AKT and β-catenin signalling pathways273, 304. They showed that overexpression of SULF2 
in cell lines facilitated the binding of FGF2 to its receptor on the tumour cells. This binding 
then induced the phosphorylation and activation of the AKT oncogenic pathway. In the same 
context, they demonstrated the SULF2-dependent upregulation of GPC3 using knock-down 
and overexpression experiments in cell lines with different levels of SULF2. They linked the 
two arms of their study by showing that upregulation of GPC3 mediated by tumour SULF2 
increased the autocrine binding of FGF2 to FGF receptors on the tumour cell surface304. In the 
follow up paper in 2010, they focused on the role of SULF2 in activating the β-catenin pathway, 
known to be deregulated in more than 30% of HCC273. Activation mutation in β-catenin, 
restricting it to the nucleus of the tumour cells, can be detected in about 25% of HCC and 
promotes cell survival and proliferation361. Alternatively, binding of different Wnt ligands to 
the Frizzled receptor on the tumour cell surface can liberate wild-type β-catenin from the 
receptor complex enabling translocation to the nucleus and activation of the Wnt/β-catenin 
pathway362. Using a cell line system together with in vivo studies in nude mice, Roberts et al 
showed that SULF2 induced endogenous levels of Wnt3a, one of the Wnt ligands that activates 
Wnt/β-catenin signalling, and that this effect was boosted by adding exogenous Wnt3a 
recombinant protein. SULF2-induced upregulation of GPC3 further facilitated the binding of 
Wnt3a to the Frizzled receptor, activating the downstream pathway273. The group went on to 
report that overexpression of SULF2 protected tumour cell lines from cell death and apoptosis 
induced by inhibitors to PI3K, JNK and ERK pathways. SULF2 knock-down abolished the 
expression of cyclin-D1 and BCL-2 and induced the expression of the pro-apoptotic protein 
BAD. This was driven via P13K/AKT pathway activation in vitro305. 
Earlier studies predating any focus on HCC had revealed a role for SULF2 in the liberation of 
important angiogenic and chemotactic factors from cell surfaces298. SULF2 removal of sulfate 
groups from the 6-O-positions of HSPGs immobilized heparin, releasing VEGF, CXCL12 and 
FGF1 from their heparin binding site to activate their downstream targets298. Studies reporting 
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factors released or secreted into the microenvironment, such as SULF2, which itself promotes 
the release of other factors from the ECM, are of particular relevance to the search for serum 
level biomarkers363. Serum levels of these factors offer less invasive tools, potentially for 
predicting patient prognosis, but also for enrichment, by predicting patients that may respond 
to a therapeutic strategy targeting SULF2.  
Another SULF2 regulated signalling pathway to highlight is that of TGF-β.  As previously 
described in chapter 3, SULF2 KO mice were protected from DEN-induced liver tumorigenesis 
compared to their WT control mice. In vitro and in vivo studies showed that SULF2 regulates 
the expression and secretion of certain angiogenic factors involving POSTN301. This effect was 
initiated via SULF2-dependent desulfation of TGFBR3 receptor releasing the bound TGFB1 
that, in turn, induced the expression of POSTN activating ERK and Focal adhesion kinase (FAK) 
pathways in the endothelial cells301. 
All the cited studies relied on transcriptomic data to quantify SULF2, with limited focus on its 
cellular origin.  Therefore the role of CAF-derived SULF2, CAFs being the predominant source 
of SULF2 in the HCC TME, as described in Chapter 3, has not been previously studied. 
Characterising the cellular source may inform best way of targeting the protein in the clinical 
context. Importantly, mechanistic pathways often have cell-type specific, even contradictory, 
roles137. In Chapter 3 we showed that stromal SULF2 induced tumour cell proliferation, 
migration, invasion and resistance to sorafenib treatment. The focus here was to explore the 
mechanisms involved – using in vitro models, but also publically available transcriptome data.  
4.2 Chapter 4 aim 
 
4.2.1 To explore the impact of SULF2 on different oncogenic, cell survival and chemoresistance 




4.3 Investigation of the impact of SULF2 KD from LX-2 fibroblasts  
4.3.1 The effect of SULF2 levels on the expression of different mesenchymal markers and 
inflammatory cytokines 
In human HCC, the CAFs were the predominant cellular source of SULF2 within the TME. We 
initially set out to understand the role of autocrine stromal SULF2 signalling on CAFs. 
Successful KD of SULF2 was confirmed by q-PCR (Figure 4.1A) as well as by WB and ELISA as 
shown in Chapter3 in Figure3.6. SULF2 KD from LX-2 fibroblasts led to the down-regulation of 
PDGFRβ (Figure 4.1B) and COL1a1 (Figure 4.1C) expression, with no impact on the expression 
of the mesenchymal markers αSMA (Figure 4.1D), VIM (Figure 4.1E) and TIMP1 (Figure 4.1F). 
This implied that SULF2 regulated a specific phenotype within the stromal cells, potentially 
mediated by PDGFRβ signalling. An increase in collagen deposition and tissue stiffness has 
been previously reported to be strongly associated with poor disease outcome226. Notably, 
αSMA, TIMP1 and VIM levels in LX-2 cells were not SULF2 dependent, indicating that SULF2 
KD did not affect the activation status of the fibroblasts. 
Figure 4.1 SULF2 KD 
suppressed the 
expression of certain 
markers in LX-2 myo-
fibroblasts. Graphs 
show suppression of 
SULF2 (A), PDGFRβ 
(B), and COL1a1 (C) in 
association with SULF2 
KD in LX-2 cells, while 
αSMA (D), VIM (E) and 
TIMP1 (F) were 
unaffected. 
Expression is shown as 
the relative level of 
transcriptional 
difference (RLTD) 
using HPRT as a 
control. Experiments 
were repeated three 
times (n=3) and data 
are expressed as mean 




Given that CAFs are an abundant source of pro-inflammatory cytokines and growth factors in 
the malignant niche226, gene expression of key inflammatory cytokines IL-1β, TNF-α, IL-6 and 
IL-8 was compared between control and SULF2 KD LX-2 fibroblasts. SULF2 KD from LX-2 cells 
significantly decreased the expression of IL-6 (Figure 4.2A), IL-8 (Figure 4.2B) and TNF-α 
(Figure 4.2C) compared to the control fibroblasts, while IL-1β levels were expressed at 
comparable levels regardless of SULF2 status (Figure 4.2D). 
Figure 4.2 SULF2 KD decreased the expression of protumourigenic cytokines in LX-2 myo-
fibroblasts. Graphs show decreased of IL-6 (A), IL-8 (B), TNFα (C) and IL-1β (D) expression in 
association with SULF2 KD in LX-2 cells. The expression level is shown as relative level of 
transcriptional difference (RLTD) using HPRT as a control. Experiments were repeated three 
times (n=3) and data are expressed as mean ± s.e.m; * P<0.05; ** p<0.01. 
 
 
As a confirmation to the mRNA expression data, ELISA was performed to measure the protein 
level of COL1a1, IL-6, IL-8, TNFα and MCP1 in concentrated CM from control and SULF2 KD LX-
2 cells. IL-6 (Figure 4.3A), IL-8 (Figure 4.3B) and COL1a1 (Figure 4.3C) protein levels were 
significantly higher in CM from control LX-2 cells than in SULF2 KD LX-2 CM. On the other hand, 
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there was no change in TNF-α (Figure 4.3D) and MCP1 (Figure 4.3E) protein levels in CM from 
both cell lines. 
Figure 4.3 SULF2 KD supressed the secretion of key cytokines in LX-2 myo-fibroblasts. Graphs 
show decreased protein levels of IL-6 (A), IL-8 (B), COL1a1 (C) in association with SULF2 KD 
from LX-2 cells, while the protein levels of TNFα (D) and MCP1 (E) remained unchanged. Data 
are presented in mean ± s.e.m; * p<0.05; ** p<0.01; ****p<0.0001, n=3 repeats 
 
4.3.2 The impact of SULF2 on the activation of different pathways in LX-2 fibroblasts 
Expression data of control and SULF2 KD LX-2 cells confirmed the deregulation of PDGFRβ, 
together with key inflammatory markers. To understand the underlying mechanism 
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responsible for this change in the fibroblast secretome, WB of protein lysate from control and 
SULF2 KD LX-2 cells grown in SF conditions first confirmed the stable KD of SULF2 at 24 and 48 
hours from cell seeding (Figure 3.6). Control LX-2 cells showed higher levels of p-PDGFRβ 
compared to SULF2 KD LX-2 cell at 24 hours with modest levels between cell lines at 48 hours. 
The upregulation of total PDGFRβ in the control LX-2 cells compared to SULF2 KD LX-2 
fibroblasts was evident at 24 hours but similar at 48 hours (Figure 4.4). In summary, mRNA 
and WB confirmed the SULF2-dependent activation and upregulation of PDGFRβ in the LX-2 
fibroblasts.  
Looking downstream of PDGFRβ signalling, p-JNK1/2 and p-STAT3 levels were strongly 
downregulated upon SULF2 KD from LX-2 fibroblasts compared to control cells, with no 
change in the total JNK1/2 and STAT3 levels between the two cell lines (Figure 4.4). While the 
increase in phosphorylation of the RelA subunit of NF-κB at serine 536 (pP65) was more 
obvious in control LX-2 compared to SULF2 KD LX-2 cells at 48 hours, there was no change in 
p-AKT and p-ERK1/2 levels between both fibroblasts cell lines at either time point. In 
conclusion, stromal SULF2 might activate PDGFRβ/JNK/STAT3, but not ERK and AKT pathways 
in the LX-2 fibroblasts (Figure 4.4). 
Previous reports confirmed the link between JNK and STAT3 pathways with the production of 
different inflammatory cytokines137. The development of HCC depended on the activation of 
JNK pathway in liver fibroblasts via an increase in cytokines levels and especially IL-6137. This 
was consistent with our hypothesis that SULF2-mediated activation of the PDGFRβ/JNK 
pathway contributed to the production of IL-6 and IL-8 pro-inflammatory and tumour 
promoting cytokines. Indeed, addition of recombinant IL-6 protein to the CM from SULF2 KD 
LX-2 cells partially rescued the proliferative phenotype of Hep3B spheroids compared to 
SULF2 KD LX-2 CM (Figure 4.5).  Thus, in addition to the direct mitogenic effect of stromal 
SULF2 on tumour cells (demonstrated previously by adding SULF2 antibody to tumour cells – 
Chapter 3), SULF2 may indirectly increase tumour cell proliferation via activation of the 

















Figure 4.4 SULF2 KD deactivated PDGFRβ, JNK and STAT3 pathways in LX-2 myo-fibroblasts. 
Western blots show reduced phosphorylation of pPDGFRβ, pJNK1/2 and pSTAT3 in response 
to SULF2 KD from LX-2 cells. Phosphorylation levels of AKT and ERK1/2 were unaffected with 








Figure 4.5 Addition of recombinant IL-6 to SULF2 KD CM rescued the proliferative phenotype 
on Hep3B spheroids. Graph Shows increase in the growth of Hep3B spheroids when IL-6 was 
added to SULF2-deficient LX-2 CM (A). Representative images show the partial rescue of 
Hep3B spheroids growth phenotype after adding IL-6 recombinant protein to the SULF2 KD 




4.4 Validation of the association between SULF2, PDGFRβ and IL-6 
Interrogation of the publically available (TCGA) human liver cancer dataset on the cBioPortal 
website (http://www.cbioportal.org/) revealed that SULF2 expression positively associated 
with the expression of both PDGFRβ (Spearman’s Rho 0.58, q-value=2.53e-32) and IL-6 
(Spearman’s Rho 0.38, q-value=2.42e-13) (Figure 4.6). In combination, these data support a 
key role for SULF2 in modulating autocrine secretion of pro-tumourigenic IL-6 from fibroblasts, 
via activation of the PDGFRβ/JNK pathway.   
Figure 4.6 Significant associations between SULF2 and PDGFRβ and IL-6 expression in human 
TCGA gene expression data.  Graphs show the correlation between log2 SULF2 expression 
and log2 PDGFRβ (A) or log2 IL-6 expression (B) expression. Data are presented as mRNA 
expression (RNA seq V2 RSEM) for 373 samples. 
 
 
4.5 Investigation of the paracrine role of stromal SULF2 on the tumour cells 
The paracrine role of stromal SULF2 on activation of different oncogenic pathways within the 
tumour cells was then investigated by culturing Hep3B spheroids in CM from control or SULF2 
KD LX-2 cells in the presence of inhibitors to various oncogenic pathways. Inhibitors to JNK 
pathway (SP600125), TAK-MAPK pathway ((5Z)-7-Oxozeaenol), IKKβ-NF-κB pathway (CAS 
507475-17-4), ERK1/2 pathway (FR 180204) and TGFβ pathway (SB525334) were applied to 
the tumour spheroids to test whether or not they would limit stromal-SULF2 mediated HCC 
proliferation. Before treating tumour spheroids with inhibitors, the optimal, non-toxic dose 
from each inhibitor was assessed first in 2D HCC cultures. Hep3B cells seeded in 96-well plate 
were treated with different concentrations from each inhibitor and the dose that inhibited the 
growth of cells (measured by MTT viability assay) without being toxic over 24, 48 and 72 hour 
time points was considered for the 3D spheroids experiment. 
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As Hep3B spheroids grown in SULF2-rich CM were protected from the sorafenib-induced 
cytostatic/cytotoxic effect compared to spheroids in SULF2-deficient CM, we wanted to know 
whether or not the pathways activated by stromal SULF2 would also be responsible for the 
SULF2-induced sorafenib resistance. So in parallel to the spheroid experiment, Hep3B cells in 
6-well plate were treated with SF media, SF-CM from control or SULF2 KD LX-2 cells in absence 
and presence of sorafenib. Protein lysates of the treated cells were then immuno-blotted for 
possible SULF2-dependant phosphorylated and total forms of downstream targets of the 
deregulated pathways. 
The JNK inhibitor SP600125 was able to limit both SULF2-dependent and independent growth 












Figure 4.7 The JNK1/2 inhibitor had no stromal SULF2-dependent impact on tumour growth. 
Graph shows MTT viability data for Hep3B cells treated with different concentrations of a JNK 
inhibitor for a number of time points (A), presented as mean ± s.e.m of three experiments. 
Representative images (B) and graph (C) show changes in the growth of Hep3B tumour 
spheroid treated with CM from both control and SULF2 KD LX-2 cells in presence or absence 
of 5µM of JNK1/2 inhibitor. Data are presented are expressed as mean ± s.e.m of 10 
spheroids/condition (n=10); * p<0.05; ****p<0.0001. 
 
WB for phospho- and total JNK1/2 showed that addition of CM promoted an increase in p-
JNK1/2 phosphorylation and activation of the pathway in the tumour cells independent of 
101 
 
SULF2 (Figure 4.8). Moreover, sorafenib inhibited p-JNK1/2 activation in a SULF2-independent 
manner (Figure 4.8). The same pattern was shown in p-STAT3 and STAT3 proteins (Figure 4.8) 
implying that stromal SULF2-induced oncogenic and sorafenib-evading mechanisms were 
driven via activation of neither JNK nor STAT3 pathways. 
Figure 4.8 Stromal SULF2 had no independent impact on JNK or STAT3 signalling in tumour 
cells. Western blots show that stromal 
CM induced the phosphorylation of 
pJNK1/2 and pSTAT3 in Hep3B cells in a 
SULF2-independent fashion. Sorafenib 
blocked the phosphorylation of pJNK1/2 
and pSTAT3 in the Hep3B cells regardless 
to the SULF2 level in the stromal CM. The 
experiment was repeated two times 
(n=2).  
 
Consistent with this, inhibitors to ERK1/2 and TGFβ-1 pathways blocked the growth of Hep3B 
spheroids grown in SULF2 positive and negative CM (Figure 4. 9).     
Figure 4.9 The ERK1/2 and TGFβ inhibitors had no stromal SULF2-dependent impact on 
tumour growth. Graphs show MTT viability data for Hep3B cells treated with different 
concentrations of either 
ERK1/2 (A) or TGFβ (C) 
inhibitors for a number 
of time points is shown, 
and data are presented 
as mean ± s.e.m of three 
experiments. Graphs 
show changes in the 
growth of Hep3B 
tumour spheroid 
treated with CM from 
both control and SULF2 
KD LX-2 cells in 
presence or absence of 
ERK1/2 (B) or TGFβ (D) 
inhibitors. Data are 
presented are 
expressed as mean ± 




On the other hand, inhibitors to the MAPKKK (TAK1) (Figure 4.10) and its downstream target 






























Figure 4.10. TAK1 inhibitor blocked SULF2-dependent growth of Hep3B spheroids. Graph 
shows MTT viability of Hep3B cells treated with different concentrations of TAK1 inhibitor (A). 
Data are presented as mean ± s.e.m of three experimental repeats. Representative images (B) 
and graph (C) show changes in the growth of Hep3B tumour spheroid treated with CM from 
both control and SULF2 KD LX-2 cells in presence or absence of TAK1 inhibitor. Data are 





Figure 4.11 IKKβ inhibitor blocked SULF2-dependent growth of Hep3B spheroids. Graph 
shows MTT viability of Hep3B cells treated with different concentrations of IKKβ inhibitor (A). 
Data are presented as mean ± s.e.m of three experimental repeats. Representative images (B) 
and graph (C) show changes in the growth of Hep3B tumour spheroid treated with CM from 
both control and SULF2 KD LX-2 cells in presence or absence of IKKβ inhibitor. Data are 
presented as mean ± s.e.m of 10 spheroids/condition (n=10); P<0.01; *** P<0.001; 
****p<0.0001. 
 
WB for the phospho- and total RelA ser(536) subunit of NF-κB pathway, a classical target of 
TAK1/IKKβ pathway, showed upregulation of p-RelA ser(536) in Hep3B cells treated with 
SULF2-containing CM compared to both SF CM or SF CM from SULF2 KD LX-2 (Figure 4.12). 
Total RelA ser(536) remained unchanged, confirming the SULF2-dependent activation of this 
particular pathway. Furthermore, this SULF2-induced RelA ser(536) phosphorylation persisted 
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even in presence of sorafenib, suggesting a link between NF-κB activation and sorafenib 
resistance in a SULF2-dependent manner. Consistent with the inhibitor data, neither the 








Figure 4.12 Stromal SULF2 activation of NF-κB, not AKT and ERK, persisted in the presence 
of sorafenib in tumour cells. Western blots show that stromal SULF2 induced the 
phosphorylation of RelA-P-ser356 (pP65), but not pAKT or pERK1/2 in Hep3B cells. This SULF2-
dependent phosphorylation of P65 remained even in the presence of sorafenib, n=4 repeats.  
 
 
These data confirm that stromal-SULF2 and its related secretome induced the activation of 
the TAK1/IKKβ/NF-κB pathway in the tumour cells in a paracrine manner. The impact was 
associated with an increase in the tumour cell proliferative capacity, but also an increase in 
their ability to resist chemotherapy.   
4.6 The role of SULF2 in promoting a cancer stem cell (CSC) phenotype in tumour cells 
The stromal SULF2-driven aggressive tumour behaviour was in keeping with a CSC 
phenotype364, 365, known to be regulated by NF-κB pathways in different human cancers 
including HCC366. Sorafenib resistance was also reminiscent of this phenotype367. The mRNA 
expression level of different CSC markers was investigated in Hep3B cells challenged with 
DMSO, control LX-2 CM and SULF2 KD LX-2 CM, with or without sorafenib (Figures 4.13 - 4.19). 
The presence of SULF2 in the fibroblast CM dramatically induced CD44 compared to either 
untreated cells or cells treated with SULF2 KD CM at 12 and 24 hours. This SULF2-dependent 
upregulation of CD44 persisted with concurrent sorafenib treatment. Thus, stromal SULF2 
induced CSC features and sorafenib resistance in association with the upregulation of CD44 in 
105 
 
the tumour cells (Figure 4.13 A,B). Sorafenib-only treatment also upregulated VIM and CDH1, 
but in a SULF2-independent manner (Figure 4.13 C-F). Neither sorafenib nor SULF2 
significantly changed the expression profile of EpCAM, KRT7, KRT19, AXIN2, LGR5, CDH2, 
PDGFRα, PDGFRβ, TCF4, COL1a1 and FZD7 (Figures 4.14 – 4.17). 
Figure 4.13 Stromal SULF2 induced the expression of CD44, but not VIM or CDH1 in Hep3B 
cells. Graphs show elevated CD44 (A,B), but not VIM (C,D) and CDH1 (E,F) in Hep3B cells 
treated with control or SULF2 KD LX-2 CM, which persists in the presence of sorafenib at 12 
and 24 hours. The expression level is presented as relative level of transcriptional difference 
(RLTD) using HPRT as a control. Experiments were repeated three times (n=3) and data are 
expressed as mean ± s.e.m; * p<0.05; ** p<0.01. 
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Figure 4.14 Stromal SULF2 didn’t affect the expression of EpCAM, KRT7 or KRT19 in Hep3B 
cells. Graphs show comparable levels of EpCAM (A,B), KRT7 (C,D) and KRT19 (E,F) in Hep3B 
cells treated with control or SULF2 KD LX-2 CM in presence or absence of sorafenib. The 
expression level is presented as relative level of transcriptional difference (RLTD) using HPRT 





Figure 4.15 Stromal SULF2 didn’t affect the expression of AXIN2, LGR5 or CDH2 in Hep3B 
cells. Graphs show comparable levels of AXIN2 (A,B), LGR5 (C,D) and CDH2 (E,F) in Hep3B cells 
treated with control or SULF2 KD LX-2 CM in presence or absence of sorafenib. The expression 
level is presented as relative level of transcriptional difference (RLTD) using HPRT as a control. 






Figure 4.16 Stromal SULF2 didn’t affect the expression of PDGFRα, PDGFRβ or TCF4 in Hep3B 
cells. Graphs show comparable levels of PDGFRα (A,B), PDGFRβ (C,D) and TCF4 (E,F) in Hep3B 
cells treated with control or SULF2 KD LX-2 CM in presence or absence of sorafenib. The 
expression level is presented as relative level of transcriptional difference (RLTD) using HPRT 




Figure 4.17 Stromal SULF2 didn’t affect the expression of COL1A1, CXCR4 or FZD7 in Hep3B 
cells. Graphs show comparable levels of COL1A1 (A,B), CXCR4 (C,D) and FZD7 (E,F) in Hep3B 
cells treated with control or SULF2 KD LX-2 CM in presence or absence of sorafenib. The 
expression level is presented as relative level of transcriptional difference (RLTD) using HPRT 
as a control. Experiments were repeated three times (n=3) and data are expressed as mean ± 




Of note, IL-6 expression in the tumour cells was induced by stromal SULF2 and also persisted 
in SULF2/sorafenib treated tumour cells at 12 hours, but this failed to reach statistical 
significance (Figure 4.18 A). The expression levels of FGFR1, GADD45β, MDR1 and TNF-α was 
not altered by stromal SULF2. 
Figure 4.18 Stromal SULF2 didn’t affect the expression profile of the inflammatory cytokines 
IL6, FGFR1 or GADD45β in Hep3B cells. Graphs show comparable levels of IL6 (A,B), FGFR1 
(C,D) and GADD45β (E,F) in Hep3B cells treated with control or SULF2 KD LX-2 CM in presence 
or absence of sorafenib. The expression level is presented as relative level of transcriptional 
difference (RLTD) using HPRT as a control. Experiments were repeated three times (n=3) and 




Figure 4.19 Stromal SULF2 didn’t affect the expression of TNFα and MDR1 in Hep3B cells. 
Graphs show comparable levels of TNFα (A,B) and MDR1 (C,D) in Hep3B cells treated with 
control or SULF2 KD LX-2 CM in presence or absence of sorafenib. The expression level is 
presented as relative level of transcriptional difference (RLTD) using HPRT as a control. 
Experiments were repeated three times (n=3) and data are expressed as mean ± s.e.m. 
 
In summary, in association with enhanced prolferation, invasivion and therapy resistance, 
stromal SULF2 activated NF- κB and preferentially induced the expression of CD44 in HCC cells. 
CD44 is an established direct target of the NF-κB pathway366, 368. In Hep3B cells treated with 
SULF2-rich stromal CM in presence of an IKKβ inhibitor, the inhibitor abrogated SULF2-induced 
upregulation of CD44, confirming stromal SULF2 as a regular of the tumour IKKβ/NF-κB/CD44 








Figure 4.20 IKKβ inhibitors abrogated the stromal SULF2-dependent upregulation of CD44 in 
Hep3B cells. Graph shows comparable levels of CD44 in Hep3B cells treated with SULF2 KD LX-
2 CM or with IKKβ inhibitor added to the SULF2-rich CM, while CD44 level was significantly 
higher in tumour cells treated with control LX-2 CM. The expression level is presented as 
relative level of transcriptional difference (RLTD) using HPRT as a control. Experiments were 
repeated three times (n=3) and data are expressed as mean ± s.e.m.; *p<0.05, ** p<0.01. 
 
4.7 Validation of the CAF-SULF2 driven activation of tumour NF-κB/CD44 axis in vivo 
IHC staining in human biopsies further supported the CAF-tumour cross-talk driven by SULF2. 
In 20 of the HCC cases previously assessed for SULF2, the presence of CAF-SULF2 (Figure 4.21 
A,D) was strongly associated with nuclear localisation of p-RelA ser(536) in the adjacent 
tumour cells (Spearman’s Rho 0.776 p<0.001, Pearson Chi-squared test p=0.005) (Figure 4.21 
B,E). Membranous CD44 expression in the tumour cells correlated with SULF2 positivity in the 
contacting CAF (Spearman’s Rho correlation 0.744 p<0.001, Pearson Chi-squared test 
p=0.001) (Figure 4.21 C,F). In addition, CD44 protein expression was associated with the p-
RelA ser(536) nuclear positivity (Spearman’s rho 0.741 p<0.001, Pearson Chi-squared test 
0.047). In CAF-SULF2 null tumours, nuclear p-RelA ser(536) and membranous CD44 protein 




Figure 4.21 Co-expression of SULF2, CD44 and pRelA ser536 in human HCC biopsies 
Representative images show IHC staining SULF2 (A,D), pRelA ser536 (B,E) and CD44 (C,F) in 
two different HCC patients. CAF-SULF2 positivity was evident with nuclear positivity of pRelA 
ser536 and membranous CD44 positivity in the adjacent tumour cells. Representative images 
show IHC staining SULF2 (G), pRelA ser536 (H) and CD44 (I) in HCC patient biopsy. The three 
markers were negative in this particular case. Images were captured using Aperio Imagescope 
software at x20, x10 and x5 magnifications, n=20 biopsies. 
 
4.8 SULF2 co-expression with Glypican-3 promotes Wnt signalling and a poor prognosis   
GPC3 is a HSPG morphogen often upregulated in HCC tissues and its immunohistochemical 
detection has been proposed as an HCC histopathology diagnostic biomarker369. GPC3 
overexpression stabilises cytoplasmic β-catenin in HCC cells and stimulates canonical Wnt 
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signalling in vitro370, while SULF2 reportedly regulates both expression and 6-O sulfation of 
GPC3304. Our own studies in patient tissues and cell lines indicate that SULF2 co-expression 
with GPC3 is associated with cytoplasmic accumulation of β-catenin and promotes its nuclear 
localisation (Figures 4.22 – 4.23). GPC3 expression was absent in non-tumour tissues (Figure 
4.22) and 16/60 tumours, but present in tumour cells in 44/60 (73%) cases, graded as 1 
(cytoplasmic dot like or focal positivity, n=17), 2 (diffuse weak positivity in cytoplasm or 
membrane, n=9) or 3 (intensely positive membranous or cytoplasmic staining, n=18). Strong 
membranous or cytoplasmic GPC3 expression (Grade 3) was more common in cases with 
SULF2 expression in either tumour or stromal tissues (14/35 SULF2 present versus 4/25 SULF2 




















Figure 4.22 Tumour GPC3 
and CAF SULF2, in 
association with nuclear 
β-catenin in HCC 
Representative images 
show H&E staining, GPC3, 
SULF2 and β- catenin IHC 
in both HCC (T) and 
adjacent non-tumour liver 
(NT). (A) GPC3, SULF2 and 
β- catenin was 
upregulated in T 
compared to NT. Nuclear 
β- catenin was evident in 
the T cells compared to 
NT, where its localisation 
was mainly membranous. 
(B) GPC3+ cells were 
present in T, with SULF2+ 
CAFs and nuclear β-
catenin. (C) Shows NT, 
with no GPC3or SULF2 
and membranous β- 
catenin. Images were 
captured using Aperio 
Imagescope software at 












Figure 4.23 tumour cell β-catenin localisation is membranous in the absence of tumour GPC3 
even in the presence of tumour stromal cells expressing SULF2. Representative images show 
a grade 2 HCC stained with GPC3 (left), SULF2 (middle), and β-catenin (right). SULF2 positive 
CAFs, GPC3 negative tumour cells and membranous β-catenin are shown. Images were 
captured using Aperio Imagescope software at x20 magnifications. 
 
In our non-surgically treated patients (n=50), GPC3 expression (absent n=13 or present n=37) 
was not significantly associated with survival, although Grade 3 GPC3 identified a small group 
with a particularly poor prognosis (n=14, median survival 6.7 months). In contrast, 
stratification of all GPC3 positive cases based on SULF2 co-expression discriminated 
significantly between those with a good or poor prognosis. GPC3 and SULF2 co-expression 
remained significantly associated with poorer survival in a multivariate Cox Regression 
analysis (HR 3.63 (1.4-9.2), p=0.007) (Figure 4.24).  
 
Figure 4.24 SULF2 co-
expression discriminates 
prognosis in the presence 
of Glypican-3 Kaplan Meier 
curves show GPC3 only (A) 
or GPC3 and SULF2 co-
expression (B) correlating 
with patient survival.  
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The relationship between SULF2, GPC3 and β-catenin was explored in-vitro in Huh7 cells, 
which express SULF2 in the presence of wild type (WT) Wnt/β-catenin signalling60. In WT Huh7 
cells, stromal SULF2 induced GPC3 expression (Figure 4.25A) as well as membranous and 
cytoplasmic accumulation of β-catenin (Figure 4.25B). Addition of Wnt3a promoted further 
cytoplasmic accumulation of β-catenin, with evidence of nuclear localisation (Figure 4.25C). 
Taken together our in vitro data support the upregulation and activation of the GPC3 Wnt/β-




























Figure 4.25 Stromal SULF2 upregulated membranous GPC3 and β-catenin in Huh7 cells 
Confocal images from the immuno-fluorescence staining of Glypican-3 expression in Huh7 
cells treated with control LX-2 (SULF2 producing) or SULF2 KD LX-2 (no SULF2) cell CM (A). 
Confocal imaging from the immuno-fluorescence staining shows β-catenin expression and 
localisation in Huh7 cells treated with control LX-2 or SULF2 KD LX-2 cell CM ± frizzled receptor 






Activation of Wnt signalling is one of the main regulators CSC phenotype in different 
cancers366, 371, and given the fact that SULF2 activated Wnt signalling in our patient series, the 
association between Wnt signalling and NF-κB signalling was investigated. Notably, there was 
no correlation between nuclear β-catenin and RelA-P-ser536 (Pearson Chi-squared test 
p=0.331) or between β-catenin and CD44 (Pearson Chi-squared test p=0.336) in our cases, 
consistent with a SULF2 dependent phenotype. 
4.9 Discussion 
CAFs affect both the composition of the TME and the behaviour of the other cells in this niche. 
CAFs regulate many growth factors that bind different receptors, including integrins and 
laminins372, as well as secreting ECM factors such as collagens, fibronectin and 
glycoseaminoglycans335, 373, 374.  Deposition of these factors in the TME renders the tissue more 
rigid, a mechanical property that influences the phenotype of CAFs and tumour cells335, 375, 376. 
CAFs can also inhibit the infiltration of the lymphocytes to the tumours, decrease the survival 
of the mononuclear cells and increase the number of Treg cells that favour a more immuno-
suppressive TME377, 378. Many angiogenic factors like VEGF353, 379 or angiopoietins380 are 
produced and secreted by the CAFs, initiating neo-angiogenesis by activating the relevant 
receptors in the endothelial cells. Finally, CAFs also regulate a plethora of cytokines and 
growth factors that can either directly or indirectly impact on the malignant cells, for example 
PDGF, IL-6, HGF and TGF-β 350, 381, 382.  
Our mechanistic work aimed to characterise the role of stromal-SULF2 on the behaviour of 
the fibroblasts, but also to investigate the paracrine role of this novel SULF2 positive CAF 
phenotype, on activation of signalling pathways in the tumour cells. We used in vitro, in silico 
and human tissues to test and validate our hypotheses. Our results showed distinct SULF2-
dependent pathways in both the fibroblasts and tumour cells. Some of these observations 
confirmed previously reported SULF2 dependant activities.  The identification of SULF2 as a 
mediator of fibroblast cytokine production associated with a CD44 stemness phenotype in 
tumour cells was particularly novel. 
In an autocrine fashion, SULF2 induced PDGFRβ expression, leading to activation of the JNK 
pathway in fibroblasts. This SULF2-mediated activation of PDGFRβ/JNK pathway increased the 
production of the inflammatory cytokines IL-6 and IL-8 by fibroblasts, compatible with their 
known tumour-promoting role. The JNK pathway in fibroblasts has a key pro-tumorigenic role 
in HCC, with a previous study having shown that global KO of JNK1/2 in mice was protective 
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against HCC development137. Notably, the conditional KO of JNK1/2 from mice fibroblasts, but 
not from hepatocytes, rendered the mice protected against carcinogenic induction of HCC137. 
This cell-type dependent role of JNK pathway was attributed to an increase in IL-6 cytokine 
expression and production. Activation of the JNK pathway also has clinical relevance as the 
deregulation of JNK-associated genes in human HCC is reportedly associated with 
upregulation of CSC markers, early disease recurrence and a poorer prognosis383. Although 
not previously shown in HCC, the link between tumour SULF2 and IL-6 was previously reported 
in lung cancers384. Ionizing radiation induced IL-6 expression in lung cancer cell lines in a SULF-
2 dependent manner leading to induction of metastasis and poorer outcome 384.  CAFs385-387 
and tumour associated macrophages186 are major sources of IL-6 in the TME, with a paracrine 
impact on proliferation of adjacent tumour cells previously reported186. 
Figure 4.26 Schematic of a model depicting the key mechanistic findings from this study: 
SULF2-dependent pathways activated in the CAFs (with red arrows) and in the adjacent 
tumour cells (black arrows). 
 
The cross-talk between tumour cells and CAFs within the TME is believed to be essential in 
maintaining tumour cell proliferation and give them resistance against environmental 
challenges. Here we have further characterised a novel paracrine pathway through which CAFs 
promote a more aggressive tumour phenotype. CAF-SULF2 and its regulated secretome 
activated IKKβ/NF-κB pathway in the tumour cells and was associated with a proliferative, 
invasive, CD44 expressing sorafenib resistant phenotype. These finding supported and bring 
together a previous in silico study linking SULF2 with the progenitor cell, hepatoblast subclass 
in human HCC patients388, and a study describing CAFs as regulators of stemness352. While the 
role of IKKβ cascade in the expansion of stem cell features in lung, breast389 and intestinal 
cancer390 was described, similar data in HCC was previously lacking. The role of RelA in the 
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development of inflammation-associated liver cancer has been previously reported120, with 
the paracrine release of TNFα from the adjacent portal and inflammatory cells established.  
The Human biopsies data presented further validated a proposed paracrine role for SULF2, 
showing a strong association between CAF-SULF2 and the nuclear translocation of the RelA 
NF-κB subunit and CD44 membranous expression in neighbouring tumour cells.  IL-6 
production and therapy resistance associated with CSC features has been previously 
documented186, 391, with IL-6 regulating both the transcription and the alternative splicing of 
CD44 in multiple myeloma cell lines392.  
 
SULF2 has been previously implicated in the regulation of a number of signalling pathways in 
HCC, including activation of the Wnt pathway and upregulation of the well-known oncogene, 
GPC3273, 304,393. GPC3 is frequently expressed in HCC and often used as a diagnostic tissue 
biomarker. However, the pattern of GPC3 expression varies in HCC and prognostic 
associations with grade or outcome are not consistent as reviewed previously270, 369. Our data 
suggests that GPC3 co-expression with SULF2 offers a novel stratification for GPC3 positive 
cases, identifying those in whom GPC3 had poor prognostic relevance. In vitro, we also showed 
that stromal SULF2 upregulated GPC3 expression in the tumour cells. The role of SULF2 in the 
upregulation of GPC3 was previously reported273, although our data cast a novel focus on the 
role of stromal SULF2 on upregulating GPC3 in the tumour cells. Targeting the component 
proteins or regulators of Wnt pathway has the potential to benefit many HCC patients394. Our 
clinical data suggests that the cross-talk between GPC3 in the tumour cells and SULF2 in the 
CAFs is important for the upregulation and nuclear translocation of β-catenin, thereby 
activating the Wnt/β-catenin signalling. In vitro, we showed that stromal SULF2 upregulated 
β-catenin, in the membrane of the tumour cells which was translocated to the cytoplasm and 
nucleus by adding Wnt3a to the SULF2 positive CM. Although the upregulation of 
membranous β-catenin in the SULF2 positive CM-treated Huh7 cells was evident, the nuclear 
translocation of β-catenin was not very convincing. Therefore, investigating the nuclear 
translocation of β-catenin using TopFlash/FopFlash reporter assay was used to confirm a 
potential role for stromal SULF2 in Wnt/β-catenin pathway activation.    
 
Both Wnt/β-catenin and NF-κB signalling pathways are implicated in the regulation of liver 
cancer stemness395-397. CSCs are plastic cells and are able to self-renew, proliferate, migrate 
and resist chemotherapy367, 398, 399. Although a direct RelA-P-ser536/β-catenin/CD44 pathway 
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driving the expansion of CSCs in intestinal tumorigenesis366 has recently been described, with 
RelA-P-ser536 promoting β-catenin translocation, we did not demonstrate a direct 
relationship between RelA-P-ser536 and nuclear β-catenin in our HCC cases. We do, however, 
highlight a novel mechanism whereby CAFs releasing SULF2 activates both NF-κB and β-
catenin in association with the upregulation of CD44. 
 
Our data derived from a combination of in vitro and in vivo studies are compelling and may 
have clinical relevance in a number of contexts. We corroborate that CAF-driven SULF2 
expression has prognostic relevance in HCC. As an active protein released into the TME and 
associated with tumour progression, targeting SULF2 represents a novel therapeutic 
candidate. While there are currently no therapies directly targeting SULF2, its role potentially 
regulating stemness and therapy resistance make it noteworthy, as does the potential to use 
SULF2 expression in a predictive fashion.  HCC SULF2 has been implicated in the regulation of 
the established morphogen, GPC3273, 304. Stromal SULF2 in part exerts its pro-tumorigenic 
actions through up-regulation and activation of the GPC3, Wnt/β-catenin signalling pathway 
in tumour cells and may similarly have biomarker potential in this context. Stratification of 
patients according to SULF2 and GPC3 tissue positivity provided a better prognostic tool, 
identifying those with poorest outcomes. These candidate biomarkers might also be useful for 
identifying patients less likely to respond to sorafenib, or perhaps more likely to respond to 
an inhibitor of GPC3 or SULF2 activity.  In conclusion, SULF2 in the TME, derived from either 















Chapter 5: Characterisation of SULF2 in Non-alcoholic fatty liver 
disease (NAFLD) and non-alcoholic steatohepatitis (NASH) in vivo. 
 
5.1 Background. 
NAFLD, or fat deposition in the liver in the absence of excessive alcohol consumption, 
describes a wide spectrum that ranges from mild simple steatosis to higher levels of fat with 
necro-inflammatory changes known as NASH400. The prevalence of NAFLD exceeds 25% of the 
population globally39 and is typically associated with obesity, insulin resistance as well as other 
features of the metabolic syndrome like hypertension and hyperlipidaemia401. As a 
consequence of the breakthrough of direct acting antiviral agents (DAAs) in the treatment of 
HCV, in combination with the dramatically rising prevalence of global obesity, NAFLD is 
becoming one of the commonest causes of advanced liver diseases and HCC41. NAFLD-HCC 
arises in patients who are typically older, of male gender, with features of metabolic 
diseases402, 403. Approximately one third of NAFLD-HCC develops in the absence of cirrhosis, 
with NAFLD-HCC patients more likely to be non-cirrhotic compared to those with HCV-HCC42. 
Why people with non-cirrhotic NAFLD develop HCC is not well understood, but it is 
increasingly appreciated that people with the metabolic syndrome have a higher risk of 
developing cancers, with both obesity and T2DM independently associated with HCC risk, 
even in the absence of NAFLD26. Understanding the mechanisms involved will be key to the 
development of preventive strategies. 
Previous studies have reported a link between SULF2 and obesity, with SULF2 having a role 
clearing remnant triglycerides and influencing blood triglyceride levels404-406. Glycomic 
focused microarray analyses in livers from obese mice, exploring various HSPG assembly-
related genes, T2DM-related HSPG genes and genes involved in the posttranslational 
modification of HSPG structures, revealed a dramatic upregulation of Sulf2404. Mechanistic 
studies suggested that Sulf2 mediated the degradation of syndican-1 - a HSPG receptor on the 
surface of responsible for the uptake of apo-lipoprotein B (apoB) remnants. The upregulation 
of hepatic Sulf2 was associated with decreased clearance of these atherogenic lipoproteins, 
which, in theory, could contribute an increased risk of developing atherosclerosis as a part of 
the metabolic syndrome in mice404.  Notably, a single nucleotide polymorphism (SNP) 
rs2281279 in SULF2 has been previously reported to be associated with lower SULF2 levels 
and also with removal of postprandial triglyceride rich remnants in healthy donors405.   
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Hepatic SULF2 expression in patients with NAFLD 
In Prof Reeves lab, as part of an FP7 European Commission funded award entitled Fatty Liver 
Inhibition of Progression (FLIP), a role for SULF2 in NAFLD was explored in human tissues.  
SULF2 IHC was performed in 36 diagnostic biopsies from patients with NAFLD (by MRes 
student, Rebecca Harrison).  Details of the pilot cohort are shown in Table 5.1. The histological 
severity of NAFLD was scored by liver pathology staff at the Newcastle upon Tyne Hospitals 
NHS Foundation Trust. SULF2 immunostained slides were assessed by two observers (Prof 
Reeves and liver pathologist, Dr Dina Tiniakos), blinded to clinical details at 100x 
magnification, as detailed in Table 5.1.  
Table 5.1: Demographic and clinico-pathological features of NAFLD/NASH patients 
Abbreviations: T2DM; Type-2 Diabetes mellitus, BMI; body-mass index, NAS score; NAFLD 
activity score, ALT; Alanine aminotransferase, AST; Aspartate aminotransferase, ALP; Alkaline 
phosphatase, LDL; Low density lipoprotein and HDL; High density lipoprotein. *NAS – NAFLD 
activity score derived from adding scores for steatosis, ballooning and lobular inflammation. 
Table 5.1 patients (36)  Patients (36) 
Age (median) 55 Sex (male/female) 26/13 
BMI (median) 35.8   
T2DM no/yes 17/19   
Steatosis (0/1/2/3) 0/12/20/4 ALT 69.3 ± 5.8 
Ballooning (0/1/2) 8/22/6 AST 47.2 ± 2.8 
Lobular inflammation (0/1/2) 9/17/9 ALP 95.5 ± 6.7 
Portal inflammation (0/1/2) 17/14/4 Bilirubin 9.5 ± 0.8 
Mallory-Denk bodies (0/1/2) 14/18/2 Albumin 46.1 ± 0.5 
Acid bodies (0/1/2) 21/5/1 Prothrombin time (PT) 10.6 ± 0.13 
Megamitochondria (0/1) 28/2 HBA1c 8.2 ± 1.2 
Lipogranuloma (0/1) 15/21 Triglycerides 2.1 ± 0.18 
Fibrosis (0/1/2/3/4) 6/12/5/10/3 LDL 3.2 ± 0.22 
NAS score* (1/2/3/4/5/6) 2/7/6/10/7/4 HDL 1.1 ± 0.04 
SULF2 Immunohistochemistry - The percentage of SULF2-positive hepatocytes (cytoplasm, cell membrane, 
canalicular) was semi-quantitatively assessed with a score from 0-4 (0 = no hepatocytes positive, 1 = 1-25% 
positive, 2 = 26-50% positive, 3 = 51-75% positive, 4 = 76-100% positive). The SULF2-specific staining intensity 
(SI) was assessed with a score from 0-3 (0 = no staining, 1 = weak, 2 = moderate, 3 = strong). If a range of 
staining intensity was noted the predominant score was used. Presence and intensity of endothelial staining 
was recorded on all cases as an internal positive control. 
% Hepatocyte cytoplasmic score (0/1/2/3) 0/12/14/10 
Hepatocyte cytoplasm intensity score (0/1/2/3) 12/22/2/0 
Hepatocyte canalicular surface score (0/1/2/3) 1/28/3/4 
Hepatocyte cell membrane score (0/1/2/3/) 4/16/12/5 
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The median age of patients was 55 years, with a median BMI of 35.8.  26 were male (66%) and 
19 patients (55.9%) had type 2 Diabetes mellitus (T2DM).  Only 3 of 36 (8%) were graded 
histologically as having cirrhosis, but 10 had grade 3 fibrosis and 21 patients had a NAS score 
greater than 3 – indicating at least an element of NASH being present in over half of the cases. 
SULF2 expression was elevated in patients with NAFLD 
As previously described in Chapter 3, SULF2 was detected by IHC in bile ducts and in 
endothelial cells, serving as an internal positive control. In patients with simple steatosis, 
SULF2 expression was scant and detected on the canalicular surface of the hepatocytes, also 
as previously described in normal liver. In general, however, it was noted that while 
cytoplasmic hepatocyte expression of SULF2 is uncommon in normal liver, SULF2 was present 
at some level in the cytoplasm of every case with NAFLD.  In 24/36, it was present in over 25% 
of hepatocytes.  In fact, the % of hepatocytes with SULF2 cytoplasmic expression did not 
correlate with any markers of histological severity, and in a number of cases the intensity score 
overall was regarded as zero, as the majority of hepatocytes had no cytoplasmic SULF2.  On 
the other hand, the intensity of SULF2 expression did have some notable associations, 
correlating with the steatosis score and the severity of portal inflammation (Spearman 
Correlation steatosis 0.357, p=0.033; portal inflammation 0.392, p=0.020).   
Membranous SULF2 expression was increased in more advanced NAFLD 
Prominent in some cases with NAFLD, was an increase in the % of hepatocytes with 
membranous expression of SULF2. Rather than expression on the canalicular surface, as is 
frequently observed at low levels in normal liver, this increase was most evident on the 
hepatocyte surface membrane.  The data are summarised in Table 5.1, with examples shown 
in Figure 5.1. Notably, membranous expression of SULF2 was significantly associated with 
more severe NAFLD. It correlated weakly with the presence of ballooning (Spearman Rho 
0.344, p=0.04), more so with portal inflammation (Spearman Rho 0.434, p=0.009), the 
presence of acidophil bodies (Spearman Rho 0.519, p=0.006) and megamitochondria 
(Spearman Rho 0.434, p=0.016), as well as with the severity of fibrosis (Spearman Rho 0.466, 
p=0.004).  
SULF2 expression in non-parenchymal cells 
In addition to expression of SULF2 in healthy bile ducts, positive cytoplasmic immunostaining 
of variable intensity was often noted in areas of ductular reaction, or proliferating immature 
bile ducts. Cytoplasmic expression was also noted in some portal lymphocytes and 
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macrophages, although not in every case.  Similarly, positive Kupffer cells and lymphocytes 
were noted within sinusoids, but not in all cases.  
Figure 5.1 SULF2 expression patterns in NAFLD.  Representative images show IHC staining of 
SULF2 in human biopsies from five patients with graded NAFLD (A-F). In (A), with steatosis 
grade 1, no fibrosis and a NAS score of 1, SULF2 was scant, detected in the canalicular and 
sinusoidal areas (black arrows). In (B), with grade 2 steatosis, stage 2 fibrosis and a NAS score 
of 5, SULF2 was present in the hepatocytes, inflammatory cells in the sinusoids, portal areas 
(white arrows) and immature bile ducts (black arrows). In (C), with grade 1 steatosis, stage 2 
fibrosis and a NAS score of 3, SULF2 was expressed in the membrane of ballooned hepatocytes 
(black arrow) and hepatocytes. In (D), with grade 2 steatosis, stage 2 fibrosis and a NAS score 
of 4, membranous hepatocyte SULF2 was notable. In (E and F), with grade 2 steatosis, stage 3 
fibrosis and a NAS score of 6, SULF2 was present in inflammatory cells in areas of lobular 
inflammation (green arrow), in some sinusoidal cells (E), and in inflammatory cells adjacent to 
portal tracts, (black arrows) (F). Images were captured using Aperio Imagescope software at 
x20 magnification.   
In summary, SULF2 was upregulated in liver biopsies from patients with NAFLD, with a distinct 
membranous pattern in those with more advanced disease. Expression in immunoregulatory 
cells was also noted.  To explore further the expression of SULF2, in a longitudinal fashion in 
the development and progression of NAFLD, with an opportunity to characterise the 
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expression further in inflammatory cells as well as hepatocytes, we planned to characterise 
expression in a relevant in an animal model of disease.   
5.2 Chapter 5 aims  
5.2.1 To define the histological changes accompanying disease development in a diet-induced 
murine model of NAFLD-HCC. 
5.2.2 To perform SULF2 focused pathway analyses of RNA-sequencing data from the murine 
NAFLD-HCC model. 
5.3 A relevant murine model for NAFLD/NASH and NASH/HCC 
As part of the FP7 funded FLIP study referred to above, the Reeves/Oakley lab explored a 
number of different experimental mouse models, aiming to identify one that recapitulated 
the features of human NAFLD and NAFLD-HCC. Research Associate Dr Gillian Patman and 
research technician Anna Whitehead were responsible for delivering the model, including the 
handling of the blood and liver tissues. As it is aged patients with the metabolic syndrome and 
NAFLD that are more susceptible to developing HCC402, the selected model centred on 
studying the impact of a fat-rich diet on ageing mice.  For the purpose of studying the impact 
of the metabolic syndrome and HCC, C3H/He mice were chosen as they are known to develop 
impaired glucose tolerance and spontaneous HCC with age. C3H/He mice are less susceptible 
to HCC than B6C3F1 (a hybrid of C57BL/6 ♀ and C3H/He ♂) mice, but more susceptible to HCC 
than the relatively resistant strain C57BL/6. The mice were fed an American life style diet 
(ALIOS), with high fat and sugar water330.  A pilot study in 2012 confirmed the development of 
steatosis and HCC at 1 year of age. Sulf2 expression was assessed in mRNA extracted from 
whole liver by real time PCR.  In the livers of mice fed the ALIOS diet, Sulf2 was significantly 
elevated (p=0.003) and correlated with body weight (Spearman Rho 0.542, p=0.011), liver 
weight (Spearman Rho 0.599, p=0.004) as well as tumour number (Spearman Rho 0.752, 





Figure 5.2 Hepatic Sulf2 is upregulated in ALIOS-fed mice compared 
to matched controls. Graph shows the expression of Sulf2 in the 
liver of 10 control and 11 ALIOS-fed mice. Data are presented as 





Encouraged by these findings, a larger study including animals culled at different time points, 
with formal histopathology grading of NAFLD, was performed thereafter, as summarised 
below and described in more detail in Methods Chapter 2. 
5.3.1 Gross features and Histological characterisation of the ALIOS-fed C3H/He model 
Two groups of C3H/He mice were on control or ALIOS diet for 12, 24, 36 and 48 weeks, and 
two more groups were introduced where the Dietary intervention was co-administered with 
the carcinogen DEN (Figure 5.3).  
Figure 5.3: Work flow of the murine mouse 
model of diet-induced NASH/HCC. Mice on 
dietary intervention alone or with DEN liver 
carcinogen were culled 12, 24, 36 and 48 weeks 
after the intervention. Abbreviation: w; week, 




ALIOS-fed C3H/He mice exhibited obesity, represented by the increase in their body weight 
compared to the control group. This increase in body weight was significant throughout the 
whole study except for the 12 week time point (Figure 5.4A). Similarly, the livers of ALIOS mice 




Figure 5.4: ALIOS diet induced obesity and higher liver weight in C3H/He mice. Graphs show 
the change of both body weight (A), liver weight (B) and liver/body weight ratio (C) between 
control (C) and ALIOS (A) fed mice at 12 (n=8 per group), 24 (n=8 per group), 36 (n=8 per group) 
and 48 weeks (n=24 per group). Data are presented as mean ± S.E.M, * p<0.05; ** p<0.01, *** 
p=0.001, **** p<0.001. 
 
The strongest Histological criteria associated the development of human NAFLD and NASH 
includes the grade of steatosis (scored 0-3), the severity of fibrosis (scored as 0-4 stages), the 
presence of lobular inflammation, the presence of hepatocyte ballooning and 
lipogranuloma341. Ancillary diagnostic features include microvesicular steatosis, pigmented 
kupffer cells, the presence of Mallory denk bodies and presence of megamitochodria. These 
histological features were comprehensively assessed in the livers of both the control- and 
ALIOS-fed mice and scores are listed in (Table 5.2A and 5.2B).  
At the 12 week time point, all ALIOS-fed mice developed steatosis scored as grade of 1 or 2 
(Figure 5.5A), while the control-fed mice were graded as 0 and 1 steatosis (Figure 5.5C). 
Inflammatory changes, represented by portal inflammation and lobular inflammation, and 
architectural change (hepatocyte ballooning) were comparable between control and ALIOS 
fed mice at this time point, as was the NAS score (Table 5.2A). No fibrotic changes were 
observed (Figure 5.5B&D).  The ancillary features commonly seen in patients with NASH were 







Table 5.2 Histological characterisation of the C3H/He mice fed with control or ALIOS diet 
5.2A Classical features for diagnosis and severity assessment in NAFLD and NASH  
 Control Diet ALIOS diet p value 
Steatosis grade (0/1/2/3) 
12 weeks  4/4/0/0 0/5/3/0 0.0196 
24 weeks 0/1/7/0 0/2/5/1 >0.9999 
36 weeks 2/2/4/0 0/0/6/2 0.0326 
48 weeks 4/10/9/0 0/1/19/4 <0.0001 
Hepatocellular ballooning (0/1/2) 
12 weeks 6/2/0 6/2/0 >0.9999 
24 weeks 2/6/0 2/3/3 0.4671 
36 weeks 3/4/1 5/3/0 0.4365 
48 weeks 8/11/4 1/21/2 0.1213 
Lobular Inflammation score (0/1/2) 
12 weeks 4/3/1 5/3/0 0.7063 
24 weeks 7/1/0 5/3/0 0.5692 
36 weeks 6/1/1 2/3/3 0.1058 
48 weeks 12/11/0 1/17/6 <0.0001 
NAFLD activity (NAS) score  
12 weeks 1.375 ± 0.3750 2.125 ± 0.3981 0.2752 
24 weeks 2.750 ± 0.2500 3.500 ± 0.4226 0.2340 
36 weeks 2.375 ± 0.3750 3.625 ± 0.4199 0.0665 
48 weeks 2.522 ± 0.2802 4.417 ± 0.1989 <0.0001 
Portal Inflammation score (0/1/2) 
12 weeks 1/6/1 2/2/4 0.3629 
24 weeks 3/5/0 2/4/2 0.4499 
36 weeks 0/6/2 0/1/7 0.0406 
48 weeks 21/2/0 18/4/2 0.1914 
Peri-sinusoidal fibrosis score (0/1) 
24 weeks 0/8 0/8 >0.9999 
48 weeks 7/16 0/24 0.0039 
Peri-portal fibrosis score (0/1/2) 
24 weeks 3/5 0/8 0.2000 
48 weeks 17/6/0 12/11/1 0.1152 
Fibrosis stage (0/1/2/3) 
24 weeks 0/6/2/0 0/1/7/0 0.0406 
48 weeks 7/10/6/0 0/12/11/1 0.0097 
 
At 24 weeks of age, steatosis in the livers of both ALIOS- and control-fed mice was scored as 
grade 1 and 2 with no statistical difference between the two groups (Figure 5.6). Most of the 
ALIOS fed mice had a score 2 fibrosis, however, 75% of the aged matched mice had a fibrosis 
score of 1, and this higher fibrosis stage in the ALIOS group was statistically significant 
(p=0.0406) from that in the control diet (Table 5.2A). Importantly, hepatocyte ballooning 
(Figure 5.6A&C) was similarly present in both groups. Portal and lobular inflammation 
appeared more common in the ALIOS mice compared to the matched control, but without 
statistical significance (Figure 5.6C). Ancillary features of NASH features were absent in both 
groups at this time point (Table 5.2B). 
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Table 5.2B Ancillary Features of NASH 
 Control Diet ALIOS diet p.value 
Lipogranuloma (0/1) 
12 weeks 8/0 8/0 >0.9999 
24 weeks 8/0 8/0 >0.9999 
36 weeks 8/0 8/0 >0.9999 
48 weeks 22/1 3/21 <0.0001 
Microvesicular steatosis (0/1) 
12 weeks 8/0 8/0 >0.9999 
24 weeks 8/0 7/1 >0.9999 
36 weeks 8/0 8/0 >0.9999 
48 weeks 23/0 16/8 0.0039 
Pigmented Kupffer cells (0/present) 
12 weeks 8/0 8/0 >0.9999 
24 weeks 8/0 8/0 >0.9999 
36 weeks 8/0 7/1 >0.9999 
48 weeks 16/7 9/15 0.0454 
Mallory Denk bodies (0/present) 
12 weeks 8/0 8/0 >0.9999 
24 weeks 8/0 8/0 >0.9999 
36 weeks 8/0 7/1 0.4286 
48 weeks 18/5 10/14 0.0188 
Megamitochondria (0/present) 
12 weeks 8/0 8/0 >0.9999 
24 weeks 8/0 8/0 >0.9999 
36 weeks 8/0 8/0 >0.9999 
48 weeks 20/3 14/10 0.0509 
 
Control mice had grades 0, 1 and 2 steatosis (Figure 5.7A) at the 36-week time point, whereas 
the ALIOS diet increased the steatosis grade in C3H/He mice towards grades 2 and 3 (p=0.03) 
(Figure 5.7B). Consistent with the previous time point hepatocyte ballooning was evident in 
both groups (Figure 5.7A&C), but the development of portal inflammation was statistically 
significant in the ALIOS-fed mice compared to the control group (P=0.04) (Figure 5.7D). Other 














Figure 5.5 No major steatotic or fibrotic changes were observed in liver tissue from C3H/He 
mice fed on control or ALIOS diet at the 12-week time point. Representative images show 
H&E and Sirius red stained liver tissue from C3H/He mice fed with control (A,B) and ALIOS 
(C,D) diet. (A) Liver tissue from control-fed mouse, scored as 0 grade steatosis and 0 fibrosis 
(B). (C) Liver tissue from ALIOS-fed mouse, scored as 1 grade steatosis and stage 0 fibrosis (D). 








Figure 5.6 Both ALIOS and control-fed mice developed ballooning at 24 week time point. 
Representative images show H&E stained liver tissues from C3H/He mice fed with control (A) 
and ALIOS (B&C) diets. (A) Liver tissue from control-fed; this tissue showed few ballooned 
hepatocytes (grade1) (black arrows). (B) Liver tissue from ALIOS-fed mouse, scored as 2 grade 
steatosis, stage 2 fibrosis, hepatocellular ballooning (grade 2) (black arrow) and lobular 
inflammation (black arrow) (C). CV; central vein, PV; portal vein. 















Figure 5.7 Increased steatosis with features of NASH in ALIOS-fed mice, but not the matched 
controls, at 36 weeks Representative images show H&E stain of liver tissues from C3H/He 
mice fed with control (A) and ALIOS (B-D) diet. (A) Liver tissue from control-fed mouse, scored 
as 1 grade steatosis with few ballooned hepatocytes (grade1) (black arrows). (B) Liver tissue 
from ALIOS-fed mouse, scored as 3 grade steatosis and stage 2 fibrosis. (C) Hepatocellular 
ballooning was present (black arrow). (D) Portal inflammation was also evident in this ALIOS-
fed mouse. CV; central vein, PV; portal vein. 
 
At the 48-week time point, all ALIOS-fed mice developed (S2-S3) grade compared to age 
matched chow fed mice (p<0.0001) (Figure 5.8A&B). The presence of lipogranuloma was also 
evident in the ALIOS fed mice but not the control mice (p<0.0001) (Figure 5.8B). In addition, 
livers of the ALIOS-fed mice, but not control mice livers, showed strong fibrotic changes 
(p=0.0097) (Figure 5.8C&D). All of the ALIOS-fed mice (100%, 24/24) developed peri-
sinusoidal fibrosis at compared to 69.5% (16/23) from the controls. Similarly, 74% (17/23) of 
the control mice did not develop peri-portal fibrosis and this percentage decreased to 50% 
when mice were fed on the ALIOS diet (Table 5.2A). Only one mouse in the ALIOS-fed group 
didn’t develop hepatocyte ballooning compared to 12 mice that lacked this feature in the 
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control group (Figure 5.8E). Considering ballooning scored as (0/1/2), no significant 


















Figure 5.8 C3H/He mice fed the ALIOS diet developed characteristic features of human 
NAFLD/NASH at 48 weeks of age. Representative images show H&E and Sirius red staining of 
liver tissues from control (A,C) or ALIOS-fed mice (B,D-F). ALIOS diet induced more steatosis 
(grey arrow), lipogranulomas (black arrows) (B) and fibrosis (D). (E) Hepatocellular ballooning 
(black arrow) was evident in both groups, but this phenotype was more pronounced in ALIOS 
fed mice. (F) Portal inflammation was present in the ALIOS fed mice. 
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Although some control mice did develop quite marked ballooning, overall the presence of 
ballooning was more common in ALIOS fed mice. When ballooning was scored as present or 
absent, this was significantly different (95% of ALIOS diet fed mice versus 65% of control diet 
developed ballooning; p=0.0102). Lobular inflammation was also evident at 48 weeks in ALIOS 
mice, and as a consequence of these mentioned histological changes, the NAS score was 
higher in the ALIOS fed mice compared to the age matched control diet fed mice (p<0.0001) 
(Figure 5.9).  
Figure 5.9 Histopathological differences in the livers of C3H/He mice at 48 weeks, fed either 
control or ALIOS diets. Graphs summarise the changes in steatosis, fibrosis, lobular 
inflammation (Lob. Inflamm) and hepatocyte ballooning (A), lipogranuloma, portal 
inflammation (portal inflamm) and microvesicular steatosis (Microves. steatosis) (B), or the 
NAS score (C) in mice fed with control (C) (n=23) or ALIOS (A) (n=24) diets. Data are presented 
as mean ± S.E.M, ** p<0.01, **** p<0.001. 
 
Other features of NASH including microvesicular steatosis (p=0.0039), pigmented kupffer cells 
(p=0.045) and presence of Mallory denk bodies (p=0.018) were also evident in the ALIOS-fed 
mice rather than in the control group at the 48 week time point (Table 5.2B). A trend towards 
increased in portal inflammation (Figure 5.8F) in ALIOS fed mice was not significantly different 
to control and neither was the presence of megamitochodria. It is important to note that none 
of the mice in either group or any of the study time points was scored as having stage 4 
fibrosis, or cirrhosis (Table 5.2A).  
Taken together, ALIOS feeding of C3H/He mice exacerbated the severity of fatty liver disease, 
more so as the mice aged. The phenotypic changes observed in the livers of the mice were 
similar to those observed in human NAFLD and NASH. A summary of all histological changes 
at the 48 week time point between the study groups is shown in Figure 5.9. 
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5.3.2 Development of HCC in ALIOS-fed C3H/He mice 
As expected in this mouse strain, 5/23 of the control C3H/He mice developed small tumours 
at 48 weeks (21.7%). However, 23/24 (96%) of ALIOS-fed mice developed HCC in the same 
time frame (Figure 5.10). Furthermore, the number of tumours developed in the ALIOS fed 
mice was significantly higher than in control diet mice (2.04±0.4 versus 0.3±0.1, p<0.0001), 
and were typically larger in size in ALIOS fed mice compared to the control group (7.6±1.1 
versus 0.9±0.4, p=0.0003). Concurrent administration of the carcinogen DEN with the diet 
exacerbated the tumour development phenotype, with tumour number (7.9±2.1 versus 
0.7±0.2, p=0.0025) and tumour size (6.3±1.7 versus 2.6±1.1, p=0.08) compared to mice that 
administered DEN and fed a control diet. 
 
Figure 5.10 Aged C3H/He mice developed more HCC when challenged with ALIOS diet 
Representative images show a macroscopic tumour in a fatty liver from ALIOS-fed mice 
compared to a control liver (A), and an H&E stained section of non-tumour (NT) fatty liver 
tissue from ALIOS-fed mouse with a tumour (T) (B).  The graph (C) shows the number of 
tumours in livers of C3H/He mice fed with control (C) and ALIOS (A) alone (grey columns) or in 
combination with DEN (black columns) after 24, 36 and 48 weeks. 
  
5.3.3 The gene expression profile in C3H/He mice 
We wanted to explore changes in Sulf2 in association with histopathological features of NAFLD 
and NASH in a temporal fashion. Also, with greater numbers, we hoped to establish if 
associations with HCC were independent of other contributory factors, such as diet, liver 
weight and histopathological features.  Disappointingly, an exhaustive exploration failed to 
identify a sensitive and specific anti-mouse Sulf2 antibody for the immunohistochemical 
characterisation of Sulf2 expression and cellular localisation in the mouse tissues.  
Consequently our assessments were limited to whole tissue studies at the RNA level.  In the 
hope of characterising these in a more comprehensive fashion, RNA sequencing (RNAseq) was 
performed in tissues from 48 weeks old mice, including 23 non-tumour and 27 tumour liver 
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tissues from the control and ALIOS-fed C3H/He mice. The heat map in Figure 5.11 was 
generated using R package software. The non-tumour and tumour transcriptomic data 
clustered into two distinct groups.  A list of the top 100 differentially expressed genes based 
on the adjusted p value is included in the Appendix 1. 
Figure 5.11 The landscape of C3H/He mice tumour 
and non-tumour transcriptomic data. The heat map 
shows the top 50 differentially expressed genes 
between the non-tumour tissue (green) and the 
tumour tissue (purple) transcriptomic data. Red 
colour indicates gene upregulation, while blue colour 








Sulf2 was not markedly changed, but – as expected from the pilot study - it was upregulated 
in the ALIOS group compared to diet matched controls (p=0.0005), albeit with a small fold 
difference (Figure 5.12A). The Sulf2 level was comparable between the tumour and the non-
tumour groups (Figure 5.12B). 
Figure 5.12 The mRNA 
expression levels of 
Sulf2 in non-tumour and 
tumour tissues Graphs 
show the difference in 
sulf2 mRNA expression 
in the non-tumour liver 
tissue from control diet 
and ALIOS-fed mice 
(n=11 per group) is 
shown in (A). Sulf2 expression in the non-tumour versus tumour liver tissues of the C3H/He 




5.4 Sulf2 associations with HCC in C3H/He mice 
In keeping with the pilot study, Sulf2 in the whole liver tissues – this time quantified by RNAseq 
– correlated significantly with the development of tumours (Spearman Rho 0.476, p=0.022), 
but more so with the number of tumours (Spearman Rho 0.551, p=0.006) and size of tumours 
(Spearman Rho 0.509, p=0.013) as well as with the tumour burden (Spearman Rho 0.576, 
p=0.004) as estimated using the sum of the diameter of all tumours in an individual mouse. 
The numbers studied were still relatively small and while interesting, by binary logistic 
regression of categorical variables (presence or absence of a tumour; tumours less than or 
greater than 5mm), the associations were not independent of other factors associated with 
tumour development, namely the diet, body weight and liver weight.   
5.5 Sulf2 and histological features of NAFLD in the livers of C3H/He mice 
Bivariate associations between Sulf2 and the graded histological features of NAFLD are 
summarised in Table 5.3, with notable highly significant associations with steatosis, 










Table 5.3 Association between sulf2 and the histopathological features of the C3H/He mice 
 
 
 Sulf2 (continuous variable) 
 Spearman’s 
Rho p value 
Diet (control vs ALIOS) 0.827 <0.0001 
Body weight 0.582 0.004 
Liver Weight 0.717 <0.0001 
Steatosis (0/1/2/3)  0.772 <0.0001 
Microvesicular steatosis (0/1) 0.582 0.004 
Ballooning (0/1/2) 0.465 0.026 
Lobular inflammation (0/1/2) 0.639 0.001 
Portal inflammation (0/1/2) 0.599 0.002 
Mallory-Denk bodies (0/1/2) 0.669 <0.0001 
Megamitochondria 0.253 0.244 
Apoptotic cells 0.373 0.079 
Lipogranuloma (0/1) 0.840 <0.0001 
Fibrosis (0/1/2/3/4) 0.827 <0.0001 
NAS score (1/2/3/4/5/6) 0.639 0.001 
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5.6 Sulf2 pathways analysis in NAFLD development and progression in the C3H/He mice 
The complete list of differentially expressed genes created by comparing transcriptomic data 
of the ALIOS fed mice versus control-fed mice is in Appendix 2.  In this list, Sulf2 was elevated 
in the ALIOS fed mice, although in a non-significant fashion after correction for multiple testing 
(adjusted p.value=0.06).  Hampered by the lack of a suitable antibody to define more subtle 
changes in cellular source and location, but hypothesising an important biological role in 
NAFLD progression, this trend to Sulf2 elevation was explored using a bioinformatics approach 
in groupings of mice based on grading of steatosis and fibrosis, as hallmarks of disease severity 
and progression. The first focus presented here was on fibrosis.  
5.,6.1 Fibrosis directed bioinformatics analyses with a focus on Sulf2 
Accordingly, mice were grouped into two groups; the first group included mice scored with 
high fibrotic changes (F(2-3); N3, N13, N14, N15, N16, N17, N18, N19, N20, N22, N23 ), while 
the second group involved mice with no or few fibrotic changes (F(0-1); N1, N2, N4, N5, N6, 
N7, N8, N9, N10, N11, N12, N21) (Appendix3).  
Running DE gene analysis between the above groups identified 2746 genes differentially 
expressed, with Sulf2 upregulated (as expected) in the more advanced fibrosis group (Log2FC 
0.56, q.value=0.002).  Subsequent pathway analysis was performed using Ingenuity pathway 
analysis (IPA) software, after applying a cut off value of absolute Log2FC of 0.5 and an adjusted 
p value of 0.05. Activation of different inflammation-related canonical pathways, including 
activation of T-cell, natural killer T cells and phagosomes is shown in (Figure 5.13).  
 
Figure 5.13 Activation of inflammatory pathways in association with more advanced fibrotic 
stages in C3H/He transcriptomic datasets. The bar chart (A) shows canonical pathways 
identified by IPA, ranked according to –log (q.value) of overlap. Orange represents activation, 
blue inhibition, and grey a z-score not calculated in the dataset. The intensity of colour is 
proportional to the increase in absolute activity z-score. The table (B) shows the –log (q.value) 




Notably, cell survival and cell viability were the top activated diseases and bio-functions in this 
high fibrosis associated list, together with activation of different inflammatory responses. 
Signalling pathways associated with different types of neoplasms were among the top 


















Figure 5.14 Viability, homeostasis and inflammation pathways were activated in the C3H/He 
mice liver transcriptome in association with fibrotic stages  The Heat map (A) shows the IPA 
defined deregulation of different diseases and bio-functions, ranked according to –log 
(q.value) of overlap. Orange represents activation, blue inhibition, grey an uncalculated z-
score and white an activity score of zero. The intensity of colour is proportional to the increase 
in absolute activity z-score. The bidirectional bar chart (B) shows the top 10 activated (red 





As expected in this fibrotic directed list, IPA network analysis also identified pathways 
activated in connective tissue disorders, tissue development and cell-to-cell communications 
(Figure 5.15A). Of note, fibrosis and activation hepatic stellate cells pathways were not among 
the top enriched ones in the dataset. 
Sulf2 didn’t appear in any of the top deregulated canonical pathways in this dataset, although 
diseases and bio-function analysis suggests the involvement of Sulf2 in cytoskeleton 
organisation. This was supported by network analysis (Figure 5.15B) reporting Sulf2 in 
“network 2”. These were genes reportedly involved in directing cell morphology, but also 
associated with a cell-mediated immune response – introducing a previously unsuspected 
candidate role for Sulf2. Also interestingly, upstream analysis identified two novel candidates 
as potential regulators of Sulf2 expression in liver, namely IL2 Inducible T Cell Kinase (Itk) and 
















Figure 5.15 A sulf2-related network identified in association with advanced fibrosis in 
C3H/He liver tissues The Table (A) shows the top 10 IPA enriched networks, scored according 
to the number of genes in the mouse DE gene list overlapping the network. The image (B) 
shows the 2nd activated network in Table A, “cell morphology, cell-mediated immune response 
and cellular movement“, in which Sulf2 (circle) is involved. Red indicates gene upregulation, 











Figure 5.16 itk and tfrc identified as candidate regulators of liver fibrosis related Sulf2 
expression The IPA generated Wheel charts suggest upstream regulators and their candidate 
downstream targets, based on relationships between gene expression in the tissues.  Sulf2 
was identified in both Inducible T cell Kinase (itk) (A) and transferrin receptor (tfrc) (B) wheel 
charts, suggesting their involvement in the upstream regulation of Sulf2 expression in 
association with more advanced fibrosis. Red indicates upregulation of the gene in the fibrotic 
tissues, orange indicates activation of the regulator, while blue indicates inhibition of the 
regulator. An orange line represents upregulation of the downstream gene consequent to 
activation (A) or inhibition (B) of the regulator. A yellow line indicates an inconsistent direction 
of change between downstream gene and the corresponding regulator.  
 
5.6.2 The role of sulf2 in steatosis related pathways in the C3H/He mice 
The second DE gene list created (using R package software) by grouping mice into two groups 
based on the histological scoring of fat deposition in liver tissue. The first group included mice 
with severe steatosis graded as 2-3 (N1, N2, N4, N11, N13, N14, N15, N16, N17, N18, N19, 
N20, N21, N22, N23), while the second group comprised mice that didn’t develop steatosis or 
mice that had steatosis graded as 1 (N3, N5, N6, N7, N8, N9, N10, N12). In this DE gene list, 
Sulf2 was among 1253 DE genes that were significantly upregulated (Log2FC 0.68, q.value=4.6 




The subsequent IPA canonical pathway analysis of this DE gene list is summarised in (Figure 
5.17). Inhibition of the LXR/RXR pathway and an increase in the degradation of Melatonin, 
Nicotine and Bupropion pathways were the most striking steatosis reported changes. Sulf2 








Figure 5.17 Changes in metabolic pathways in association with advanced steatosis The bar 
chart (A) shows the IPA top 10 changed canonical pathways, ranked according to the –log 
(q.value) of overlap. Orange represents activation, blue inhibition, and grey an uncalculated 
z-score, with intensity proportional to the increase in absolute activity. The table (B) shows 
the –log (q.value) and z.score of top 10 changed canonical pathways.  
 
Pathways activated in diseases and associated with biofunctions were explored next and it 
wasn’t surprising – given the DE gene list was created based of the degree of steatosis - to see 
“fatty acid metabolism” in the top ten list (Figure 5.18), alongside two related to 
gluconeogenesis (synthesis of monosaccarhide and synthesis of D-glucose). Of note, a number 
of pathways related to immune cell infiltration and movement were inhibited in the presence 



















Figure 5.18 Diseases and bio-functions analysis of steatosis related hepatic gene expression 
in C3H/He liver tissues. The IPA heat map (A) shows the deregulation of different diseases 
and bio-functions in the mouse liver tissues, ranked according to –log (q.value) of overlap. 
Orange represents activation, blue inhibition, grey an uncalculated z-score and white 
represents a zero activity score. The intensity of colour is proportional to the increase in 
absolute activity z-score. The bidirectional bar chart (B) shows the top 10 activated (red) and 



























Figure 5.19 A metabolic role for Sulf2 in suggested by Ingenuity Pathway Analysis (IPA) The 
table (A) shows the steatosis associated top 10 enriched networks in the mouse fatty liver, 
scored according to the number of steatosis DE gene overlapping the network. The image (B) 
shows the network ‘4’, entitled “Carbohydrate metabolism, lipid metabolism, small molecule 
biochemistry“, in which upregulated Sulf2 (circle) may play a part. Red indicates gene 





IPA was also used to explore lipid metabolism, molecular transport and small molecule 
biochemistry-related networks (Figure 5.19). Sulf2 was identified as controlling carbohydrate 
metabolism, lipid metabolism and small molecule biochemistry, shown as network 4 in the 
table in Figure 5.19A and graphically in Figure 5.19B. 
In summary, Sulf2 was upregulated in the whole liver tissues of 48 week C3H/He mice with 
dietary induced fatty liver, by Sulf2 real time PCR in a pilot study of 21 mice and by exploration 
of its transcript in RNAseq analyses in an independent experiment including 23 mice. However, 
Sulf2 was not identified as a significant dietary intervention induced DE genes by 
bioinformatics analyses of the RNAseq cohort.  When the mice were grouped according to the 
histological scoring, Sulf2 was differentially expressed in some of the lists created, but was not 
one of the top changing genes. Fold differences in Sulf2 were not as striking as other genes, 
perhaps because changes were present in a minority of cells or a particular cellular 
compartment not so well captured in ‘whole tissues analyses’.  Despite this limitation, the 
bioinformatics analyses have raised some interesting associations.  
5.8 Discussion 
Over the last decade a number of approaches have been adopted to find clinically relevant 
biomarkers and novel therapeutic targets for NAFLD/NASH.  The wide spectrum of the disease 
and the lack of experimental models that accurately reflect the whole range of the human 
disease have proved challenging. The increasing burden of NAFLD-HCC, even in the absence 
of cirrhosis, further emphasizes the need for research in this area, including the development 
of experimental models that recapitulate the features of human disease407. 
In the introduction to this chapter, I have put together and presented IHC data generated 
previously by our group, exploring SULF2 expression in biopsies from human NAFLD/NASH 
patients. SULF2 was expressed in a number of different cell types in normal liver, including in 
endothelial cells and bile ducts, as well as at low levels on the canalicular surface of 
hepatocytes, in keeping with essential roles in the liver microenvironment. Notably, 
cytoplasmic expression of SULF2 was present to come degree in every patient with NAFLD. 
Within patients with NAFLD, the more pathological association was with an increase in surface 
membrane expression of SULF2, often associated with a reduction of expression at the 
canalicular surface.  This increase was significant associated with both the presence of 
ballooning and portal inflammation, but most notably with the presence of fibrosis.  Also 
observed was SULF2 expression in immune cells such as lymphocytes and macrophages, more 
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noticeable in those cases with histologically more advanced disease. These data complement 
the pivotal role we believe stromal SULF2 plays in the progression of HCC and the aim of our 
group was to develop an animal model which would enable the further exploration of Sulf2. 
Moving forward, I have described here the tissue characterisation of Sulf2 in a pilot study of 
dietary induced fatty liver disease and HCC, confirming it to be increased and associated with 
tumour stage.   
Subsequently I have analysed phenotypic data in a larger follow up study in C3H/He mice, fed 
with control or ALIOS diet, in which the histopathology of NAFLD and the cancers was 
comprehensively scored by liver pathologist, Dr Dina Tiniakos.  While the ALIOS diet in murine 
models of NAFLD was reported previously330, 331, the use of the C3H/He adipogenic mouse 
strain in the diet-induced NASH was a novel aspect.  In similar studies focused on C57BL/6 
mice challenged with ALIOS diet, ballooned hepatocytes, Mallory-Denk bodies and liver 
fibrosis have not been reported330. Although C57BL/6 mice develop liver tumours, these are 
just a few mm in diameter and too small to characterise330. In our C3H/He mice, in addition to 
the obesity, hyperlipidaemia and impaired glucose tolerance (data not shown), mice also 
developed steatosis, fibrosis, lobular inflammation, Mallory-denk bodies and lipogranuloma – 
regarded as key features of human NASH. In addition, the presence of ballooned hepatocytes 
– an essential diagnostic feature of human NASH - was a common feature in control diet aged 
(48 weeks) C3H/He mice liver (12/23, 52%), exacerbated by ALIOS feeding (23/24, 96%).  
We had aimed to characterise Sulf2 by IHC, exploring temporal relationships in different 
cellular compartments as NAFLD develops and progresses to fibrosis and/or HCC.  However, 
the lack of a suitable sensitive and specific antibody has been a major limitation.  The only 
useful human antibody is a mouse monoclonal and despite significant investment – both in 
technician time and alternative antibody generation – it has not yet been possible to 
characterise murine Sulf2 in the way we had hoped.  
My subsequent focus in this chapter, was on whole liver RNA-seq data from the C3H/He mice. 
Cluster analysis defined two groups which reassuringly reproduced the non-tumour and the 
tumour tissues. As described previously, the Sulf2 increase in liver tissue of ALIOS-fed mice 
compared to control mice was modest and did not reach statistical significance after adjusting 
for multiple comparisons in the whole RNAseq dataset.  We have proposed that this reflects 
the use of whole tissues, lacking the sensitivity to capture increases in a small subset of cells. 
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Regarding the parenchymal cells or hepatocytes, which make up 90% of all liver cells, our 
human data suggest that modest heterogeneous increases in the cytoplasm in the presence 
of even minor degrees of NAFLD – present actually in the majority of our mice.  In Human 
disease, even striking membranous increases were heterogeneous in character, localised in 
steatotic regions.  Furthermore, the human data suggested expression in non-parenchymal 
cells, most consistently bile ducts and endothelial cells present in all tissues regardless of 
NAFLD stage (hence contributing to background), but also present in a variable fashion in 
inflammatory cells which contribute a relatively small proportion of whole liver RNA.  These 
patterns of expression may be biologically important, but challenging to capture by whole liver 
transcriptomic analysis. The generation suitable tool antibodies to characterise mouse sulf2 
will be important for future work and their generation is being pursued with collaborators. In 
the absence of an antibody, an alternative may be to use another techniques like RNA-scope, 
for detecting sulf2 in the mouse tissue.  
Despite the limitations of whole tissues analysis, Sulf2 was differentially regulated in the 
presence of steatosis or fibrosis, corroborating the Human IHC data showing its cytoplasmic 
and membranous elevation in the presence of steatosis, correlating with fibrosis.  
Furthermore, IPA analysis of disease stage specific gene lists has suggested Sulf2 involvement 
in cytoskeleton organisation- and small molecule biochemistry-related networks. Of particular 
note was the suggested relationship between Sulf2 and Itk in the liver tissue. ITK is a non-
tyrosine receptor kinase present in the plasma membrane of T cells, NKT cells and mast cells, 
and it is involved in T cell activation408-410.  ITK regulates the Th2 response in different organs 
and initiates the production of different cytokines and growth factors411-413. Further 
exploration of the interaction between Sulf2 and Itk would be worth pursuing in the future, 
potentially identifying a novel role for Sulf2 in T cell function.   
In conclusion, SULF2 is an exciting candidate contributing to the pathogenesis of NAFLD/NASH.  
For future work, Golbal sulf2 -/- knock-out (KO) mice are available and challenging these mice 
with different diets may be worthwhile, to explore if they are protected from NAFLD or its 
progression to fibrosis and/or HCC. Studies of this nature, in combination with antibody 
generation or tools such as RNAscope, may help to define the roles on mechanisms of this 
extracellular sulfatase in fatty liver disease.  If confirmed as a key driver or master regulator 




Chapter 6: Non hypothesis-driven investigation of regulators of 
NAFLD progression to NASH and HCC 
 
6.1 Background  
Tumourigenesis is a complicated and multistep process involving tumour initiation, 
development and progression414. Tumours usually arise on a background of inherited or 
acquired genetic alterations that divert the affected cells from regulatory mechanisms and 
encourage clonal expansion and invasion415, 416. Genetic alterations can destabilise an organs 
gene expression leading to phenotypic changes that promote cancer- liver tumours arising in 
diseased liver being the focus here. Characterising the transcriptomic changes and genetic 
aberrations associated with premalignant disease and analysing network deregulation 
involved in the development and progression of HCC may identify pathways worthy of pursuit 
as predictive biomarkers or therapeutic targets. Highly heterogeneous in nature, the common 
changes in HCC gene expression have been extensively studied in the hope of understanding 
the tumours biology and generating tumour subclasses useful for guiding therapy57-59, 87, 229, 
417.  As yet these efforts have not impacted clinical practice, but transcriptomic analyses 
combined with ‘immunophenotyping’ of the tumour and its microenvironment may change 
that.  The Llovet group229 has recently used this kind of approach to show that HCC can be 
categorized into an “immune active” and “immune inactive” subclasses, with the ‘immune 
active class’ potentially including the patients most likely to benefit from treatment with 
checkpoint inhibitors.  Thus, these types of study may have particular importance for the 
translation of immunotherapies, helping to identify the patients most likely to benefit, as well 
as those best treated with combination approaches or entry into ongoing clinical trials.  
In the previous chapters, we demonstrated that the presence of SULF2 in the TME was a poor 
prognostic marker in HCC patients. Moreover, SULF2 had a unique expression pattern in 
human NAFLD, associated with the presence of NASH and fibrosis. We then explored of Sulf2 
in the livers of C3H/He mice, demonstrating its upregulation in association with steatosis and 
fibrosis in a targeted or ‘hypothesis’ driven fashion, while identifying some interesting 
candidate upstream regulators and mechanisms that may be relevant to NAFLD progression.  
Although this directional-driven transcriptomic analysis was biologically relevant and 
underpinned by a human NAFLD scoring system341 adapted for ALIOS mice, recent studies 
suggest that this supervised grouping approach has limited value as it does not necessarily 
reflect ‘real changes’ in the tissues and changes in mice often poorly mirror the most 
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important changes in the human context418.  Notably, there were DE genes identified in both 
supervised and unsupervised clustering that had far greater magnitude change and 
significance than Sulf2.  Thus, non-directional analysis of the transcriptomic data may, in 
theory, help to identify novel pathways and candidate therapeutic targets involved in disease 
progression418. 
6.2 Chapter 6 aims 
6.2.1 To perform an un-supervised clustering of the transcriptomic landscape of the non-
tumour liver tissues of the C3H/He mice to identify candidate drivers of tumour development. 
6.2.2 To explore identified candidates in biopsies from patients with NAFLD. 
6.2.3 To assess the overlap between the human HCC transcriptome and C3H/He tumour 
transcriptome. 
6.3 Non-hypothesis driven exploration of the C3H/He NAFLD transcriptome  
6.3.1 Unsupervised clustering of the transcriptomic data of C3H/He mice non-tumour liver tissue 
Unsupervised clustering of the mouse non-tumour transcriptomic data identified two sub-
clusters (Figure 6.1). The first group was defined as group 1 (G1) and included all the control-
fed mice plus two ALIOS-fed mice. The second group was defined as group 2 (G2) and included 
all the ALIOS-fed mice plus one control-fed mice (Figure 6.2A).  
Assessment of the correlation between the transcriptomic clustering and different gross and 
histopathological criteria of the C3H/He mice revealed that mice in G2 cluster were obese with 
bigger livers and higher VAT weight than G1 mice (Figure 6.2). Non-tumour liver tissue of the 
G2 mice had higher steatosis grade, more fibrotic changes, a higher NAS score and more 
lipogranulomas compared to tissues of G1 mice (Figure 6.2). Notably, tumours in G2 mice 
were larger than tumours in G1 mice (Figure 6.2). Professor Reeves previously analysed the 
predictors of tumour development in the C3H/He mice (Appendix-5) showing that the liver 
weight, body weight, presence of lipogranuloma and steatosis grade were strongly associated 
with HCC development. This implies that unsupervised clustering of the C3H/He mice 
transcriptome was associated with the key predictors of the tumour development. Of note, 
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most of the mice in G2 cluster developed tumours compared to mice in G1; however, with no 
statistical significance (Figure 6.2P). 
Figure 6.1 Identification of two 
distinct hepatic non-tumour 
sub-clusters in the C3H/He 
mouse transcriptomic data The 
heat map shows the top 50 DE 
genes in the G1 and G2 mice. G1 
group is colour coded yellow, 
while G2 group is colour-coded 
green. Upregulated genes are 
denoted in red and 
downregulated genes are 











Figure 6.2 Unsupervised hepatic clustering of C3H/He mice transcriptome was associated 
with features of the metabolic syndrome, more advanced NAFLD and HCC. Graphs show the 
grouping of mice in G1 and G2 clusters based on diet (A), liver weight (B), Lipogranuloma (C), 
Tumour size (D), tumour burden (E), Body weight (F), steatosis (G), fibrosis (H), NAS score (I), 
VAT weight (J), pigmented Kuppfer cells (K), Mallory-Denk body (L), tumour number (M), 
microvesicular steatosis (N), lobular inflammation (O), presence of tumour (P), portal 
inflammation (Q), megamitochondria (R) and hepatocellular ballooning (S). Data is presented 
as mean±s.e.m, *p<0.05, **p<0.01 and ***p<0.001. 
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6.3.2 Pathway analysis of the G2 versus G1 DE gene list using IPA 
A list of DE gene between G2 group (more diseased) and G1 group (less diseased) was created 
and included 3900 DE genes between the two groups (Appendix-6), exceeding the number 
identified in supervised clustering studies based on histological characterisations of mice liver 
tissue in (chapter 5) – supporting a role for un-supervised analysis when looking at gene 
expression data. The Top 10 enriched canonical pathways in the IPA analysis were exclusively 
T cell-related (Figure 6.3), strongly supporting the association between lobular inflammation 
and tumour development in the C3H/He mice (Appendix-5).  
Figure 6.3 Activation of T cell canonical pathways was evident in the C3H/He non-tumour 
subclass G2 versus G1 comparison The IPA bar chart shows the top 10 activated canonical 
pathways in the mouse non-tumour tissue, ranked according to –log (q.value) of overlap. 
Orange represents pathway activation, blue represents pathway inhibition, grey represents 
an uncalculated z-score and white represents zero activity score. The intensity of colour is 
proportional to the increase in absolute activity z-score.  
 
Cell survival and cell viability were the top ‘disease and bio-function pathways’ activated in 
the G2 group transcriptomic data compared to G1, while ‘organismal death and apoptosis bio-
function’ pathways were inhibited (Figure 6.4). This supported data previously generated by 
PhD student, Ahmed Mahdi. He showed that the number of Ki67 positive hepatocyte nuclei, 
where Ki67 is a marker of cell proliferation, was elevated in the non-tumour tissue of the 
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C3H/He mice fed the ALIOS diet and correlated with the development of HCC in our murine 
model (Data not shown). 
Figure 6.4 Cell survival was the top IPA identified bio-function activated in C3H/He non-
tumour tissue subclass G2 versus G1 The heat map (A) shows the deregulation of different 
diseases and bio-function pathways in the mouse non-tumour tissues, ranked according to –
log (q.value) of overlap. Colour orange represents bio-function activation, blue represents bio-
function inhibition, grey represents an uncalculated z-score and white represents an activity 
score of zero. The intensity of colour is proportional to the increase in absolute activity z-score. 
The bidirectional bar chart (B) shows the top 10 activated (red bars) and inhibited (blue bars) 
diseases and bio-functions in the mouse non-tumour tissue, ranked according to the activation 
z.score. 
 
The IPA upstream analysis tool was used to identify candidate regulatory molecules that 
potentially control the transcription of genes in the analysed list. Csf2, Ifnɣ, Cd44, Mitf and 
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Ptger2 were the top regulators identified in the non-tumour gene list.  Cd44 was the regulator 






Figure 6.5 IPA upstream analysis identifies the top upstream regulators in the hepatic non-
tumour G2-G1 comparison in C3H/He mice. The bar graph shows the top 5 regulators of the 
expression of DE genes in the G2-G1 list. Red bars represent the activation z-score of the 
upstream regulators, and the blue bars represent the log2FC of their expression.  
 
Regulator-effect analysis, using an IPA tool that links the top upstream regulators with top 
changing diseases and bio-function, ranked Cd44 first amid other regulators (Table 6.1), 
followed by Il27. Bioinformatics suggested a role for Cd44 in the recruitment of T lymphocytes 
to the diseased liver via regulating the expression of key chemokines and T cell attractors 
(Figure 6.6).   
Rank Symbol Disease and functions Consistency score 
1 Cd44 Homing of T lymphocytes 3.479 
2 Il27 Differentiation of mononuclear leukocytes 3.357 
3 Il27 Hematopoiesis of mononuclear leukocytes 3.357 
4 Il17 Lymphopoiesis  3.357 
5 Tcr Cytotoxicity 3.207 
Table 6.1 The top 5 molecules in the IPA regulator-effect analysis of G2-G1 DE gene list. Cd44 
was ranked first molecule regulating T cell recruitment in diseased mice liver 
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Figure 6.6 Cd44 regulates the expression of key chemokines responsible for T cell 
recruitment Network analysis identified the elevated expression of genes regulated by Cd44, 
including those involved in recruitment of T cells to the site of injury in diseased non-tumour 
liver tissues of C3H/He mice. The colour orange of Cd44 indicates positive regulation of the 
process. Red colour indicates upregulation of genes downstream to Cd44. The orange colour 
of the “homing of T lymphocytes” function indicates activation of the process as a results of 
upregulation of upstream genes.   
 
In conclusion, IPA suggested an important role for T cells in the pathogenesis of NAFLD and 
NAFLD-HCC in the C3H/He mice. Upregulation of T cells chemokines, influenced by Cd44, 
potentially drives the infiltration of T cells to the liver in response to fat associated damage. 
6.3.3 Pathway analysis of the G2 versus G1 DE gene list using GSEA 
Gene set enrichment analysis (GSEA) is another powerful platform for analysing gene lists and 
is commonly cited in peer reviewed publications. The G2-G1 gene list was analysed against 
the GSEA molecular signatures database (MSigDB) that is composed of hallmark, positional, 
curated, motif, computational, gene ontology (GO), oncogenic and immunological gene lists. 
GSEA identified Macrophage-Enriched Metabolic Network (MEMN) as the top enriched 
network amongst all pathways in the MSigDB (Figure 6.7A) suggesting a role for macrophages 
in disease progression. Complementing the IPA analysis, the top 10 GSEA immune panel-
enriched pathways showed activation of CD4 and Treg cells, together with activation of other 









Figure 6.7 GSEA analysis confirms the activation of immune cell-related pathways in the G2-
G1 comparison Panel (A) shows the gene set enrichment of the ‘macrophage enriched 
metabolic network’. Key: NES; normalised enrichment score, FDR; false discover rate, FWER; 
family wise error rate. The graph in (B) shows the top 10 enriched pathways in GSEA immune 
signatures. Data are ranked according to the normalised enrichment score (NES). 
 
The GSEA Hallmark signature analysis revealed activation of a number of different mechanistic 
pathways, including activation of NF-kB and IL6/STAT3 pathways (Figure 6.8). This finding was 
of particular note due to the reported link between their activation in the non-tumour tissue 
of patients and the recurrence of HCC57. In other words, activation of these pathways in the 
C3H/He non-tumour mouse liver tissues supports the validity of the preclinical model as one 





Figure 6.8 GSEA hallmark analysis showed activation of NF-kB and STAT3 pathways in livers 
of G2 versus G1 mice Gene set enrichment of NF-kB and STAT3 pathways G2-G1 comparison. 
Key: NES; normalised enrichment score, FDR; false discover rate, FWER; family wise error rate. 
 
In summary, GSEA analysis supported IPA findings, highlighting the importance of T cell 
pathways in the disease progression in C3H/He mice. In addition, GSEA identified 




key inflammatory molecular pathways might explain the progression of simple steatosis to 
advanced stages including HCC.  
6.4 Investigating the role of macrophages and T cells in livers of C3H/He mice 
6.4.1 Expression of Cd44 in mouse liver tissue  
Pathway analysis of the non-tumour tissue proposed a role of macrophages and T cells in liver 
disease progression in C3H/He mice, with a suggested link between Cd44 and the process of 
T cell infiltration. Cd44 IHC was performed to explore the protein levels and cellular source of 
Cd44 in liver tissue of C3H/He mice, together with IHC staining for Cd68 and F4/80 
macrophage markers. Notably, Cd44 was expressed exclusively in macrophages in both 
control and ALIOS groups (Figure 6.9). The number of Cd44 positive macrophages in control-
fed mice was 5 fold less than Cd44 positive macrophages in ALIOS fed mice (14.32±2.39 in 
control mice versus 88.79±9.099 in ALIOS-fed mice). There was a modest increase in Cd68 
(66.67±4.066 versus 93.46±4.4 positive cells/HPF) and F4/80 (49.91±6.44 versus 118±22.34 
positive cells/HPF) (Figure 6.9) positive macrophages. In combination, given the higher fold 
diet induced change in Cd44 macrophage count relative to total macrophage count, the data 









Figure 6.9 A preferential increase in Cd44 positive macrophages in lipogranuloma rich areas 
of steatosis in ALIOS-fed C3H/He mice Representative images show IHC stain for Cd68 (A) and 
Cd44 (B) in liver tissues of ALIOS-fed mouse. Lipogranulomas were Cd68 and Cd44 positive. 
Images were captured using Aperio Imagescope software at x20 magnification. Graphs show 
the number of Cd44 (C), Cd68 (D) and F4/80 (E) positive macrophages in control and ALIOS-
fed mice (n=12 per group). Data are presented as mean ± s.e.m; ** p<0.01, *** p=0.001, **** 
p<0.001. 
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Histological assessment also revealed that lipogranulomas, congregations of macrophages 
around cell-free lipid droplets, were the strongest predictor of HCC development in the 
C3H/He mice, and were rich in Cd44 and Cd68 positive cells. When mice were grouped into 
Cd44 high (above median number of Cd44 positive macrophages) and Cd44 low (below 
median), a significant association between Cd44 and the presence of lipogranuloma was 
confirmed (lipogranuloma was absent in 10/11 of Cd44 low mice, while all Cd44 high mice had 
lipogranuloma, chi square p<0.0001). On applying similar groupings to Cd68 and f4/80 
macrophages, there were no significant associations with the presence of lipogranulomas 
(Cd68 p=0.084; f4/80 p=0.198). The development of tumours in C3H/He mice correlated with 
the number of Cd44 (Spearman rho 0.561, p=0.007) and Cd68 (Spearman rho 0.509, p=0.019), 
but not f4/80 (Spearman rho 0.401, p=0.065) positive macrophages.  
In summary, macrophages surrounding the lipogranulomas in the C3H/He mice acquired a 
Cd44 positive macrophage phenotype that was associated with the development of HCC. 
6.4.2 CD44 positive macrophages and HCC development in patients with NAFLD  
The translational impact of the association between Cd44 and the development of HCC in the 
C3H/He mice was assessed in human disease by counting the number of CD44 and CD68 
positive macrophages in non-tumour liver biopsies from patients with NAFLD, with and 
without HCC. This cohort included 42 patients with a median age of 67 years, 64.3% of whom 
(27/42) had developed HCC.  In keeping with the animal model (NAFLD-HCC in the absence of 
cirrhosis), cirrhosis was absent in 31/42 (75.6%) of patients. The median BMI of the patients 
was 31.35 and 23/42 (57.5%) had T2DM.  
The number of CD44 and CD68 positive macrophages in livers of patients with NAFLD-HCC was 























Figure 6.10 CD44 and CD68 positive macrophages were elevated in non-tumour tissues of 
NAFLD-HCC Graphs show numbers of CD44 positive (A &B) and CD68 positive (C & D) 
macrophages per at least 5 HPF, in the non-tumour liver biopsies from NAFLD patients with 
and without HCC, in all cases (n=42) (A,C) or excluding cirrhotic cases (n=31) (B,D) excluded 
the cirrhotic cases. Data are presented in mean±s.e.m, ****p<0.0001.      
 
The number of CD44 positive macrophages was also strongly associated with age (Spearman 
rho 0.660, p<0.0001), and tumour number (Spearman rho 0.758, p<0.0001) with a weaker 
association with T2DM (Spearman rho 0.344, p=0.04). When considering only the macrophage 
counts in the non-cirrhotic cases, the number of CD44 positive macrophages remained 
significantly higher in patients who developed HCC (Figure 6.10). The association between the 
number of CD44 and CD68 positive macrophages was very strong regardless of presence or 
absence of cirrhosis (Spearman rho 0.736, p<0.0001 for all patients and Spearman rho 0.744, 













Figure 6.11 The number of CD44 positive macrophages in NAFLD correlated with the number 
of CD68 positive macrophages. Graphs show the association between the number of CD44 
and CD68 positive macrophages in all patients (A) and in non-cirrhotic cases (B).  
 
In conclusion, macrophage counts in the non-tumour tissues of patients with NAFLD was 
higher in those with HCC compared to those without, supporting a role for CD44 in tumour 
development. The association between CD44 and CD68 cell counts supports the observation 
that macrophages were the primary cell source of CD44 in diseased human liver. The number 
of CD44 positive macrophages remained higher in liver biopsies of NAFLD patients who 
developed HCC independently of the presence of cirrhosis.     
6.4.3 Exploring the role of different chemokines in macrophage recruitment in mice 
Increased infiltration of steatotic livers with macrophages raised questions about the 
processes underlying their accumulation, with suspected roles for increased expression and 
production of certain monocyte/macrophage chemokines. These include CCL5, CCL4 and 
SPP1, released in response to damage, that attract macrophages to sites of injury419, 420. 
Investigation of the expression level of these macrophage-attracting chemokines in the non-
tumour DE gene list confirmed upregulation of Ccl5 (p<0.0001), but not Ccl2 (p=0.25) in the 
liver of ALIOS mice compared to the control mice. Spp1 or osteopontin, a known ligand of 
CD44421, was also upregulated in ALIOS mice (p=0.001). mRNA validation of this by RT-PCR 
confirmed the upregulation of Ccl5 and Spp1 in ALIOS versus control mice, but the 
upregulation of Spp1 didn’t reach the statistical significance (Figure 6.12). Looking for the 
cellular source of chemokines, recent reports suggested hepatocytes as one possible source 
of the expression of Ccl5422 and Spp1423, so the expression of both genes was investigated in 
vitro in lipid loaded mouse hepatocytes.  
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Figure 6.12 Hepatic expressions of Ccl5 and Spp1 
were upregulated in ALIOS versus control 
C3H/He mice. Graph shows the upregulation of 
Ccl5 (light grey) and Spp1 (dark grey) in ALIOS 
versus control-fed mice (n=12 per group). 
Expression is shown as the relative level of 
transcriptional difference (RLTD) using gapdh as a 





Hepatocytes isolated from C57BL/6 mice were treated with either bovine serum albumin 
(BSA) or Oleate/palmitate for 24 hours to see the effect of lipid on the expression profile of 
Ccl5 and Spp1. The levels of Ccl5 and Spp1 in lipid loaded hepatocytes; however, didn’t change 
(Figure 6.13) compared to their level in hepatocytes treated with BSA control.  
Figure 6.13 ccl5 and spp1 levels were comparable 
between control and lipid loaded mouse 
hepatocytes in vitro. Graph shows non-significant 
upregulation of Ccl5 (light grey) and Spp1 (dark grey) 
in hepatocytes treated with control or with 
oleate/palmitate for 24 hours. Expression is shown as 
the relative level of transcriptional difference (RLTD) 
using gapdh as a control. Data are presented as 




In summary, liver expression of Ccl5 and Spp1 was upregulated in response to the ALIOS diet 
in vivo, and this might contribute to higher macrophage counts in the ALIOS mouse tissue. 
Lipid loading of hepatocytes in vitro was not associated with increases in these chemokines. If 
damaged hepatocytes are the source, this might be in association with other DAMPs and/or 
TGFβ with lipids, rather than lipid loading alone. Alternatively, these chemokines may be 
secreted from other cell types in response to injury.  
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6.4.4 Investigating the link between macrophages and T cells recruitment 
6.4.4.1 The association between the macrophages and T cell counts in C3H/He mice 
The link between the macrophages and HCC was supported by the bioinformatics analyses 
and IHC studies in murine and human tissues. IPA and GSEA analyses also implicated another 
type of immune filtrate, suggesting a role for T cells in disease pathogenesis. Given that 
monocytes and macrophages may favour T cell tolerance within the diseased liver 
environment424, we next investigated the interplay between T cells and macrophages. Joao 
Mauricio, a PhD student in our group, did IHC staining and scoring for Cd4, Cd8 and Foxp3 T 
cell subtypes (Appendix-7). Although the counts of the three T cell types were significantly 
higher in the ALIOS mice compared to control mice, the number of Cd4 T cells (Spearman Rho 
0.701, p<0.0001) rather than Cd8 T cell counts (Spearman Rho 0.410, P=0.058) was associated 
with tumour development. In addition, the number of Foxp3 positive Cd4 T cells was higher in 
mice who developed HCC compared to those who didn’t (16.33±3.20 versus 8.35±2.68; 
p=0.041). This supported the GSEA immune-signature analysis (Figure 6.7) that revealed an 
enrichment of Cd4 and Foxp3-related pathways. We created categorical datasets by dividing 
C3H/He mice into two groups, based on the median number of counts, for each immune cell 
subtype in order to study associations between different macrophage phenotypes and the T 
cell subsets. Table 6.2 shows a strong association between macrophages of Cd44 phenotype 
and the infiltration of different T cell subtypes into the liver of C3H/he mice. There was no 
association between Cd68 or F4/80 with T cell counts. 



















cd44 0.009 0.636 0.001 0.03 0.548 0.008 0.009 0.636 0.001 
cd68 0.198 0.365 0.095 1 0.083 0.712 0.67 0.183 0.416 
f4/80 0.086 0.455 0.035 0.198 0.365 0.095 0.395 0.273 0.219 
Table 6.2 Hepatic Cd44 positive macrophages were positively associated with different T cell 
subsets. Fisher exact t.test and Spearman correlation were used to explore associations 




The strong association between Cd44 counts and Foxp3 and Cd4 positive cells was notable 
given that the three cell counts were also associated with the development of HCC in C3H/He 
mice (Figure 6.14). Interestingly, Foxp3 positive T cells were detected in the periportal 
steatotic areas in mice liver tissues where lipogranuloma were common (Figure 6.15) and the 
number of Foxp3 positive T cells was significantly associated with the presence of 
lipogranuloma (Spearman Rho 0.533, p=0.009). The presence of lipogranulomas was also 
associated with Cd4 and Cd8 T cell count (Cd4 Spearman Rho 0.525, p=0.01; Cd8 Spearman 
Rho 0.502, p=0.019). 
 
 
Figure 6.14 Cd44 macrophages correlated with Foxp3 and Cd4 T cell counts. Graphs show the 
associations between the numbers of Cd44 positive macrophages and the number of Foxp3 









Figure 6.15 Accumulation of T-reg cells in areas rich with Cd44 positive macrophages. 
Representative images show IHC stain for Cd44 (A) and Foxp3 (B) in liver of ALIOS-fed mouse. 
Cd44 positive macrophages accumulated in the portal areas around lipogranuloma (A; black 
Cd44 Foxp3 



























arrows); an area enriched with Foxp3 positive Cd4 T-reg cells (B; black arrows). Images were 
captured using Aperio Imagescope software at x20 magnification. 
6.4.4.2 Exploring the T cell chemokines responsible for T cell recruitment in C3H/He mice 
Mining the list of DE genes to identify candidate T cell chemokines revealed an elevated 
expression of classical T cell attractants Cxcl9 (p=7.85E-08) and Cxcl10 (p=2.53E-07) in livers of 
ALIOS-fed mice compared to age matched controls. In addition, the level of the specific Treg 
attractant Ccl22 (p=0.013), but not Ccl17, was also upregulated in the steatotic livers. This was 









Figure 6.16 Upregulation of different T cell chemoattractants in vivo in livers of ALIOS fed 
C3H/He mice. Graph shows the increased expression of Cxcl9, Cxcl10 and Ccl22, but not Ccl17 
in control- (light grey) and ALIOS- (dark grey) fed mice. Expression is shown as the relative 
level of transcriptional difference (RLTD) using Gapdh as a control. Data are expressed as mean 
± s.e.m; *P<0.05; ** p<0.01, n=12 mice per group. 
 
The association between hepatic Cxcl9, Cxcl10 and Ccl22 and the count of different T cell 
subsets is listed in table 6.3. In summary, Cxcl9 was the only chemokine that was associated 
with the T cell counts in the C3H/He mice, while Cxcl10 showed no significant associations 
with different T cell infiltrates. Interestingly, Ccl22 was strongly associated with the infiltration 
of foxp3 T cells and cd4 cells, but not the Cd8 T cells, confirming the specificity of this 
chemokine in attracting T cells of Foxp3 regulatory phenotype. 
 
 








** ** * 0.95
cxcl9 cxcl10 ccl22 ccl17 
164 
 
Table 6.3 Cxcl9 and Ccl22 levels were associated with Cd4 and Foxp3 T cell counts. Spearman 
correlations between categorical datasets are shown. Significant associations are in bold. 
 
6.4.4.3 Investigation of the link between macrophages and T cell chemokines 
We have shown the Cd44 macrophage count to be associated with the infiltration of different 
T cell subsets, and we have also suggested an association between Cd44 positive 
macrophages, Cd4 and Foxp3 positive T cells and the development of HCC. This association 
between macrophages and T cells might be a result of macrophage-induced expression of T 
cell chemoattractants, as suggested from the IPA regulator analysis (Figure 6.6). In fact, the 
number of Cd44 positive macrophages was strongly associated with Cxcl9 (Spearman Rho 
0.603, p=0.004) and Ccl22 (Spearman Rho 0.597, p=0.003) (Figure 6.17); both of which were 








Figure 6.17 Cd44 positive macrophages correlated with key T cell recruiting chemokines in 
C3H/He mice Graphs show the association between the numbers of Cd44 positive 
macrophages and Cxcl9 (A) and Ccl22 (B) levels in the non-tumour livers of C3H/He mice, n=21. 
 













Cxcl9 0.609 0.003 0.647 0.001 0.517 0.016 
Cxcl10 0.409 0.052 0.410 0.053 0.119 0.599 
Ccl22 0.466 0.025 0.671 <0.0001 0.371 0.089 


















Notably, none of the other macrophage phenotypes (Cd68 or F4/80 positive macrophages) 
were associated with the expression of the above cytokines, adding another tier of support a 
role for Cd44 in recruitment of T cells to the fat-loaded livers of C3H/He mice (Table 6.4). 
Table 6.4 cd44 positive macrophages were associated with T cell chemokine expression in 
C3H/He mice. Spearman correlation was used. Significant associations are in bold. 
 
The above association might imply that macrophages (of Cd44 phenotype) can modify the 
liver microenvironment, increasing the recruitment of T cells and consequently the 
development of HCC in C3H/He mice. Depending on the cellular source of each T cell 
chemokine, this macrophage-regulated cross-talk could be directly via macrophage-secreted 
chemotactic factors or indirectly via interaction with other cell types within the diseased liver 
niche. 
6.4.4.4 Investigation of the effect of macrophage polarisation on the autocrine secretion 
of T cell chemokines 
Bone marrow-derived monocytes (BMDMs) were isolated from C57BL/6 mice as described in 
the materials and methods. Polarisation of BMDMs from M0 (unpolarised macrophages) into 
M1 classical inflammatory macrophage phenotype or M2 restorative macrophage phenotype 





Figure 6.18 Treatment of mouse BMDMs with LPS/Ifnƴ or Il4/Il13 changed their polarisation 
into M1 and M2 macrophages respectively. Images show the morphological changes 
accompanying the change from (M0) into the inflammatory macrophage (M1) or restorative 
macrophages (M2) phenotypes. M1 macrophages acquired a rounded, fried-egg like 
morphology, while M2 macrophages were more elongated and spindle in shaped. Images 
were taken at 50x magnification using Zeiss software, n=3 biological replicates. 
 Cxcl9 Ccl22 
Spearman Rho Spearman p.value Spearman Rho Spearman p.value 
Cd44 0.603 0.004 0.597 0.003 
Cd68 0.362 0.116 0.343 0.128 
F4/80 0.399 0.073 0.075 0.740 
M0 M1 M2 
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Upon stimulation with lipopolysaccharides (LPS) and interferon-ƴ (Ifnƴ), the unpolarised M0 
macrophages acquired an M1 fried-egg like shape, while M0 macrophages treated with both 
Il4 and Il13 adopted a spindle like shape typical of the M2 phenotype (Figure 6.18). Gene 
expression profiles for markers of different macrophage phenotypes was explored, and M1 
macrophages showed upregulation of Il6, Tnfα and Nos2 markers compared to M0 and M2 
macrophages (Figure 6.19A). On the other hand, M2 macrophages showed the upregulation 
of the M2 classical markers Arg1 and Ch3i3, compared to M1 and M0 macrophages (Figure 
6.19B) further supporting the success in the induction of macrophage polarisation. Other 
markers of M2 macrophages were, on the other hand, comparable between the three 







Figure 6.19 Upregulation of classical M1 and M2 markers in BMDMs polarised with either 
LPS/Ifnƴ or Il4/Il13. Graphs show the gene expression of the classical M1 markers tnfa, Il6 and 
Nos2 (A) and M2 markers Arg1, Ch3i3, Bank1, Tg2 and Itgm1 (B) in M0 (black bars), M1 (light 
grey) and M2 (dark grey) macrophages. Expression is shown as the relative level of 
transcriptional difference (RLTD) using Gapdh as a control. Data are presented as mean ± s.e.m 
of 2 biological replicates (n=2), * p<0.05, ***p<0.001. 
 
The Cd44 level was comparable between M0 and M1, while slightly decreased in M2 
macrophages, albeit with no statistical significance (Figure 6.20A). Notably, Cd44 was highly 
expressed in all the three macrophage phenotypes (average cycle number of 22), suggesting 
a poor correlation with hepatic macrophages (low in resident macrophages by IHC) and those 
derived from Bone Marrow, with limited relevance for further parallels in the Cd44 context.   
On the other hand, M1 polarised macrophages showed strong upregulation of Ccl22 and Ccl17 
compared to M0 and M2 macrophages (Figure 6.20B). This upregulation was significant in 













Figure 6.20 Polarisation of mouse BMDMs show difference in the level of ccl22, but not cd44 
and ccl17. Graphs show the levels of Cd44 (A), Ccl22 and Ccl17 (B) in M0 (black bars), M1 (light 
grey) and M2 (dark grey) macrophages. Expression is shown as the relative level of 
transcriptional difference (RLTD) using Gapdh as a control. Data are presented as mean ± s.e.m 
of 2 biological replicates (n=2), * p<0.05. 
 
In summary, polarisation of DMDMs into M1 and M2 macrophage phenotypes was 
successfully achieved. M1 macrophages showed higher levels of the Treg chemokine Ccl22 
(formerly called macrophage derived chemokines (MDC)) compared to other macrophage 
phenotypes, while Ccl17 and Cd44 levels were comparable among different phenotypes. A 
better way to study the phenotype of the Cd44 positive macrophage would ideally be 
comparing the polarisation status of macrophages isolated from diet- challenged C3H/He mice 
based on their cd44 expression pattern (Cd44high versus Cd44low).      
6.4.4.5 Investigation of the effect of macrophage polarisation on the paracrine secretion 
of T cell chemokines from hepatocytes 
CXCL9 and CXCL10 were reported to be expressed by diseased hepatocytes in patients with 
chronic HCV infection425, so we hypothesised that macrophages might stimulate hepatocytes 
to produce chemokines that, in turn, induce the recruitment of T cells. Isolated mouse 
hepatocytes were treated in vitro with CM from M0, M1 and M2 macrophages for 24 hours, 
and the expression of Cxcl9 and Cxcl10 was measured. Hepatocytes treated with M1 
macrophages showed dramatic upregulation of cxcl9 and cxl10 compared to hepatocytes 












Figure 6.21 The upregulation of Cxcl9 and Cxcl10 in mouse hepatocytes is induced by M1 
macrophage secretome. Graphs show the levels of Cxcl9 and Cxcl10 in mouse primary 
hepatocytes treated with complete media or CM from in M0, M1 and M2 macrophages. 
Expression is shown as the relative level of transcriptional difference (RLTD) using Gapdh as a 
control. Data are presented as mean ± s.e.m of 3 biological replicates (n=3), ** p<0.001, 
****P<0.0001. 
 
In summary, in vitro studies showed that M1 macrophages contributed to the recruitment of 
T cells in an autocrine fashion (production of Ccl22 from macrophages) or in a paracrine 
fashion via cross-talk with parenchymal cells to produce Cxcl9 and Cxcl10. Further validation 
for the role of Cd44 in the production of T cell chemokines is still outstanding. 
6.5 The association between human and mouse tumour transcriptomic data 
6.5.1 Exploring the overlap between the mouse tumour RNA-seq data and the human TCGA gene 
expression profile  
The reason for analysing the C3H/He mice non-tumour transcriptomic data was to detect 
factors which might contribute to the development of NAFLD-HCC in the absence of cirrhosis. 
In order to investigate whether the HCC developed in the C3H/He mice would mirror human 
HCC, we compared C3H/He tumour RNA-seq data with publically available Tumour Cancer 
Genome Atlas (TCGA) transcriptomic database. Sirintra Nakjang from the Newcastle 
bioinformatics unit has analysed the human TCGA of 374 patients and 50 normal tissue 
samples. Unsupervised class discovery of the human data identified 6 robust HCC metagene 
signatures (defined as V1-V6, blue colour) and one non-tumour tissue signature (defined as 
V7, light green colour) shown in the heat map (Figure 6.22).  
NAFLD-HCC transcriptome data (denoted in dark blue) in this cohort distributed between 
different metagenes and failed to form coherent signature, implying that the presence of 
other stronger factors driving this metagene signature.  












Figure 6.22 Overlapping signatures between Human TCGA and C3H/He mice transcriptome. 
The heat map shows the TGCA gene expression derived metgene level (V1-V7), which defined 
subgroup membership (red indicates high metagene levels, blue indicates low levels). Each 
row represents a metagene and columns are different samples. These 7 metagenes split 
normal tissue (NT) from tumour tissues (NAFLD and non-NAFLD) as well as splitting tumours 
samples into several subgroups. Overlapped metagenes are defined by black boxes, mouse 
non-tumour and tumour transcriptome are highlighted by green box and orange boxes. 
 
The mouse non-tumour transcriptome overlapped with the human non-tumour tissue 
metagene (V7 signature; denoted in green Figure 6.22). Of note, mouse tumour transcriptome 
also overlapped with the human non-tumour signature, but to lesser extent compared to the 
non-tumour tissue. The reason for this might be due to the contamination of the sequenced 
mice tumours from the adjacent non-tumour liver tissue. In contrast, the mouse tumour 
transcriptome profile, but not the non-tumour profile, showed a signature in the human HCC 
V2 metagene (denoted in red; Figure 6.22) reflecting a resemblance between C3H/He mice 
tumour transcriptome and a certain subclass of human HCC. 
6.5.2 Investigating the gene signature shared between C3H/He and human TCGA tumour data  
The DE gene list was created comparing gene transcription profile of V2 human metagene 
with other human metagenes (Appendix-8). GSEA analysis of this list showed strong 






















Figure 6.23 Mouse tumour gene expression profile represents a specific subclass of HCC 
patients. The table (A) shows the top 5 overlapping human HCC subgroups with the human 
V2 metagene signature using GSEA. Gene set enrichment scores of the top enriched human 
HCC subclass that is characterised by high proliferation and high AFP levels (B-C).   
 
This human HCC subclass was characterised by high proliferation, chromosomal aberration 
and high AFP levels. The above data was complimented from the fact that afp was the top DE 
gene when comparing mouse tumour versus mouse non-tumour expression profile 
(Appendix-1). Thus, tumours in C3H/He mice might provide a good preclinical model, relevant 
particularly to the human HCC subclass characterised by high proliferation index. 
6.5.3 Exploring common causative oncogenic pathways in C3H/He tumours and V2 human metagene   
Analysing the DE lists of the human V2 metagene and the mouse tumour versus non-tumour 
against the GSEA oncogenic signatures revealed common pathways responsible for tumour 




















Figure 6.24 Top oncogenic pathways shared between the human V2 signature and mouse 
tumour transcriptomics The heat map (A) shows the top 10 activated oncogenic pathways in 
the human metagene V2 and mouse tumour transcriptomics using GSEA software, 
represented by –log (qvalue of overlap). Gene set enrichment score of the NRF2 pathway in 
the human V2 signature is shown in (B) . Western blotting of NRF2, pERK1/2, total ERK1/2 and 
GAPDH house keeping gene in tissue lysates from tumour and matched non-tumour of 4 
different ALIOS-fed mice (C). 
 
The NRF2 oncogenic pathway was the top activated pathway in the human V2 metagene and 
was also activated in the mouse tumour tissue (Figure 6.24). On the other hand, activation of 
KRAS pathway was the top enriched pathway in the mouse tumour versus normal data with 
similar activation in the human signature. In fact, this data confirmed what Gillian Patman, 





pERK1/2 proteins in mouse tumour tissue compared to matched non-tumour controls (Figure 
6.24). In conclusion, the tumour developed on the background of ALIOS diet resembled a 
group of HCC patients with unique phenotypic features. This subclass was characterised by 
the activation of NRF2 and ERK oncogenic pathways. 
6.7 Discussion 
Early molecular programming studies used microarray analysis to link the change in 
organism’s gene expression profile with different physiological and pathological features426, 
427. This research area was significantly improved after the introduction of the whole genome 
high throughput next generation sequencing (NGS) that provided a faster and more cost-
effective way to study molecular datasets428, 429. The combination of RNAseq, with advanced 
data analysis pipelines has aided comprehensive characterisation of the molecular landscape 
and gene expression of different pathological conditions,  especially in the cancer field430. Early 
microarray studies in paraffin embedded formalin fixed resections from HCC in patients 
undergoing resection failed to characterise a tumour gene signature predicting patients’ 
prognosis57. Instead, this study identified a liver non-tumour gene signature that predicted 
HCC patients’ outcome. Authors also found an enrichment of different inflammatory 
pathways in the non-tumour tissue of patients, like IL6/STAT3 and NF-kB pathways57. Other 
studies centred on HCC molecular classifications were discussed in the introduction chapter. 
In this chapter, unsupervised clustering of the non-tumour C3H/He mice transcriptomic data 
identified an important role of inflammation in HCC development. Interrogation of IPA and 
GSEA analyses of this DE list revealed an enrichment of macrophages, CD4 and FOXP3-related 
pathways. Analysis also showed an enrichment of cell proliferation and survival pathway in 
line with activation of STAT3 and NF-kB pathways in the diseased non-tumour tissue.  The 
RNAseq pathway analysis corroborated the previous histopathology characterisation showing 
that during accumulation of lipids in ALIOS-mice tissue, Lipogranulomas - cell free fat droplets 
surrounded by macrophages - were the strongest predictor of HCC development in the mice. 
This macrophage phenotype was particularly characterised by Cd44 and Cd68, rather than 
F4/80 positive. A previous study has suggested a cancer associated role for CD44, showing 
CD44 expression in the non-tumour liver tissue to predict poorer HCC patients’ outcome431. 
Another study showed that the presence of CD68 positive monocytes in the peri-tumoral 
regions was also associated with poorer outcome in HCC patients432.  
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As shown by the bioinformatic analysis, the number of different T cell subsets was higher in 
livers of ALIOS fed mice. The number of Cd4 positive and Foxp3 positive, rather than Cd8 
positive, T cells were associated with the tumour development. Cd44 positive macrophages 
were the only macrophage phenotype associated with the number of infiltrating T cell subsets. 
Histological assessment of ALIOS-liver tissue showed an enrichment of Treg cells in the areas 
with Cd44 positive lipogranuloma. Moreover, Cd44 positive macrophages were associated 
with chemokines responsible for the recruitment of Treg cells. In combination, these data 
support a key role for Cd44 in the induction of immune suppressive premalignant 
microenvironment characterised by increase the infiltration of Treg cells424.  
Rather than analysing the DE gene list produced by comparing the ALIOS tumour and the non-
tumour transcriptomic data, we projected these data against the tumour and non-tumour 
metagene signatures provided by our non-hypothesis clustering of the human TCGA data. This 
human HCC 6 signature classification was previously created by another group433. The normal 
human liver metagene was enriched from the mouse non-tumour transcriptomic data, while 
a certain human tumour metagene was exclusively enriched from our mouse tumour data. 
Further analysis of the human subclass represented by this metagene identified a unique 
group of patients with high proliferation and activation of ERK/NRF2 pathways. This patient 
subclass was originally described by Chiang58 among 5 different HCC subclasses and it was 
characterised also by higher frequencies of 4q loss and 13q loss and lower frequencies of 6q 
loss. 
In conclusion, the ALIOS fed C3H/He mice recapitulated the features of human NASH and 
NASH/HCC. This model represents a valuable tool to study the mechanisms related to the 
development of and progression of HCC in the patients with the metabolic syndrome, 






Chapter 7: Discussion, conclusion and future directions 
The current staging systems and treatment options of human HCC 
The global incidence of HCC is 1/10000 person per year ranking the sixth most common cancer 
and the third cause of cancer related mortality5. HCC is the predominant form of primary liver 
cancer and is mostly preceded by chronic liver diseases434. The development of HCC in Asia 
and sub-Saharan Africa is attributed to the prevalence of HBV infection and ingestion of 
Aflatoxin-B435, while HCV, alcohol consumption, and metabolic syndrome are among the 
common causes of HCC in USA and Europe41, 436. Prevalence of HCC reached a plateau in 
certain areas in Europe and Japan; however, HCC is on the rise in the USA and developing 
countries437. The advant of DAAs in the eradication of viral hepatitis reduced the number of 
chronically-infected patients who are more likely to develop HCC with age24, 438. Safety profile 
and the non-inferior risk for HCC development once the cirrhosis is established are the major 
limitations of treatment with the DDAs25. A large body of evidence supports the increased risk 
of HCC development on the background of metabolic syndrome and its other co-morbidities. 
In NAFLD patients, retrospective studies made an association between obesity, T2DM and 
metabolic syndrome with the development of HCC439. Male, aged NAFLD patients with high 
BMI are more likely to develop HCC compared to non-obese controls440, and T2DM is reported 
to be an independent risk factor for the development of HCC441. To this end, the active role of 
NAFLD and metabolic syndrome in setting the stage for the development of HCC primes the 
need for more in depth studies to characterise and validate novel therapeutic targets to HCC. 
Median life expectancy of HCC patients is stage-dependent, but at best, it doesn’t exceed 2 
years in the advanced stage HCC349, 442, so novel therapeutic targets might be efficient alone 
or in concert with the existing treatment protocols to improve the outcome of HCC patients.  
The Barcelona Clinic Liver Cancer (BCLC) prognostic assessment system is paired with 
treatment protocols to manage patients with HCC taking into account the stage of the tumour, 
other related symptoms and the degree of liver function preservation443. Patients who had 
solitary tumour of less than 5cm, or up to three nodules of less than 3 cm with preserved liver 
functions and no extrahepatic diseases are staged as BCLC-0 and BCLC-A, and they benefit 
from tumour resection, ablation or transplantation444. Absence of cirrhosis is the benchmark 
for tumour resection in early stage patients with HCC. Tumour recurrence and absence of 
approved adjuvant or neo-adjuvant therapies for patients undergoing resection are the main 
limitation of the procedure444. Despite the high survival rate in patients undergoing liver 
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transplantation as a better alternative to resection in early stage HCC, the availability of donor 
remains the main obstacle445. No adjuvant therapy is given to those who are in the waiting list 
for liver transplantation, thereby increasing the risk of disease progression446. Necrosis-
inducing ablation is the third option for early stage HCC patients, and is highly recommended 
for patients with single malignant focus447. Ablation is considered curative in single nodules 
less than 2cm in size, and the survival of Child-pugh stage-A patients undergoing ablation is 
similar to those having resection448. If histological examination is not necessary for the 
treatment strategy and the liver transplantation is not possible, resection should be a second 
line therapy after ablation in very early stage HCC patients444. Patients with larger multifocal 
tumours, preserved liver functions and no distant metastasis are staged as BCLC stage-B and 
would benefit from transarterial chemoembolization449. Repeating the chemoembolization 
should be considered if the necrosis is established after two rounds, or if the second 
chemoembolization induces substantial necrosis after initial progression following the first 
treatment444. If tumour progresses upon transarterial chemoembolization, treatment with 
sorafenib should be considered. The only available treatment for patients with advanced HCC 
(BCLC-C stage) is the tyrosine kinase inhibitors sorafenib349 as a first line therapy, and 
regorafenib442 and cabozantinib450 as second line treatment. Patients with end-stage HCC 
(BCLC-D) are not amenable for transplantation as they have the poorest survival and the best 
supportive care seems to be the only treatment for this category444. Despite the efforts 
exerted in the management of HCC, the 5-year survival of patients with HCC doesn’t exceed 
at best 12%434 priming the need for more effective therapy. 
The role of immune editing in the development of HCC 
The development of HCC is mostly preceded by chronic liver diseases, and the inflammatory 
response is an integral part of the liver damaged state. The activation of the non-parenchymal 
cells within liver microarchitecture and the infiltration of inflammatory cells help the 
resolution of acute liver damage caused by drugs, viral infection or fat deposition. However, 
repeated cycles of damage, hepatocyte regeneration, release of reactive oxygen species (ROS) 
and DNA damage together with the presence of different immune cell subtypes provide a 
fertile environment for the development of HCC216, 451. An elegant study by Llovet et al, 
published in Gastroenterology in July 2019452, supports the substantial role of the immune 
infiltrate in the non-tumour chronically-diseased livers in patient progression into HCC in 
cirrhotic patients. Authors of this study identified an immune cancer field (ICF) in the 
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surrounding non-tumour liver tissue in more than half of patients who developed early stage 
HCC. Activation of classical inflammatory pathways (NF-kB, IL6/STAT3 and IL2/STAT5) as well 
as different T cells and macrophage pathways was the hallmark in the analysed non-neoplastic 
tissues. Interestingly, this non-tumour ICF signature was associated with poor prognosis in the 
analysed cohort, in line with other studies about the role of the non-tumour signatures in 
predicting the prognosis of HCC patients57. Three distinct molecular subtypes were further 
identified within the ICF group, and were defined as high infiltrate ICF (characterised by more 
T, B cell and macrophage infiltration pathways), immunosuppressive ICF (characterised by T 
cell exhaustion and M2 macrophages pathways) and pro-inflammatory ICF (IFNɣ activation 
and M1 macrophage pathways). Validation of the ICF signature in another cohort of cirrhotic 
patients within the HCC surveillance programs confirmed its existence in nearly 51% of 
patients. Among the three ICF subgroups, the presence of the immunosuppressive ICF was the 
strongest predictor for the development of HCC. Finally, there was no correlation with this ICF 
signature and the peri- or intra-tumoral immune infiltration reflecting that once the tumour 
is established, the stromal infiltration is regulated by the tumour cells themselves rather than 
by the surrounding tissue452.  
We focused on combining the RNA-sequencing, unsupervised clustering, and pathway analysis 
to leverage the impact of the murine model of NAFLD-HCC established in our group. In 
particular, we aimed for unleashing the contributing factors and the features responsible for 
the development of dietary induced-HCC in C3H/He mice in the absence of established 
cirrhosis. C3H/He mice challenged with the ALIOS diet faithfully recapitulated the histological 
features of the human NAFLD and NASH. In addition, C3H/He mice developed HCC with age, 
and this phenotype was exacerbated in mice on the ALIOS diet. The liver weight, the presence 
of lipogranuloma, steatosis grade, lobular inflammation and stage of fibrosis strongly 
predicted the development of HCC regardless to the diet.  
The gene expression data of the C3H/He non-tumour liver tissue split into two groups, and 
most of the ALIOS-fed mice were clustered in the G2 group that represented more chronically 
injured liver. Mice in G2 group showed all features associated with the development of HCC; 
namely, larger liver weight, lipogranuloma and higher tumour burden and tumour size 
compared to mice in G1 cluster. Analysing the DE gene list resulting from comparing the above 
non-tumour clusters showed the activation of macrophage and T cell pathways consistent 
with what was shown in Llovet’s study in human non-tumour liver tissues452. Histological 
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characterisation to the different immune infiltrates in the non-tumour tissue revealed a 
significant increase in the number of macrophages and the T cell infiltrates in the diseased 
livers. Of these, the number of cd4 positive T cells and foxp3 positive cells and the number of 
cd68 positive macrophages were associated with tumour development. Bioinformatics 
suggested cd44 as one of the main drivers in the G2 vs G1 comparison, and IHC stain for cd44 
in mice showed a predominant expression in the macrophages. The number of cd44 positive 
macrophages was strongly associated with the presence of lipogranuloma; the strongest 
predictor of HCC. The cd44 macrophage count was also strongly associated with the 
development of HCC in C3H/He; a finding that was validated in human NAFLD/NASH non-
tumour tissues. The number of CD44 positive macrophages was higher in the non-tumour 
tissue of NAFLD/NASH patients who developed HCC compared to those who didn’t develop 
HCC regardless to the presence of cirrhosis. This is clinically relevant in many aspects; first, 
CD44 macrophage count can be considered as predictive marker for tumour development in 
non-cirrhotic NAFLD patients by setting up a certain threshold for CD44 positive macrophage 
above which NAFLD patient could develop HCC. This subclass of patients is not subjected to 
the surveillance programs453, and lack of predictive markers increases patients’ risk of 
developing HCC with age. Preventive strategies against HCC development could also consider 
targeting CD44 in macrophage as a prophylactic therapy against HCC in the high risk patients. 
Virtually all reports about CD44 in non-malignant conditions link its expression with different 
immune cell activation, trafficking and homing processes454-458. Wang J and Kubes P458 showed 
that sterile liver injury stimulates the infiltration of peritoneal cavity macrophages in a cd44 
dependent manner. Once recruited to the liver, these macrophages acquire the restorative 
M2 macrophage phenotype contributing to the process of injury repair and healing458. It is 
noteworthy saying that authors didn’t measure cd44 level in the liver-recruited macrophages 
once acquired the M2 phenotype to see whether or not this phenotype switch changes cd44 
expression. cd44-/- KO mice challenged with Methionine-choline deficient (MCDD) diet 
showed macrophages skewed to M2 polarisation compared to control mice. In the same 
context, macrophages isolated from cd44-/- KO mice were less responsive to LPS activation456. 
Expression of cd44 in different macrophage phenotypes showed counterintuitive results. 
Stimulation of human THP1 monocyte cell line with M1 and M2 stimuli showed increased 
CD44 expression in M1 macrophage phenotype compared to M0 and M2 macrophages. M2-
polarised THP1 cells; however, expressed CD44 isoform v6 that was associated with better 
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uptake of hyaluronic acid-based material compared to M1-polarised macrophages that had 
the strongest CD44 expression459. Another study by a different group showed upregulation of 
cd44 in bone marrow-derived monocytes stimulated with either LPS/IFNɣ (M1 stimuli) or with 
IL4 (M2 stimuli) adding more complexity to identify the association between cd44 expression 
and different macrophage polarisation460. Further studies are needed to confirm the 
phenotype associated with CD44 expression. 
Regardless to the phenotype of the cd44 positive macrophages, IPA analysis and the 
association between cd44 macrophage counts with cell count of T cell subsets suggested a 
role of cd44 in regulating the homing of different T cell subsets in the lipid-loaded livers. The 
infiltration of T cells to the injured livers was influenced by the upregulation of cxcl9 in mice 
tissue, and cxcl9 expression in the C3H/He mice was strongly associated with the number of 
cd44 positive macrophages.  In vitro, cxcl9 level was strongly upregulated in isolated mouse 
hepatocytes incubated with CM from M1 classical macrophages compared to hepatocytes 
stimulated with CM from other macrophage polarization. In line with this, the level of ccl22, 
another T cell chemoattractant whose mRNA levels were associated with cd44 positive 
macrophages, was upregulated in the in vitro experiments in M1 macrophages compared to 
other macrophage phenotypes. Of note, CCL22 was reported to be associated with the TAM 
phenotype461, 462. This might be explained by the difference between the tumour infiltrating 
macrophages and macrophages that exist in the precancerous-lesion. The paradigm of M1-
M2-TAM is grossly challenged with recent findings of macrophages that carry shared M1/M2 
features463-465. Further work is needed to characterise the macrophage phenotype in the 
C3H/He mice that is linked with infiltration of immune suppressive T cells and with the 
development of HCC. 
CAFs are important modulators of human HCC progression     
The HCC milieu includes the transformed hepatocytes as well as other non-parenchymal cells 
including CAFs, TMAs, infiltrating T cells and angiogenic factors466. The role of the stromal 
components within the tumour microenvironment is to induce the proliferation and 
metastasis of the tumour cells, to favour immunosuppressive environment and to increase 
the tumour vasculature466. In line with this, the infiltration of αSMA-positive CAFs is associated 
with tumour recurrence after resection in HCC patients351. The accumulation of TAMs in HCC 
is also associated with the larger tumour size and poor patients’ outcome225. Elevation of 
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serum VEGF is associated with tumour stage and size and worse prognosis467. Hence, tumour 
stroma is rewarding target to downstage tumour and improve patient outcome.    
The elevation of SULF2 in HCC resections was associated with post-resection tumour 
recurrence304; however, the cellular source of SULF2 and its prognostic role in diagnostic HCC 
biopsies was yet to be determined. Our studies showed that CAFs were the predominant 
source of SULF2 in the HCC biopsies, and patients whose HCC biopsies were CAF-SULF2 
positive showed the poorest survival. In vitro studies using fibroblast cell line with 
manipulated SULF2 level supported the profound role of stromal SULF2 in inducing aggressive 
tumour microenvironment. HCC cells cultured in SULF2-rich CM or co-cultured with SULF2 
expressing fibroblasts were more proliferative, migratory and invasive compared with cells 
grown in the absence of SULF2. Moreover, tumour spheroids grown in stromal SULF2 positive 
media were less amenable to the cytostatic effect exerted by sorafenib in comparison with 
spheroids grown in SULF2 deficient conditions. This finding was further supported by IHC stain 
for SULF2 in biopsies from sorafenib-treated HCC patients where the CAF-SULF2 positivity was 
associated with sorafenib tolerability and poor survival. SULF2 works in different, but yet 
complimentary, mechanisms depending on its cellular source. SULF2 KD from the fibroblasts 
reduced the activation of PDGFRβ/JNK/STAT3 pathway leading to deficient secretion of the 
pro-tumourigenic cytokines IL6 and IL8. Previous studies showed that in vivo activation of JNK 
pathway in mice liver stromal cells was responsible for regulating the fibroblast secretome 
preceding the development of experimental HCC137. Consistently, the role of SULF2 in the 
expression and production of IL6 in lung cancer cell lines was previously proved384. Yet, this is 
the first study to link SULF2 with the production of IL6 and IL8 cytokines in the context of HCC. 
SULF2 and SULF2-regulated secretome activated NF-kB pathway in the tumour cells in a 
paracrine fashion. This SULF2-dependent activation of NF-kB pathway upregulated the 
stemness marker CD44 in the tumour cells and this was associated with the proliferation and 
invasion seen in the HCC cell lines. Activation of NF-kB pathway and upregulation of CD44 was 
evident even if the cells were treated with sorafenib, thereby suggesting this pathway as the 
driver of sorafeib resistance being a feature of CAF-SULF2. This finding was further supported 
from HCC biopsies where SULF2 positive CAFS existed in the vicinity of tumour cells with 
positive membranous CD44 and nuclear Pp65 (RelA) positivity. Recently, Michael Karin’s 
group has published an elegant study that support the role of CD44 in the process of HCC 
development and progression186. In this study, IL6 secreted from activated macrophages was 
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associated with CD44 expression in hepatocytes and progenitor cells, treatment of primary 
hepatocytes with recombinant IL6 induced CD44 expression. CD44 was then responsible for 
switching of P53 surveillance program leading to the development and progression of HCC186. 
As a regulator of IL6 production and secretion, we provide a novel evidence about the role of 
SULF2/IL6/CD44 axis in the transformed/malignant hepatocytes.   
In 2017, Llovet and his group identified a novel immune profile of HCC229 by integration of 
transcriptome analysis, IHC stain and patients data. HCCs in this immune class showed more 
T cell infiltration and more PD1 and PDL1 positivity compared to the immune-null group. 
Further dissection of the immune profile within the immune class showed two distinct groups; 
namely referred as “immune active” and “immune exhausted” groups. The immune active 
class was characterised by less active stroma, better patient outcomes and activation of 
different effector cell pathways like IFNɣ reflecting the activation of the anti-tumour 
immunity. In clear contrast to the immune active class, the immune exhausted class was 
characterised by the enrichment of T cell exhaustion, M2 macrophages and worse patient 
prognosis. Notably, this class was associated with active stroma and activation of TGFβ as a 
driver pathway to this immune class229. Accumulating data from our group has suggested a 
role of SULF2 to this immune exhausted class. We show that SULF2 level was significantly 
higher in the “immune exhausted” subclass compared to the “immune active2 and “immune-
null” classes. IHC stain to CD45, CD4, CD8, CD68 and CD66b in HCC biopsies previously stained 
with SULF2 showed an association between CAF-SULF2 and the CD45 and CD68 positive 
counts (data not shown). Given the strong upregulation of SULF2 in the LX2 cells upon 
treatment with rhTGFβ, we propose another inevitable role of SULF2, as an integral part of 
the active tumour stroma, in the infiltration of macrophages and leukocytes to the tumour; 
and this role is mediated by TGFβ. These data were collected in the time course after 
completion of this thesis and are considered as supporting material for the CAF-SULF2 
manuscript.   
Conclusion 
In summary, the focus of the current study was to explore the active role of different non-
parenchymal cells present in the proximity of the tumour niche on the development and 
progression of HCC. This study used both hypothesis driven and non-hypothesis driven 
approach to reveal the irrefutable role of SULF2 within the tumour microenvironment side by 
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side with characterization of cd44, cxcl9 and ccl22 as possible novel therapeutic targets that 
predispose malignancy in the chronically injured livers.  
Future directions 
• As a part of the Epos grant, RNAseq was performed on NAFLD/NASH patients with 
different disease stage in a multi-centre study in Europe. Among different DE genes, 
SULF2 was upregulated in the advanced disease stage compared to simple steatosis. 
In addition, SULF2 was differentially hypo-methylated in patients with more advanced 
disease explaining the SULF2 upregulation in the RNAseq. These data corroborated our 
preliminary SULF2 IHC in NAFLD/NASH patients, thereby encouraging further 
characterisation of SULF2 as a rewarding therapeutic target in NAFLD/NASH. 
• Sulf2 expression in the murine mouse model of NAFLD-HCC was associated with 
certain histopathological criteria of mice, most importantly with the development and 
the size of the developed tumours. Sulf2-/- mice are available, and challenging Sulf2-/- 
mice with ALIOS diet might give an insight about the role of Sulf2 in tumour 
development and progression. 
• Bioinformatics suggested a novel association between Sulf2 and Itk in the fibrosis-
related DE gene list linking Sulf2 with inflammatory changes accompanying fibrosis. 
Exploring this association between SULF2 and inflammation could provide a novel 
therapeutic angle in fibrotic patients, but could also indirectly reduce the number of 
patients developing HCC after deposition of the fibrotic scars. Isolation and FACS 
sorting of peripheral and liver resident T cells can identify the SULF2-specific T cell 
subtype and its clinical and translational relevance.    
•  Unsupervised clustering of the non-tumour tissue provided a significant role of the 
inflammatory changes in setting the scene for the development of HCC reassuringly 
reproducing what was very recently published. CD44 positive macrophages 
orchestrate the microenvironment favouring an immune suppressive and anti-tumour 
evasion mechanisms. The phenotype of CD44 positive macrophages should be 
carefully characterised with the hope to produce tool therapy that could, in theory, 
reduce CD44 levels and confer the reduction of the tumour development of the 
preclinical NAFLD-HCC models before testing in diseased NAFLD/NASH patients. 
Rerunning the ALIOS model with isolation and characterisation of the CD44 positive 
macrophages is one of the important future directions for our group. 
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• The interplay between different cell compartments in the liver microarchitecture could 
influence the infiltration of immune subsets preceding the development of 
malignancy. On the other hand, certain immune cells are responsible for the anti-
tumour activity and removal of senescent liver parenchymal cells. Careful investigation 
should dissect the pathways responsible for the tumour development from these 
responsible for tumour eradication before adopting immune-related therapeutic 
strategies in the diseased patients.      
 
Erratum 
Myofibroblast cells used in these studies were subsequently confirmed to be of primate 
COS cell origin, rather than being human hepatic stellate ‘LX-2’ cells. 
After submission of this thesis to the post graduate office for examination, Professor Oakley 
was informed by a collaborator performing routine checks on shared ‘LX-2 cells’, that they 
were likely of primate rather than human origin. Our group have subsequently confirmed that 
the cells called ‘LX-2’ cells used in this thesis are in fact derived from COS monkey embryonic 
fibroblasts.  While the SULF2 mechanistic in-vitro experiments presented remain valid, as COS 
cells are frequently used as a tool cell line producing SULF2, submission of my first author 
SULF2 manuscript for publication has been delayed pending confirmatory mechanistic studies 
in additional validated human cells.  The thesis examiners were subsequently informed and it 
was agreed that an addendum be added, to highlight this issue, in the final copy of the thesis, 
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Appendix-1 List of top 100 DE genes in tumour versus non-tumour comparison  
symbol log2FoldChange pvalue padj 
Afp 8.44263783 1.87E-179 4.14E-175 
Akr1c18 8.840960881 1.97E-163 2.18E-159 
Igdcc4 8.615427477 2.77E-125 2.05E-121 
Gpc3 8.170529223 3.29E-119 1.83E-115 
Alox5 8.730666917 8.86E-105 3.93E-101 
Kif5c 8.030015624 4.74E-102 1.75E-98 
Msantd3 5.605312611 3.11E-95 9.86E-92 
Ipcef1 6.562819115 7.56E-93 2.10E-89 
Galnt6 5.825448131 2.00E-92 4.94E-89 
Prom2 10.04177835 4.95E-92 1.10E-88 
Rasgrp2 3.57811106 1.49E-91 3.01E-88 
Col4a3 6.950164867 1.68E-89 3.10E-86 
Lama5 4.910575041 4.21E-87 7.18E-84 
Dusp5 5.335998931 3.20E-86 5.07E-83 
Tnfrsf12a 3.748370371 7.15E-86 1.06E-82 
B4galt6 4.589440132 4.47E-83 6.20E-80 
Cdkn2b 6.001067766 3.08E-82 4.02E-79 
Erich4 9.386133729 1.32E-81 1.63E-78 
Rhbdf1 2.643264609 9.39E-80 1.10E-76 
Nid1 4.402575535 1.50E-79 1.66E-76 
Psrc1 8.877126359 7.11E-79 7.51E-76 
Fhl3 4.328825075 2.24E-78 2.26E-75 
Scn8a 4.845982965 2.68E-78 2.59E-75 
Smox 4.043392409 6.38E-78 5.90E-75 
Mtcl1 6.387750686 2.97E-77 2.64E-74 
Golm1 4.528479505 2.24E-76 1.92E-73 
Rasal1 5.675415429 1.33E-75 1.10E-72 
Cacna1c 6.309070622 2.36E-75 1.87E-72 
Dlx4 4.517503056 1.95E-74 1.50E-71 
Ccdc120 4.039612377 1.51E-73 1.11E-70 
Casc4 4.651520753 1.61E-73 1.15E-70 
Nxn 3.921810917 2.87E-73 1.99E-70 
Psat1 5.071135972 1.59E-72 1.07E-69 
Col6a6 4.914607104 3.84E-71 2.51E-68 
Pdlim7 1.953325248 1.08E-70 6.84E-68 
Miox 8.891304282 1.45E-70 8.95E-68 
Hdac7 1.612690754 3.01E-69 1.76E-66 
Calml4 4.400926207 3.01E-69 1.76E-66 
Ankrd13b 2.63750931 6.24E-69 3.56E-66 
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Tlr1 6.141791134 1.42E-68 7.90E-66 
Cd63 4.486462294 1.57E-68 8.48E-66 
Trpm4 3.958149081 1.78E-67 9.42E-65 
Prom1 5.290290336 3.39E-67 1.75E-64 
Mthfd1 -0.951720594 7.48E-67 3.78E-64 
F2rl1 7.800368191 1.02E-66 5.06E-64 
Tnfsf13 4.224962755 1.10E-66 5.31E-64 
Osbpl10 4.958871016 1.14E-66 5.37E-64 
Arhgap22 6.206632025 1.85E-66 8.55E-64 
Lepr 4.649332481 2.10E-66 9.53E-64 
Atg3 -0.787483744 1.02E-65 4.52E-63 
NA 3.890633773 2.29E-65 9.98E-63 
Airn 3.383042887 4.53E-65 1.93E-62 
Panx1 3.479654956 7.04E-65 2.95E-62 
Glp2r 7.589349413 1.08E-64 4.45E-62 
Fst 4.086710818 3.68E-64 1.48E-61 
Gria3 3.472563135 3.86E-64 1.53E-61 
Adamtsl5 4.802755354 1.38E-63 5.39E-61 
Card10 1.961035451 2.53E-63 9.69E-61 
Ajuba 3.278486537 2.79E-63 1.05E-60 
Abcc5 2.815835715 2.87E-63 1.06E-60 
Adamts14 3.90103299 3.25E-62 1.18E-59 
Rhoc 2.792729513 9.60E-62 3.39E-59 
Lysmd2 4.777428706 9.62E-62 3.39E-59 
Nrg1 4.017130998 1.11E-61 3.86E-59 
Fblim1 5.293882663 1.28E-61 4.37E-59 
5330417C22Rik 4.873890377 2.63E-61 8.85E-59 
Cd40 4.371609382 2.71E-61 8.97E-59 
Hid1 3.845462044 3.73E-61 1.22E-58 
Phgdh 6.774008614 4.06E-61 1.31E-58 
Tspan8 7.1040849 4.21E-61 1.34E-58 
Zfp57 3.709452738 7.17E-61 2.24E-58 
Plxna3 3.411804361 8.38E-61 2.58E-58 
Clip2 2.494554733 8.63E-60 2.63E-57 
Ica1 3.047246986 1.02E-59 3.07E-57 
NA 4.220050901 1.13E-59 3.35E-57 
Dlx4os 7.997350123 1.44E-59 4.19E-57 
Mtmr11 3.016697042 1.71E-59 4.92E-57 
Clcf1 3.534213256 3.43E-59 9.75E-57 
Kcp 3.879972734 1.02E-58 2.87E-56 
Tnfrsf10b 4.348620754 1.18E-58 3.27E-56 
Bmp8b 6.360670146 1.67E-58 4.59E-56 
Fhdc1 4.855459185 2.06E-58 5.58E-56 
Tmem54 7.453598065 2.59E-58 6.93E-56 
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Itih5 4.096294696 2.82E-58 7.45E-56 
Ndfip1 -0.967808705 7.39E-58 1.93E-55 
Pde6c 4.964818634 4.46E-57 1.15E-54 
Zfp641 4.525732005 1.42E-56 3.61E-54 
Hes1 1.971872516 4.28E-56 1.08E-53 
Cth -1.76997674 5.95E-56 1.48E-53 
Gch1 -0.968384519 1.60E-55 3.95E-53 
Ifnlr1 4.042596974 1.75E-55 4.26E-53 
Scn1b 3.205679602 4.24E-55 1.02E-52 
Ugt2a3 -1.601522954 5.36E-55 1.28E-52 
Itpr3 2.758916634 8.99E-55 2.12E-52 
Aldh7a1 -1.067539235 1.79E-54 4.18E-52 
Myo7b 5.700391531 2.39E-54 5.54E-52 
Pck2 3.128338573 4.53E-54 1.04E-51 
Drc1 3.576981609 1.11E-53 2.52E-51 
Scd2 4.736960337 1.43E-53 3.22E-51 




















Appendix-2 List of top 100 DE genes in the non-tumour tissue of ALIOS versus control-
fed mice comparison  
symbol log2FoldChange pvalue padj 
NA 1.203581 9.80E-12 4.49E-07 
B430212C06Rik 2.174045 2.20E-09 5.05E-05 
Spink1 2.206168 4.48E-09 6.84E-05 
Tmem86a 1.241054 3.22E-08 0.00036848 
Arhgap10 1.064582 6.38E-08 0.00058431 
Limch1 1.351157 9.84E-08 0.00075132 
Fam46a -0.89141 1.26E-07 0.0008231 
Apoa4 1.226494 2.09E-07 0.00106526 
S100g 1.930044 1.96E-07 0.00106526 
Syt14 1.380868 3.44E-07 0.00152379 
Cyp2b10 2.280894 3.66E-07 0.00152379 
Setbp1 1.030734 4.26E-07 0.0016275 
NA 1.956681 5.27E-07 0.00185646 
Rbm24 2.96117 8.40E-07 0.00256543 
Fam83a 2.478311 8.16E-07 0.00256543 
Nuggc -1.99918 1.25E-06 0.00358803 
Ucp2 1.30328 1.48E-06 0.00398737 
Spink5 -1.14312 1.64E-06 0.00411803 
Gstp1 -1.03052 1.71E-06 0.00411803 
Slc22a26 3.098045 2.68E-06 0.00613869 
Atp9a 0.323367 3.50E-06 0.00728592 
Slc22a29 2.001839 3.47E-06 0.00728592 
Tiam2 -2.18443 4.10E-06 0.00749819 
Kdm2b -0.272 3.89E-06 0.00749819 
Obp2a -2.50107 4.26E-06 0.00749819 
Slc22a27 3.005928 4.13E-06 0.00749819 
Smpd3 1.815372 4.43E-06 0.00751388 
Tnfrsf22 0.764335 4.71E-06 0.00760088 
Csf2rb 0.886089 4.81E-06 0.00760088 
Bend7 -0.44156 5.25E-06 0.00800963 
Slc35f2 2.010912 6.38E-06 0.0088517 
Fez2 0.63717 6.32E-06 0.0088517 
Slc47a2 0.616851 6.22E-06 0.0088517 
Defb1 1.379134 6.89E-06 0.00928424 
Stambpl1 0.898633 9.93E-06 0.0103455 
Acot9 0.813928 9.55E-06 0.0103455 
Man2b2 0.379897 7.97E-06 0.0103455 
Cgref1 1.143292 9.82E-06 0.0103455 
Cspg5 -1.79421 9.71E-06 0.0103455 
Pygo1 1.378602 9.79E-06 0.0103455 
Cyp2b13 3.503563 8.71E-06 0.0103455 
Serpina1e -4.11431 9.94E-06 0.0103455 
Cyp2a4 4.698236 8.80E-06 0.0103455 
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Gcnt4 -1.65543 9.70E-06 0.0103455 
Ly6d 2.794496 1.03E-05 0.01051052 
Ctsb 0.380842 1.30E-05 0.0125216 
Ctnna1 0.23484 1.27E-05 0.0125216 
Tox 1.533001 1.31E-05 0.0125216 
Stk10 0.74585 1.48E-05 0.0132576 
Vldlr 1.71538 1.42E-05 0.0132576 
Mlph 0.743616 1.45E-05 0.0132576 
Dlgap1 -0.94123 1.52E-05 0.01338657 
Plscr2 0.540279 1.58E-05 0.01361593 
Folh1 1.242719 1.76E-05 0.01417218 
Myl12b 0.453084 1.72E-05 0.01417218 
Dcaf12l1 0.744704 1.76E-05 0.01417218 
Sort1 -0.76496 1.69E-05 0.01417218 
Adap1 1.044579 1.82E-05 0.01438838 
Smarca4 0.296511 1.88E-05 0.0145966 
Mogat1 2.747028 1.94E-05 0.01474762 
Eps8 0.944197 1.96E-05 0.01474762 
Cntnap1 1.554633 2.09E-05 0.01484594 
Ptgfr 1.357083 2.05E-05 0.01484594 
Sepw1 0.363593 2.06E-05 0.01484594 
Sod3 0.663615 2.11E-05 0.01484594 
Angpt1 1.14017 2.20E-05 0.01504337 
Ttc39a 2.069874 2.19E-05 0.01504337 
Gnai1 1.071366 2.33E-05 0.01544841 
NA 1.242254 2.30E-05 0.01544841 
Vav1 0.903681 2.65E-05 0.01660274 
Olfr701 -1.35204 2.61E-05 0.01660274 
NA -0.56911 2.58E-05 0.01660274 
NA -0.79381 2.62E-05 0.01660274 
Ranbp3l -0.82942 2.69E-05 0.0166614 
Hexb 0.811295 2.75E-05 0.0167877 
Tinag 2.21548 2.88E-05 0.01726866 
Tmem98 0.6856 2.90E-05 0.01726866 
Klhl13 0.64054 3.07E-05 0.01803087 
Paip1 0.279145 3.12E-05 0.01808459 
Tnfrsf21 0.600979 3.49E-05 0.01965515 
Chchd6 0.754959 3.51E-05 0.01965515 
NA 0.92577 3.52E-05 0.01965515 
Krt23 2.005001 3.90E-05 0.02008102 
Crebbp -0.25335 4.02E-05 0.02008102 
Grm8 -1.6227 4.01E-05 0.02008102 
Zfp639 -0.28836 4.12E-05 0.02008102 
Cabp1 -0.70562 3.86E-05 0.02008102 
Gdf3 0.992756 4.07E-05 0.02008102 
Myh14 0.407161 3.73E-05 0.02008102 
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Car14 -0.93733 3.91E-05 0.02008102 
Ccdc68 0.612122 3.77E-05 0.02008102 
Mmd2 -1.30357 4.10E-05 0.02008102 
Snord104 -0.5595 4.05E-05 0.02008102 
NA 1.574364 3.74E-05 0.02008102 
NA 0.539028 4.21E-05 0.02028305 
Slc45a4 0.285824 4.25E-05 0.02028305 
Isoc2b 0.477184 4.40E-05 0.02079475 
Cd300lb 0.81459 4.52E-05 0.02110037 
Rai2 0.467298 4.70E-05 0.02174073 























Appendix-3 List of top 100 DE genes in the non-tumour tissue of high fibrosis versus low 
fibrosis comparison  
 
symbol log2FoldChange pvalue padj 
Nuggc -1.694798196 8.15E-19 1.45E-14 
Ucp2 1.106164153 2.85E-15 2.54E-11 
Sort1 -0.81540868 1.05E-14 5.10E-11 
Slc22a29 1.673442977 1.15E-14 5.10E-11 
Inpp4a -0.510388481 1.88E-14 5.58E-11 
NA 1.694951006 1.62E-14 5.58E-11 
Pparg 1.777016638 3.93E-14 9.99E-11 
Tox 1.530517023 8.77E-14 1.73E-10 
Fam83a 1.660347528 8.15E-14 1.73E-10 
Cgref1 1.128553642 2.58E-13 4.59E-10 
Slc22a26 1.693763312 4.98E-13 8.06E-10 
Vldlr 1.557519943 6.72E-13 9.96E-10 
Sh3bgrl3 0.712243064 1.71E-12 2.33E-09 
S100a11 1.244066063 1.96E-12 2.49E-09 
Acot9 0.737037245 3.57E-12 4.23E-09 
Spsb4 -0.672310537 3.87E-12 4.30E-09 
Apoa4 0.999837597 4.97E-12 5.20E-09 
Limch1 1.400578989 6.33E-12 6.26E-09 
Ctsb 0.339310065 1.10E-11 1.03E-08 
NA 1.036288427 1.24E-11 1.10E-08 
Cidec 1.581462773 1.55E-11 1.31E-08 
S100g 1.567274145 1.64E-11 1.32E-08 
Tgfbr2 0.950053027 2.05E-11 1.59E-08 
Ephb2 1.533610905 3.98E-11 2.95E-08 
Cspg5 -1.512323669 5.63E-11 4.01E-08 
Anxa2 0.992554304 6.79E-11 4.64E-08 
Aqp7 1.498185994 7.05E-11 4.64E-08 
Itgax 1.446424971 1.01E-10 6.44E-08 
S100pbp -0.355281846 1.36E-10 8.36E-08 
Angpt1 1.250545996 1.95E-10 1.16E-07 
Capns1 0.251083573 3.11E-10 1.79E-07 
Fignl1 1.428863659 3.57E-10 1.98E-07 
Obp2a -1.464956678 4.50E-10 2.29E-07 
Tmem86a 0.932759144 4.26E-10 2.29E-07 
Lgals1 1.05237804 4.51E-10 2.29E-07 
Mmp12 1.452292066 6.11E-10 3.02E-07 
Clec7a 1.254561251 6.71E-10 3.22E-07 
Cyp2u1 -0.78799999 8.93E-10 4.13E-07 
Ccnd1 1.132089917 9.16E-10 4.13E-07 
Setbp1 1.197797937 9.28E-10 4.13E-07 
Ccbl1 -0.522586273 1.01E-09 4.38E-07 
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Eps8 0.962550481 1.12E-09 4.75E-07 
Cntnap1 1.219619995 1.41E-09 5.77E-07 
Rcan2 1.371658326 1.43E-09 5.77E-07 
Psmd8 0.223676429 1.48E-09 5.86E-07 
Cars -0.413808172 1.69E-09 6.52E-07 
NA -1.380935393 1.92E-09 7.25E-07 
Kcp -0.895890518 2.14E-09 7.95E-07 
Myl12b 0.365309009 2.46E-09 8.79E-07 
H2-M2 1.401146428 2.47E-09 8.79E-07 
Ehbp1 -0.43784295 2.58E-09 9.00E-07 
Pea15a 0.353897514 2.94E-09 1.00E-06 
Zmym5 -0.249198041 3.22E-09 1.07E-06 
Fez2 0.537128198 3.25E-09 1.07E-06 
Znf512b -0.467199981 3.34E-09 1.08E-06 
Fras1 -0.855714398 3.41E-09 1.08E-06 
NA -0.707802036 3.48E-09 1.09E-06 
Plekha2 0.561161188 3.70E-09 1.13E-06 
Dcbld1 0.674542949 4.17E-09 1.26E-06 
B4galt6 0.825236448 4.74E-09 1.40E-06 
Mmp13 1.361988 5.42E-09 1.58E-06 
Fam46a -0.749469887 6.00E-09 1.72E-06 
Rims4 1.280515152 6.09E-09 1.72E-06 
Tm4sf4 0.337542188 6.39E-09 1.78E-06 
Arhgap10 0.944014344 7.12E-09 1.95E-06 
Msmp 1.355861973 7.58E-09 2.04E-06 
Krt23 1.343020312 8.14E-09 2.16E-06 
NA -0.69478318 8.89E-09 2.32E-06 
NA -0.447989931 8.98E-09 2.32E-06 
Anxa5 0.426144753 9.41E-09 2.39E-06 
Bend7 -0.440216791 1.09E-08 2.74E-06 
Defb1 1.244117371 1.18E-08 2.91E-06 
Stambpl1 0.989316789 1.21E-08 2.95E-06 
Gstp1 -0.860320047 1.23E-08 2.96E-06 
Simc1 -0.420084415 1.32E-08 3.13E-06 
Ccdc80 0.73684706 1.57E-08 3.66E-06 
Capg 0.857028219 1.74E-08 3.98E-06 
Hao2 1.321117656 1.72E-08 3.98E-06 
Ly6d 1.321679487 1.80E-08 4.06E-06 
Mcm5 1.145466109 1.84E-08 4.09E-06 
Cotl1 0.534441909 2.00E-08 4.34E-06 
Tnfsf15 1.279424754 2.00E-08 4.34E-06 
Mbp 1.116772136 2.17E-08 4.64E-06 
Fbxo22 -0.286223861 2.23E-08 4.67E-06 
Ywhah 0.359249748 2.21E-08 4.67E-06 
Stk10 0.653813006 2.36E-08 4.89E-06 
Ptgfr 1.26782392 2.55E-08 5.21E-06 
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Iqgap1 0.616734606 2.64E-08 5.30E-06 
Snhg18 0.860271327 2.65E-08 5.30E-06 
Slc16a5 1.073261323 2.69E-08 5.32E-06 
Gal3st1 1.162094172 2.93E-08 5.72E-06 
Mogat1 1.280469532 3.35E-08 6.47E-06 
Marcks 0.502725439 3.43E-08 6.56E-06 
Slc22a27 1.289934666 3.50E-08 6.63E-06 
Scai -0.784151879 4.00E-08 7.50E-06 
NA -0.798988768 4.14E-08 7.68E-06 
Myof 0.819387187 4.49E-08 8.24E-06 
Wisp3 -1.246717446 4.59E-08 8.33E-06 
Fgd3 0.858406947 4.66E-08 8.37E-06 






















Appendix-4 List of top 100 DE genes in the non-tumour tissue of high fibrosis versus low 
steatosis comparison  
 
symbol log2FoldChange pvalue padj 
Fam83a 1.464684233 5.02E-14 8.69E-10 
Csf2rb 0.841191668 7.73E-13 6.68E-09 
Tff3 -1.325676425 7.98E-12 4.60E-08 
Dnaic1 -1.270247442 2.77E-11 1.20E-07 
Itpr2 -0.462814735 1.01E-10 3.51E-07 
Dntt 1.036542481 2.10E-10 5.40E-07 
Tusc3 0.552252214 2.19E-10 5.40E-07 
Atp9a 0.274288437 2.62E-10 5.67E-07 
Slc22a29 1.25819665 5.53E-10 1.06E-06 
Aph1b -0.914399935 6.49E-10 1.12E-06 
Myl12b 0.310224903 1.06E-09 1.68E-06 
Apoa4 0.886582781 1.29E-09 1.72E-06 
Saa3 -1.087077598 1.22E-09 1.72E-06 
Serpina9 -1.238211362 1.76E-09 2.18E-06 
Def8 0.32456576 1.89E-09 2.18E-06 
NA -1.208283027 2.04E-09 2.20E-06 
Inpp4a -0.366722298 3.09E-09 3.14E-06 
H2-Q1 1.064788455 3.26E-09 3.14E-06 
Ucp2 0.806640382 6.60E-09 6.01E-06 
Msmp 1.177557703 1.22E-08 1.05E-05 
Fitm1 1.042384176 1.35E-08 1.12E-05 
Ly6d 1.167650391 1.52E-08 1.20E-05 
NA -1.104865173 1.68E-08 1.26E-05 
Enho -1.160114012 1.99E-08 1.44E-05 
Isoc2b 0.464017062 2.32E-08 1.58E-05 
Gm19619 0.876048553 2.38E-08 1.58E-05 
Fads1 0.712966091 2.64E-08 1.69E-05 
Ccbl1 -0.433225214 3.27E-08 2.02E-05 
Capns1 0.195122229 4.38E-08 2.61E-05 
Gcnt4 -1.054276755 4.62E-08 2.66E-05 
Cntnap1 1.033838061 6.01E-08 3.25E-05 
Ccnd1 0.907973169 5.84E-08 3.25E-05 
Lpar6 -0.270146494 6.74E-08 3.54E-05 
Sulf2 0.684330083 9.16E-08 4.66E-05 
Vat1 0.381589361 1.18E-07 5.75E-05 
Spink5 -1.033271422 1.20E-07 5.75E-05 
NA -1.015343286 1.77E-07 8.26E-05 
Tead3 -0.366988793 2.17E-07 9.38E-05 
Gngt1 0.784452313 2.16E-07 9.38E-05 
Dcaf12l1 0.666412274 2.17E-07 9.38E-05 
Cdkl2 0.41264676 2.28E-07 9.51E-05 
214 
 
Slc35f2 1.069397697 2.31E-07 9.51E-05 
S100g 1.059979629 2.47E-07 9.95E-05 
Znrf1 -0.404760579 2.64E-07 0.000104 
Acmsd -0.754450922 2.76E-07 0.000106 
Apoc2 0.577477286 3.23E-07 0.000122 
Ip6k1 -0.209673909 3.31E-07 0.000122 
Tpst1 -0.552946968 3.81E-07 0.000137 
NA -0.976173487 4.03E-07 0.000142 
Mcm4 0.75597425 4.54E-07 0.000156 
Cotl1 0.421261455 4.60E-07 0.000156 
Tmem86a 0.757317985 4.92E-07 0.000162 
Ern1 -0.441395258 4.96E-07 0.000162 
B430212C06Rik 0.98045074 5.27E-07 0.000169 
Sall4 1.022186981 5.94E-07 0.000187 
M6pr 0.176396552 6.35E-07 0.000193 
Mogat1 0.999937948 6.29E-07 0.000193 
NA 1.008817016 6.90E-07 0.000206 
Cops7b -0.341836561 7.09E-07 0.000206 
Rarres1 0.670831504 7.14E-07 0.000206 
Scd2 1.010883222 7.78E-07 0.000221 
Tbc1d31 0.709228526 8.19E-07 0.000228 
Acot9 0.524055917 9.44E-07 0.000259 
Fads2 0.750787347 1.08E-06 0.000292 
Anxa5 0.329673711 1.10E-06 0.000292 
Tspan33 -0.722069367 1.14E-06 0.000298 
Dynll1 -0.7392959 1.24E-06 0.000305 
Abcd1 0.553755222 1.22E-06 0.000305 
Pnpla3 1.002720547 1.21E-06 0.000305 
5830473C10Rik -0.428465402 1.25E-06 0.000305 
Klhl33 -0.840886577 1.25E-06 0.000305 
Adgrf1 -0.991756836 1.30E-06 0.000313 
Mllt10 -0.252573512 1.43E-06 0.000339 
Gpc1 0.667060399 1.47E-06 0.000343 
NA -0.389839517 1.49E-06 0.000345 
Acad9 0.294541598 1.55E-06 0.000353 
Srxn1 0.373457503 1.63E-06 0.000362 
Bmp6 -0.446832862 1.63E-06 0.000362 
BC026585 0.407562337 1.65E-06 0.000362 
Dlgap1 -0.953628566 1.77E-06 0.00037 
Sh3bgrl3 0.4661017 1.73E-06 0.00037 
Arhgap10 0.790588897 1.73E-06 0.00037 
Maml3 -0.528651182 1.77E-06 0.00037 
Taok2 -0.369297046 1.81E-06 0.000373 
Gm17296 -0.495441871 1.83E-06 0.000373 
NA -0.411192336 1.91E-06 0.000385 
Ctsb 0.246168451 2.03E-06 0.000403 
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Lama3 -0.926681279 2.10E-06 0.000414 
Cyp2c39 0.831997064 2.16E-06 0.000415 
Polr2c -0.245169655 2.15E-06 0.000415 
NA -0.848701492 2.18E-06 0.000415 
C1ql4 -0.958805894 2.27E-06 0.000422 
Ctnna1 0.171837308 2.25E-06 0.000422 
Cidec 0.964732798 2.34E-06 0.000426 
NA -0.793084899 2.33E-06 0.000426 
Nqo1 0.653664599 2.80E-06 0.000484 
Brd4 -0.171298807 2.72E-06 0.000484 
Smpd3 0.914781269 2.83E-06 0.000484 
Smarca4 0.262645781 2.81E-06 0.000484 






















Appendix-5 the histological predictors of HCC development in the C3H/He mice 
Chi2 test was performed between categorical variables, while Spearman correlation was 












 Tumour development 
 Chi2 Spearman correlation 
 NO Yes p value Correlation p value 
Gross phenotype features 
Liver weight 1.93 ± 0.11 2.67 ± 0.13  0.686 <0.001 




 0.66 <0.001 
Body weight 42.18 ± 
1.12 
45.95 ± 0.92  0.381 0.008 
Histological parameters 
Steatosis grade (0/1/2/3) 4/7/8/1 0/4/20/3 0.01 0.429 0.003 
Microvesicular steatosis 19/1 20/7 0.059 0.382 0.008 
Hepatocellular ballooning (0/1/2) 5/12/3 4/20/3 0.579 0.058 0.699 
Mallory Denk bodies (0/present) 14/6 13/13 0.172 0.305 0.1039 
Lipogranuloma (0/present) 15/5 9/17 0.007 0.481 0.001 
Lobular Inflammation score (0/1/2) 9/10/1 4/18/5 0.06 0.421 0.003 
Portal Inflammation score (0/1/2) 18/1/1 21/5/1 0.507 0.276 0.060 
Megamitochondria (0/present) 16/4 17/9 0.275 0.031 0.839 
Apoptotic cells (0/present) 15/5 22/4 0.145 -0.114 0.452 
Pigmented Kupffer cells (0/present) 13/7 11/15 0.127 0.280 0.060 
Perisinusoidal fibrosis score(0/1) 6/14 1/26 0.012 0.361 0.013 
Fibrosis stage (0/1/2/3) 6/8/6 1/14/11/1 0.064 0.355 0.014 
NAS score (sum)    0.465 0.001 
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Appendix-6 List of top 100 DE genes in the non-tumour tissue G2-G1 comparison 
 
symbol log2FoldChange pvalue padj 
Rab7b 1.359134316 8.56E-18 1.56E-13 
Rgs2 1.326200401 1.17E-16 1.07E-12 
Itgax 3.070569217 5.29E-16 3.22E-12 
Ephb2 5.037418963 2.23E-15 1.02E-11 
Fam83a 2.959473584 3.55E-15 1.30E-11 
Ccl5 2.810290262 6.37E-15 1.94E-11 
Rgs10 1.259532556 1.08E-14 2.46E-11 
Esm1 2.871008568 1.04E-14 2.46E-11 
Pparg 4.08289923 1.41E-14 2.86E-11 
Arl4c 1.210437925 1.74E-14 3.18E-11 
Clec12a 1.382969639 3.41E-14 5.37E-11 
Marcks 0.808501292 3.53E-14 5.37E-11 
Clec7a 2.06592789 7.76E-14 1.09E-10 
Iqgap1 0.95801272 1.06E-13 1.25E-10 
Rac2 1.456875313 1.09E-13 1.25E-10 
Fabp4 1.014439538 1.03E-13 1.25E-10 
Anxa2 1.50396261 1.35E-13 1.45E-10 
Epsti1 1.247936037 1.77E-13 1.80E-10 
Ncf2 1.091980182 2.08E-13 2.00E-10 
Cd300lb 1.141537474 2.32E-13 2.12E-10 
Tyrobp 1.152122859 3.40E-13 2.96E-10 
Slpi 2.829778489 3.83E-13 3.18E-10 
Laptm5 1.241558944 4.21E-13 3.25E-10 
Ctss 1.313986275 4.28E-13 3.25E-10 
Lgals1 1.750814714 4.44E-13 3.25E-10 
S100a11 1.946599023 4.69E-13 3.30E-10 
Card11 2.36672697 4.96E-13 3.35E-10 
Gltp 0.928456203 9.90E-13 6.46E-10 
Timp1 3.260114433 1.19E-12 7.45E-10 
Wdfy4 1.155041207 1.22E-12 7.45E-10 
Fam105a 1.435609461 1.43E-12 8.42E-10 
Rftn1 0.988664999 1.87E-12 1.07E-09 
Cd68 0.989247112 2.02E-12 1.09E-09 
Vav1 1.133073448 2.03E-12 1.09E-09 
Ckb 1.099940398 2.23E-12 1.17E-09 
Endod1 0.969749043 2.68E-12 1.36E-09 
Thbs1 1.940743741 2.76E-12 1.36E-09 
Kbtbd11 1.635367339 3.11E-12 1.49E-09 
Nckap1l 1.187748515 3.21E-12 1.51E-09 
Arhgap25 1.304362396 4.79E-12 2.19E-09 
Cidec 3.185851928 7.45E-12 3.32E-09 
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Ucp2 1.373021954 7.76E-12 3.36E-09 
Msmp 3.396284509 7.90E-12 3.36E-09 
Pld4 1.117857684 9.70E-12 4.03E-09 
Cotl1 0.814243272 1.06E-11 4.29E-09 
NA -4.079536802 1.65E-11 6.54E-09 
Clec4a2 1.672108973 1.72E-11 6.55E-09 
5830473C10Rik -0.688594907 1.72E-11 6.55E-09 
Gpr65 1.390705015 1.80E-11 6.70E-09 
Pak1 1.338584911 2.24E-11 8.20E-09 
Trem2 2.447214461 3.58E-11 1.19E-08 
Sash3 1.509624283 3.44E-11 1.19E-08 
Rap2b 0.900109359 3.54E-11 1.19E-08 
B4galt6 1.151351281 3.45E-11 1.19E-08 
Ms4a4b 1.87320898 3.52E-11 1.19E-08 
Uhrf1 2.780330841 3.68E-11 1.20E-08 
Tnfrsf23 1.382085065 3.86E-11 1.24E-08 
Capg 1.36288818 3.98E-11 1.25E-08 
Ly6d 3.248552011 4.06E-11 1.26E-08 
Gnai1 1.527483917 4.32E-11 1.32E-08 
Hr 2.234750158 4.40E-11 1.32E-08 
Myl12b 0.495840381 4.56E-11 1.34E-08 
Lpxn 1.126618128 5.08E-11 1.47E-08 
Dock2 1.317705168 6.39E-11 1.82E-08 
Amz1 1.831023718 7.30E-11 2.05E-08 
Ly86 1.140937813 9.25E-11 2.52E-08 
Hip1 0.687771282 9.17E-11 2.52E-08 
Mbp 1.894942589 1.04E-10 2.78E-08 
Csf1r 0.974790629 1.18E-10 3.11E-08 
Was 1.190245519 1.19E-10 3.11E-08 
Cybb 1.316363724 1.36E-10 3.50E-08 
Sh3pxd2b 1.216376464 1.43E-10 3.63E-08 
Fcer1g 1.039992004 1.70E-10 4.25E-08 
Ppm1h 0.98991467 1.81E-10 4.47E-08 
Myo1f 1.313352426 2.38E-10 5.79E-08 
Ms4a7 2.301540961 2.47E-10 5.85E-08 
Acot9 0.928396503 2.46E-10 5.85E-08 
Tnfaip8l2 1.176264257 2.67E-10 6.10E-08 
Gpsm3 0.784568538 2.66E-10 6.10E-08 
Dna2 -0.623830814 2.64E-10 6.10E-08 
Cyba 1.06235638 3.02E-10 6.81E-08 
H2-M2 3.752112724 3.10E-10 6.92E-08 
Cd52 1.801688923 3.19E-10 7.02E-08 
Cxcl9 1.874650962 3.61E-10 7.85E-08 
Fam129a 1.035352159 3.74E-10 8.03E-08 
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NA 1.21220214 3.88E-10 8.23E-08 
Wisp2 3.191471438 3.98E-10 8.35E-08 
Arhgap22 2.827918458 4.11E-10 8.54E-08 
Cyth4 1.108570951 4.43E-10 9.10E-08 
Ppp4r3a -0.432994015 4.80E-10 9.74E-08 
Myof 1.198870527 4.98E-10 1.00E-07 
Trim30d 0.999994332 5.16E-10 1.03E-07 
Pdcd1 5.134805636 5.41E-10 1.06E-07 
Ccnd1 1.695752427 5.47E-10 1.06E-07 
Sh3bgrl3 0.952296721 5.55E-10 1.07E-07 
Cd48 1.291535518 6.20E-10 1.18E-07 
Slc7a8 0.86707134 6.39E-10 1.20E-07 
Rinl 1.15276684 6.55E-10 1.22E-07 
Scube1 2.236732896 6.70E-10 1.24E-07 















Appendix-7 Different subsets of T cells were increased in the non-tumour livers of ALIOS 













Graphs show the number of CD4 (A), FOXP3 (B) and CD8 (C) positive T cells in control and 
ALIOS-fed mice. Data are presented as mean ± s.e.m of positive T cells in 10 high power fields 
















Appendix-8 List of top 100 DE genes in the V2 human signature 
 
symbol log2FoldChange pvalue padj 
AHSG -6.058814897 2.18E-145 7.98E-141 
SERPINC1 -5.864260687 1.22E-142 2.23E-138 
SLC38A3 -4.32787323 3.41E-115 4.17E-111 
NR1I3 -5.077516278 9.36E-114 8.59E-110 
CYP27A1 -3.761003529 3.47E-111 2.55E-107 
DAO -5.30121174 2.27E-105 1.39E-101 
AQP9 -5.827279902 1.52E-104 7.98E-101 
ITGA3 4.093904398 2.37E-102 1.09E-98 
PKLR -5.024888729 3.07E-102 1.25E-98 
ASPDH -5.651603803 1.42E-101 5.22E-98 
PLCD3 3.178424327 2.25E-100 7.50E-97 
PCK2 -3.849325744 1.77E-97 5.41E-94 
SPEG 5.026713439 1.71E-96 4.83E-93 
XYLB -2.787220725 8.60E-96 2.14E-92 
UPB1 -4.895203928 8.76E-96 2.14E-92 
CCL16 -5.622741858 2.29E-95 5.24E-92 
PIPOX -3.786150019 9.99E-92 2.16E-88 
CYB5A -2.833150413 2.04E-91 4.15E-88 
PFKFB1 -4.750818837 7.94E-91 1.53E-87 
ACOX2 -3.649710094 4.20E-90 7.69E-87 
HNF4A-AS1 -5.163825422 2.20E-88 3.85E-85 
APOH -4.200464675 7.10E-88 1.18E-84 
TTR -5.406958674 3.29E-87 5.24E-84 
APOM -4.265832381 3.82E-85 5.83E-82 
SARDH -3.673712608 6.37E-85 9.34E-82 
PROC -3.273232451 7.37E-84 1.04E-80 
ECI2 -2.150274885 3.33E-83 4.53E-80 
KHK -3.40762185 1.75E-82 2.29E-79 
PEBP1 -2.25206221 1.77E-81 2.24E-78 
SORD -3.502276203 2.03E-81 2.49E-78 
F7 -3.432238683 2.64E-81 3.13E-78 
PKM 3.596431766 1.25E-80 1.43E-77 
SPDYC -4.28566513 1.19E-79 1.32E-76 
EPHX1 -3.439875415 2.37E-79 2.56E-76 
KNG1 -3.954819654 4.51E-79 4.73E-76 
AC022816.1 -5.839594708 4.74E-79 4.83E-76 
GLYCTK -2.90651005 5.35E-79 5.30E-76 
AQP11 -2.683675169 2.16E-78 2.09E-75 
F12 -4.107137695 4.00E-78 3.76E-75 
SLC27A5 -4.772009392 4.30E-78 3.95E-75 
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SERPIND1 -3.746392669 1.11E-77 9.94E-75 
AC021074.3 -5.831658028 9.45E-77 8.25E-74 
SULT2A1 -4.93932307 2.46E-76 2.10E-73 
ADORA2A-
AS1 -3.551117611 6.17E-75 5.14E-72 
TWIST1 5.432555672 3.93E-74 3.20E-71 
AC008549.1 -6.04860657 4.72E-74 3.76E-71 
METTL7A -2.473909794 5.38E-74 4.20E-71 
APOA2 -4.46842969 9.28E-74 7.09E-71 
SLC9A1 2.131903526 1.55E-73 1.16E-70 
CYP2J2 -3.346562801 4.33E-73 3.18E-70 
CDR2L 2.941236853 2.17E-72 1.55E-69 
MMP14 2.904909685 2.20E-72 1.55E-69 
A1BG -4.397457218 4.17E-72 2.89E-69 
CYP7A1 -6.926743868 7.67E-72 5.21E-69 
KIF3C 3.124123625 2.21E-71 1.47E-68 
ETNK2 -3.887780034 2.49E-70 1.63E-67 
LRP8 3.465482861 2.59E-70 1.67E-67 
TF -3.853450718 4.18E-70 2.64E-67 
ACSM2A -4.532556786 5.26E-70 3.27E-67 
PECR -2.422936635 5.76E-70 3.52E-67 
FUOM -2.832956547 6.66E-70 4.00E-67 
EHHADH -3.489821075 7.18E-70 4.25E-67 
HJV -4.430666485 1.07E-69 6.24E-67 
ALDH5A1 -2.532000497 1.51E-69 8.54E-67 
ITGB4 3.432284927 1.76E-69 9.77E-67 
GPX8 2.866805273 3.18E-69 1.74E-66 
CRYL1 -2.550857174 8.95E-69 4.83E-66 
BDH1 -3.211456961 9.33E-69 4.96E-66 
DMGDH -3.838883465 3.42E-68 1.79E-65 
DCXR -3.937391633 3.75E-67 1.94E-64 
F2 -3.543676345 2.51E-66 1.28E-63 
SLC10A1 -5.785933174 7.88E-66 3.96E-63 
HCN3 -3.069305026 1.10E-65 5.40E-63 
IL27 -3.935477941 1.10E-65 5.40E-63 
ITPR2 -2.49202564 1.21E-65 5.85E-63 
ITIH5 5.453709016 4.69E-65 2.23E-62 
FETUB -5.503162238 6.01E-65 2.83E-62 
BHMT -5.333131215 7.34E-65 3.41E-62 
APOC3 -4.444012796 1.05E-64 4.80E-62 
ATP8A2 5.293811671 1.69E-64 7.66E-62 
MLXIPL -2.717543987 3.92E-64 1.75E-61 
ITIH1 -3.582177583 5.41E-64 2.39E-61 
ACSM2B -4.074571727 2.39E-63 1.02E-60 
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UGT2B10 -4.914562509 3.52E-63 1.49E-60 
HSD17B4 -2.189682806 1.60E-62 6.68E-60 
RGN -3.167765448 1.76E-62 7.26E-60 
AP003716.1 -5.300365241 1.93E-62 7.86E-60 
NMNAT2 4.80080227 2.46E-62 9.93E-60 
NADK2 -2.466323193 2.56E-62 1.02E-59 
NUGGC -4.365618537 1.22E-61 4.82E-59 
ARID3C -4.163819483 1.67E-61 6.51E-59 
ADH6 -3.778221661 2.29E-61 8.85E-59 
GIPR 4.380258306 2.56E-61 9.79E-59 
CES2 -3.221900834 4.26E-61 1.61E-58 
CAT -2.615856239 1.84E-60 6.90E-58 
DHTKD1 -2.45025276 1.91E-60 7.07E-58 
AMT -2.184604271 2.14E-60 7.83E-58 
SCTR 5.415163599 4.22E-60 1.53E-57 
MITF 2.755409371 6.89E-60 2.45E-57 
























Personal Data                    













Degree BSc. pharmaceutical Sciences, MSc. Biochemistry. 
Position Assistant lecturer in the department of biochemistry, Faculty of Pharmacy, Minia 
university, Egypt. 
PhD student in the Northern institute for cancer research/ institute of cellular medicine, 




2004-2009 Pharmaceutical sciences, faculty of pharmacy,  Minia university, Egypt 
2009 BSc in Pharmaceutical Sciences, Faculty of Pharmacy, Minia University, Egypt  
2014 MSc in Biochemistry, “Investigation of possible changes of HDGF expression in hepato-
carcinogenic mouse model”, Minia University, Egypt 
2015 to 
date 
PhD student at the NICR/ICM, school of medical sciences, Newcastle University-
Newcastle Upon Tyne, England. 
Training 
2010 Effective presentation skills course, Minia University, Egypt 
2010 Self-education training course, Minia University, Egypt 
2010 Laboratory safety training course, Minia University, Egypt 
2011 Information & communication Technology Project (ICTP) inclusive course, Minia 
University, Egypt 
2012 Practical training in Institute of Biochemistry and molecular biology, Faculty of medicine, 
Bonn University, Germany 
2013 Training course in Quality parameters in the educational process, Minia University, Egypt 
225 
 
 Training course in “ Communication skills, Minia University, Egypt 
2015 Biological safety, CHOSHH and GM training, Newcastle university, UK 
2017 Animal handling course – Pil AB, Newcastle University, UK 
2017 ePortfolio and Personal Development Planning course 
2017 Molecular Pathology Node - Training Day, Newcastle University, UK 
2017 SPSS Beginners course, Newcastle University, UK 
2018 Training in Cancer Research UK MedImmune Alliance, Granta park, Cambridge, UK for 
the development of active SULFATASE-2 recombinant protein. 
2018 Animal tissue processing in MRC Harwell, Oxford, UK as a part from current project for 
an important regulator of NAFLD/HCC. 









Characterisation of HDGF protein levels in different stages of HCC development in murine 
mouse models 
1- Synthesis of recombinant proteins. 
2- Rabbit immunisation, Antibody production and purification. 
3- Western blotting. 
4- Immunohistochemistry. 
Project 1: Characterisation of SULF2 cellular source, function and mechanistic role in 
human HCC  
1- Molecular biology: Synthesis of recombinant protein, Western blotting, Quantitative 
Real time PCR (q-PCR) 
2- Gene manipulation: CRISPR/CAS9 gene knock-out technique, shRNA gene silencing 
techniques. 
3- Cell based techniques:  Cell culture; cell lines and primary cells, Proliferation assays 
(MTT, BrdU assays), Cell migration assay, Cell invasion assay. 
4- 2D and 3D in vitro models: Trans-well 2D cell co-culture techniques, 3D tumour 
spheroid techniques. 
5- ELISA: In-house ELISA optimisation; antibody/protein coating, antibody labelling, 
target protein measurement. 
6- Tissue and cell staining: Immunohistochemistry (IHC), Immunocytochemistry (ICC), 
Immunofluorescence (IF) 
7- Tumour xenograft mouse model. 
8- Statistics: Graph-pad prism, SPSS 
Project 2: Investigating the role of different immune cells in the development of HCC in a 
dietary mouse model 
1- Bioinformatics tools; Principles of bioinformatics analysis R package, Dealing with big 
transcriptomic data; Analysing differentially expressed gene lists using Ingenuity pathway 
analysis (IPA), Gene set enrichment analysis (GSEA) and panther software 
226 
 
2- Tissue and cell staining: Immunohistochemistry (IHC), Immunocytochemistry (ICC), 
Immunofluorescence (IF) 
3- Molecular biology: Synthesis of recombinant protein, Western blotting, Quantitative 
Real time PCR (q-PCR). 
4- Animal work; Animal blood and tissue sampling and manipulation and processing, GTT 
test for mice 
5- Primary cell cultures: Isolation of primary hepatocytes and bone marrow derived 
monocytes for in vitro work 
6- statistics 
Project 3: The role of Obeticholic acid in restoring cognitive function declined in primary 
Biliary cholangitis 
Bioinformatics tools; Analysing differentially expressed gene lists using Ingenuity 
pathway analysis (IPA), Gene set enrichment analysis (GSEA) and panther software. 
Project 4: MeCP2 in organ fibrosis 
1- Primary cell culture: Monitoring isolated mouse hepatic stellate cells with specific 
MeCP2 knock-out. 
2- Immunohistochemistry staining. 
Project 5: cRel in organ fibrosis and cancer 
1- Bioinformatics tools; Analysing differentially expressed gene lists using Ingenuity 
pathway analysis (IPA). 
2- Immunofluorescence staining 
3- 3D tumour spheroid co-cultureProject 6: The development of a novel bioreactor 
technique for precision-cut liver slices 
Immunohistochemistry 
Project 7: Vanin1 single nucleotide polymorphism (SNP) in the development and 
progression of non-alcoholic fatty liver diseases 
Cell based assays; proliferation assays 
Quantitative Real time PCR (q-PCR) 
Project 8: Non-parenchymal TREM2 in HCC 
3D tumour spheroid co-culture 
Oral talks (As presenting author) 
2019 Marco Zaki, Misti V Mccain, Ahmed K Mahdi, Joao Mauricio, Caroline Wilson, Gillian 
Patman, Anna Whitehead, John Lunec, Ruchi Shukla, Quentin M Anstee, Dina Tiniakos, 
Fiona Oakley, Helen Louise Reeves-“Genome wide RNA expression analysis identifies CD44 
positive macrophages as promoters of hepatocyte proliferation and the development of 
NAFLD-HCC”, EASL HCC summit, Lisbon, Portugal.  





2018 Ahmed Mahdi, Marco Zaki, Joao Muricio, Catherine Willoughby, Misti McCain, Olivier 
Govaere, Jill Patman, Quentin Anstee, John Lunec, Dina Tiniakos, Fiona Oakley and Helen 
Reeves- “ What drives development of HCC in non-cirrhotic NAFLD?”, EASL international 
liver conference, Paris, France. 
2018 Marco Zaki, Sari Alhasan, Lee Borthwick, Ruchi Shukla, Fiona Oakley and Helen Reeves, 
“The role of Stromal SULFATASE-2 in the progression of Hepatocellular carcinoma”, British 
association for the study of the liver (BASL), Derbyshire, UK. 
2017 Marco Zaki ,Sari Al-Hasan , Lee Borthwick, Ruchi Shukla, Fiona Oakley and Helen Reeves – 
“Stromal SULFATASE-2 promotes Human hepatocellular carcinoma cell growth and is a 
potential novel therapeutic target”, Oral presentation in the EASL HCC summit in Geneva, 
Switzerland. 
Oral talks (as co-author) 
2019 Lucy Gee, Ben Millar, Jack Leslie, Claire Richardson, Diana Jurk, Saimir Luli, Marco 
Youssef William Zaki, Fiona LeBeau, Elizabeth Stoll, David Jones, Fiona Oakley-
“Obeticholic acid limits cholestasis induced cognitive decline by maintaining blood-brain 
barrier integrity and preserving neuronal health”,  accepted for oral presentation in  the 
international liver congress,  Vienna, Austria. 
Poster presentations 
2019 Marco Zaki, Misti Mccain, Ben Barksby, Lee Borthwick, Olivier Govaere, Dina Tiniakos, 
Ruchi Shukla, Helen Louise Reeves, Fiona Oakley -“Sulfatase-2 (SULF2) in the hepatocellular 
carcinoma microenvironment orchestrates disease progression and therapy resistance”, 
EASL HCC summit, Lisbon, Portugal. 
2019 Aitor Esparza-Baquer, Ibone Labiano, Omar Sharif, Fiona Oakley, Pedro Miguel Rodrigues, 
Elizabeth Hijona, Raul Jimenez-Aguero, Adelaida La Casta, Marco Youssef William Zaki, 
Colm O Rourke, Patricia Munoz-Garrido, Jesper Andersen , Sylvia Knapp, Derek A Mann, 
Luis Bujanda, Jesús María Banales, María Jesús Perugorria -“ Non-parenchymal TREM2 
halts hepatocarcinogenesis through the inhibition of liver inflammation and hepatocyte 
proliferation”, EASL HCC summit, Lisbon, Portugal. 
2019 Lucy Gee*, Marco Zaki*, Graham Smith, Dave Jones, Fiona Oakley- “High throughput RNA 
Sequencing Unravels Pathways Associated with Cognitive Deficit in Primary Billiary 
Cholangitis”,  EASL international liver congress,  Vienna, Austria. 
2018 Olivier Govaere, Jeremy Palmer, Mingqiang Zhuang, Marco Zaki, Emma Scott, Simon 
Cockell, Ann K Daly, Quentin M. Anstee- “The vanin 1-cysteamine pathway regulates 
immune tolerance upon lipidinduced oxidative stress in non-alcoholic fatty liver disease”, 
accepted for poster presentation in the international liver congress in Paris, France. 
2017 Marco Y. Zaki, Lee Borthwick, Sari Alhasan, Julie Worrell, Ruchi Shukla, Dina Tiniakos, 
Helen Reeves, Fiona Oakley, “ Stromal Sulfatase-2 – a critical regulator of hepatocellular 
carcinoma growth and migration”, AASLD Liver meeting, Washington DC, USA. 
2017 Marco Zaki, Sari Alhasan, Lee Borthwick, Ruchi Shukla, Julie C Worrell, Helen Reeves and 
Fiona Oakley – “Stromal SULFATASE-2 promotes Human hepatocellular carcinoma cell 
growth”, the director’s Day, ICM, school of medical sciences, Newcastle University, UK. 
2017 Marco Zaki, Sari Alhasan, Lee Borthwick, Ruchi Shukla, Fiona Oakley and Helen Reeves – 
“SULFATASE-2, secreted from Cancer-associated fibroblasts, promotes Human 




2017 Worrell JC, Leslie J, Smith G, O’Reilly S, Zaki M, van Laar JM, Mann DA and Oakley F – 
“Regulation Of Fibroblast Phenotype, Functionality And Matrix Production By The Nf- Κb 
Subunit C-Rel In Fibrosis”,  poster in 15th  international workshop on scleroderma research,  
university of Pittsburgh, USA. 
2014 Marco Y. William Zaki, Heba M. eltahir, Nabil M. Abdel-hamid and Mekky M M Abouzied 
- “Production and Characterization of Rabbit Anti-mouse Hepatoma Derived Growth Factor 
(HDGF) IgG for Western Blotting and Immunohistochemistry”, Poster presentation in Assiut 
University 9th international pharmaceutical sciences conference, Assiut, Egypt. 
Publications 
2019 Marco Zaki, Ahmed K Mahdi, Gillian L Patman, Joao Mauricio, Misti V McCain, Anna 
Whitehead, Despina Televantou, Robyn Watson, Jack Leslie, John Lunec, Derek Mann, 
Quentin M Anstee, Dina Tiniakos, Fiona Oakley, Sirintra Nakjang, Ruchi Shukla, Helen L 
Reeves, “ A macrophage response to free liver fat drives proliferation and hepatocellular 
carcinoma in non-alcoholic fatty liver disease”. Manuscript is under review in “Journal of 
Hepatology”.  
2019 Eva Moran-Salvador*, Marina Garcia-Macia*, Ashwin Sivaharan*, Laura Sabater, Marco 
Y.W. Zaki, Fiona Oakley, Amber Knox, Agata Page, Saimir Luli, Mann J* and Mann DA*- 
“MeCP2 regulates the myofibroblast RNA landscape and its fibrogenic activity is controlled 
by site-specific phosphorylation”, Gastroenterology. 
2019 Hannah Paish, Lee Reed, Helen Brown, Mark Bryan, Olivier Govaere, Jack Leslie, Ben 
Barksby, Marina Garcia Macia, Abigail Watson, Xin Xu, Marco Y. W. Zaki, Laura Greaves, 
Julia Whitehall, Jeremy French, Steven    White,  Derek Manas,  Stuart Robinson, Gabriele 
Spoletini, Clive Griffiths, Derek Mann, Lee A Borthwick, Michael J Drinnan, Jelena Mann* 
and Fiona Oakley*- “A  novel  bioreactor  technology  for  modelling  fibrosis  in  human  
and  rodent  precision-cut  liver slices”, Hepatology. 
2019 Jack Leslie, Julie C. Worrell, Saimir Luli, William Reilly, Hannah L Paish, Marina García Macia, 
Amber Knox, Ben S Barksby, Lucy Gee, Marco Y.W. Zaki, Hannah Hepton, Charlotte Bragg, 
Xin Xu, Git W Chung, Colin DA Brown, Andrew D. Blanchard, Carmel B. Nanthakumar, 
Morten Karsdal, Jelena Mann, Stuart M Robinson, Derek M Manas, Gourab Senn, Jeremy 
French, Steven A White, Johannes L Zakrzewski, Ulf Klein, Andrew J Fisher, Neil S Sheerin, 
Lee A Borthwick, Derek A Mann and Fiona Oakley- “c-Rel orchestrates energy-dependant 
epithelial and macrophage reprogramming in fibrosis”, Revisions are performed for 
resubmission to Nature metabolism. 
2019 Aitor Esparza-Baquer, Ibone Labiano, Omar Sharif, Fiona Oakley, Pedro M. Rodrigues, 
Elizabeth Hijona, Raul Jimenez-Agüero, Adelaida La Casta, Marco Y. W. Zaki, Colm J. 
O'Rourke, Patricia Munoz-Garrido, Gernot Schabbauer, Jesper B. Andersen, Sylvia Knapp, 
Derek A Mann, Luis Bujanda, Jesus M. Banales, and Maria J. Perugorria- “TREM2 defends 
the liver against Hepatocellular Carcinoma through multifactorial protective mechanisms”, 
Revisions are performed for resubmission to Gut. 
2019 Ramy Younes, Olivier Govaere, Salvatore Petta, Luca Miele, Anna L. Fracanzani, Chiara 
Rosso, Maria J. Garcia Blanco, Angelo Armandi, Gian Paolo Caviglia, Marco Y.W. Zaki, 
Antonio Liguori, Paolo Francione, Grazia Pennisi, Luca Valenti, *Quentin M. Anstee & 
*Elisabetta Bugianesi, “Long-term clinical and prognostic significance of serum antinuclear 
autoantibodies in patients with non-alcoholic fatty liver diseases”, Paper circulated to co-
authors before submission to Hepatology.  
2018 Marco Y. W. Zaki, Helen L. Reeves – “Long intergenic non-coding RNAs in hepatocellular 




2016 Reeves HL, Zaki MY, Day CP – “Hepatocellular Carcinoma in Obesity, Type 2 Diabetes, and 
NAFLD”, Review article, in Digestive Diseases and Sciences journal. 
2016 Marco Y. W. Zaki, Helen L. Reeves – “The genetic heterogeneity of hepatocellular 
carcinoma and the implications for personalised medicine”, Editorial in Translational 
Cancer Research. 
2011 Nabil M Abdel-Hamid, Maiiada H Nazmy, Ahmed Wahid, Michael A Fawzy, and Marco 
Youssof - “A Survey on herbal management of hepatocellular carcinoma”. Review article 
in world journal of gastroenterology. 
Peer reviewed manuscripts 
2018 OncoTargets and Therapy 
2019 Hepatology 
2019 Liver international 
Memberships 
2017 Member of the European Association for the Study of liver Diseases “EASL”. 
2017-2018 Member of the British Association of cancer research. 
2018 Member of the European Association for the Study of liver Diseases “EASL”. 
2019 Member of the European Association for the Study of liver Diseases “EASL”. 
2020 Member of the European Association for the Study of liver Diseases “EASL”. 
Awards and funding 
2015 “Newton fund” to support PhD scholarship in Newcastle, United Kingdom. 
2017 Best poster award in the ICM Directors day for the poster entitled: SULFATASE-2, secreted 
from Cancer-associated fibroblasts, promotes Human hepatocellular carcinoma cell 
growth.  
2017 Young investigator full Bursary award to attend the EASL HCC Summit in Geneva, 
Switzerland. 
2018 Young investigator full Bursary award to attend the EASL international liver conference, 
Paris, France. 
2019 2 x Young investigator full Bursary awards to attend the EASL HCC summit, Lisbon, 
Portugal. 
2019 Post submission scholarship-academic development scheme, Newcastle University. 
